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Ovarian cancer is a leading cause of mortality in gynaecological cancer in New Zealand and 
worldwide. New targeted approaches are essential to improve the survival and quality of life 
for patients with this disease. In advanced ovarian cancer, malignant cells shed off the 
ruptured ovarian tumour into the peritoneum forming 3D cellular aggregates in order to 
survive and establish secondary growth on the abdominal wall of internal organs.  
Receptor tyrosine kinases including EGFR, HER-2 and c-MET are frequently overexpressed 
in ovarian cancer cells and have been linked with poor prognosis and low survival in ovarian 
cancer patients. The ability of ovarian cancer cells to utilize these receptors for survival and 
metastasis suggests an important role for co-activation and highlights a need for a better 
understanding of their role in cancer progression and the possibility of combined drug 
targeting for a better patient outcome.  
In this thesis, an in vitro study of 3D cellular clusters and compact aggregates of two ovarian 
cancer cell lines (OVCAR-5 and SKOV-3) and their response to a combination of two 
tyrosine kinase inhibitors (TKI), canertinib ( a pan EGFR inhibitor) and PHA665752 (a c-
MET inhibitor) was investigated. The receptors were activated with their specific ligands EGF 
and HGF. The two cell lines were chosen on the basis of their molecular subtypes. 
The inhibitor combination reduced the total expression and phosphorylation of the receptors 
as well as the downstream signalling molecules Akt and ERK. This then affected cell growth. 
Both inhibitors reduced cellular adhesion to collagen gel matrix. In an attempt to mimic the in 
vivo environment of the cancer cells the effect of ascitic fluids from advanced ovarian cancer 
patients on inhibitor efficacy was tested. The ascitic fluid was found to reduce the effect of the 
inhibitors. It is suggested that a component in the ascetic fluid may be preventing the 
inhibitors from entering the cells possibly through binding with serum. 

























1.1 Ovarian cancer-Overview  
Ovarian cancer is one of the most lethal gynaecological cancers [1]. It is the eighth most 
common type of malignancy [2, 3] and the fifth cause of cancer related mortality in females 
worldwide [4, 5]. According to a recent statistics report in the USA, approximately 22,280 
new cases of ovarian cancers were diagnosed of which 14,240 disease related deaths occurred 
in 2016 [6]. This means at least 69% of ovarian cancer patients will succumb to their disease 
[7]. The disease is often misdiagnosed due to its elusive symptoms resembling other medical 
disorders [8, 9] and lack of reliable biomarkers for early detection [10], therefore, most 
patients would present with an advanced stage by the time the disease is discovered [11].  
Only approximately 20% of ovarian cancers are diagnosed in stage I, which is characterised 
by cancerous cells forming a tumour that still lie within the ovary [12]. These patients have a 
chance of being cured with conventional surgical approaches and have survival rates of up to 
90%. Unfortunately, the remaining 80% are diagnosed after the disease has progressed to 
stage II or higher [7]. As such, there are limited treatments for these patients and hence the 
recurrence of the disease and a low 5 year survival rate are typically observed [13, 14].  
The first line of treatments, the debulking surgery and chemotherapy, are unlikely to cure 
the advanced disease and ultimately most of the patients have a poor outcome [11]. Due to 
these limitations a rationale for the development of effective targeted therapeutics is critical to 
improve the survival rates and quality of life of those patients’. Relative to other 
gynaecological cancers, advanced ovarian cancer has a poor 5 year survival rate of 36% 
compared to rates of 61% and 73% for cervical and endometrial cancers respectively [15]. 
According to a report from New Zealand Gynaecological Cancer Foundation the 5 year 
survival rate for ovarian cancer patients is 39% compared to 72% for cervical cancer, 78.5% 
for uterine cancer and 87% for breast cancer [16]. 
 




All dividing somatic cells proliferate through the same highly conserved, basic cell cycle 
sequence [17]. Cells undergo the five distinct phases of the cell cycle: quiescence (G0), Gap1 
(G1), DNA replication/synthesis (S), Gap2 (G2) and mitosis (M) in order to produce new cells. 
Proteins and RNA synthesis as well as DNA repair occur in G1 phase [18]. If these activities 
are prolonged then cells may go into quiescence and enter the G0 phase (resting phase) [19]. 
Most cells would differentiate into the G0 phase or re-enter the cycle following quiescence 
period [18, 19]. The next phase is the S phase were DNA synthesis occurs. At this point cells 
enter the G2 phase with the newly replicated DNA in preparation for nuclear division and 
mitosis which occur during the M phase [20]. This synchronised transition through the 
different phases of cell cycle, which is facilitated by cyclins and cyclin dependent kinases 
[21], is pivotal for the maintenance of genome stability [18]. Normally cell proliferation is 
tightly controlled by different regulatory pathways, hence cell numbers are kept down via cell 
cycle check points e.g. pausing the cell cycle  and/or promoting programmed cell death [17, 
21].  
Cancer cells undergo mutations that may lead to dysregulation of the cell cycle proteins and 
the checkpoint genes. This allows for a prolonged active phase of replication, dysfunctional 
apoptosis [18, 20], chromosome damages, aneuploidy (the presence of an abnormal number of 
chromosomes) and consequently malignant transformation. Genes that undergo mutations that 
lead to cancer are referred to as proto-oncogenes and typically encode growth and 
proliferative proteins and DNA repair proteins [17]. Cells with these mutations are prone to 
sustained proliferation and to evade cell death signals. Consequently, cells divide and 
proliferate in an uncontrolled manner forming tumours [18].  
There are eight hallmarks that are suggested to be common to most types of cancers. Each 
hallmark offers a distinct role in the development, progression and recurrence of the tumour 
[22, 23].  These hallmarks are:  
1- Sustaining proliferative signalling. 
2- Evading growth suppressors. 
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3- Resisting cell death. 
4- Enabling replicative immortality. 
5- Inducing angiogenesis. 
6- Activating invasion and metastasis. 
7- De-regulating cellular energetics and metabolism. 
8- Avoiding immune destruction.  
The word tumour describes a broad range of solid or fluid filled cystic lesions that may or 
may not be related to cancer and the term "tumour" is usually used without a reference to the 
physical characteristics of size, shape, site, or type of the lesion [24]. Eighty percent of the 
ovarian tumours are benign tumours and mostly affect young women of 20-45 years of age. 
They usually increase in size but remain at their location and once removed they rarely appear 
again. Pre-malignant tumours are mostly found in older women; they tend to grow faster and 
might re-appear again after removal. Malignant tumours, however, are known to be life 
threatening and might re-appear locally and/or distally due to metastasis. Usually women with 
these tumours are aged 45 -65 years [25, 26].  
Cancer is a term that refers to a broad group of diseases (there are more than 200 different 
types of cancer) that are characterised by mutations and unregulated cell growth. There are 
thought to be more than 60 organs in the human body where cancer can occur. A variety of 
factors e.g. hereditary (familial germline mutations in BRCA1 and BRCA2 genes) [27], 
environmental (chemicals, smoking), viral (Epstein-Barr virus, HPV) or bacterial infections 
(Helicobacter pylori), diet ( low- roughage/high-fat, high nitrosamine intake), radiation (UV 
exposure, diagnostic exposure to CT scan, therapeutic radiation) , hormonal (exogenous 
oestrogen replacement therapy), inflammatory diseases (ulcerative colitis), and occupational 
exposure (dye and rubber manufacturing, asbestos mining, construction work, PVC 
manufacturing, petroleum industry) may contribute to the development of the disease [2, 15, 
28]. 
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As detailed above, in cancer the cells undergo mutations that involve the activation of 
proliferative signalling pathways triggered by numerous factors including autocrine 
stimulation (growth factors produced by the cancer cells) [29], downregulation of tumour 
suppressor genes, for example BRCA1 and BRCA2, the proteins that normally preserve intact 
chromosomal structure [30]. The factors described above cause the cells to divide and grow 
uncontrollably, to evade cell death signals and thus to form malignant tumours [22, 31]. The 
transformed cells may migrate from the original tumour via the bloodstream, the lymphatic 
system or through direct implantation [32] to invade surrounding tissues and other organs, a 
process that is referred to as metastasis [33].  
1.3 Gynaecological Cancers 
The term gynaecological cancer refers to malignancies of female genital tract, vulva, vagina, 
cervix, uterus and ovaries [34]. These will be described briefly below before a more in depth 
consideration of ovarian cancer. 
1.3.1  Cancer of the Vulva 
Cancer of the Vulva represents approximately 4% of all gynaecological malignancies and it 
is mostly diagnosed in early stages (I and II) of its development [35]. Therefore, it carries a 
good prognosis and a 5 year survival rate of greater than 75-90% for stages I and II. This then 
decreases to 54% for stage III and 16% for stage IV [35, 36]. An increasing incidence of 
cancer of the vulva is suggested to be due to the increased numbers of older women, mainly 
those infected with human immunodeficiency virus (HIV). HIV causes immune-T cell 
suppression, which may render the patient to be more susceptible to Human Papilloma Virus 
(HPV)-related cancers. [37].  
1.3.2 Vaginal Cancer 
Vaginal cancers are mostly secondary metastasis from nearby organs and primary carcinoma 
of the vagina is very rare with approximately only 0.45 cases per 100,000 women [6, 38]. 
Vaginal cancer incidence increases with increased age reaching its peak at around 80 years 
and is usually lower in Caucasian women in comparison to other ethnicities [39]. This cancer 
is also linked to HPV infections as according to a systematic review in 2009, 65% of the 
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patients with invasive vaginal cancer had HPV infections [40]. Other risk factors that 
contribute to vaginal cancer include multiple sexual partners, an early age of first intercourse 
and smoking, as well as women with history of vulvar and cervical cancer [41]. The disease 




1.3.3 Cervical Cancer 
Cervical cancer is the most widespread gynaecologic cancer worldwide in younger age 
groups of women. It ranks the 4
th
 among all female cancers [44]. The most common 
predisposing factor for cervical cancer is HPV infection, other factors include multiple sexual 
partners, intercourse at teenage and grand multiparity [45]. Most disease related deaths 
reported in the USA were among women with low socioeconomic status [38]. Patients 
generally have a good prognosis if the disease is detected while still in stage I with no lymph 
node involvement (a 3 year survival rate of 86%), however, in the same stage, with positive 
lymph nodes the rate is lower (74%). Rates become even lower with increased disease stage 
and metastasis in the lymph nodes [45]. 
1.3.4 Endometrial Cancer 
Endometrial cancer is a common gynaecological cancer and is the seventh leading cause of 
cancer related deaths among women [38]. There are several factors that contribute to the 
development of endometrial cancer of which obesity is the most common. The high levels of 
oestrogen and other obesity related hormones such as leptin, insulin and insulin-like growth 
factor (IGF) released from the adipose tissue may induce uncontrolled endometrial cell 
proliferation [46, 47]. Additionally, the prolonged use of exogenous oestrogen therapy for 
relieving the menopausal symptoms is also another etiological factor [48]. Other risk factors 
include early menarche, late menopause [49], low parity and age, where post-menopausal 
women over 55 years of age are more prone to develop endometrial cancer [50]. Diabetes, 
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hypertension [51, 52], smoking and family history [50] may also contribute to the 
development of endometrial cancer. Fortunately, post-menopausal bleeding is the most 
common symptom and often leads to early diagnosis and early treatment. Therefore women 
with endometrial cancer have a better prognosis than other types of gynaecologic cancers and 
patients without metastatic disease have 5 year survival rates of 74% - 91% [53].  
 
 
1.3.5 Fallopian tube cancers 
Fallopian tube cancer has been considered to be very rare, accounting for < 0.5% of all 
gynaecological cancers [54]. However, recent histologic, molecular and genetic studies 
suggest that about 40-60% of high grade serous carcinomas of the ovary may have been 
originated from tubal fimbria [30]. This means that tubal carcinoma may have been under 
estimated and, as is the case for ovarian cancer, the presentation of fallopian tube carcinomas 
resembles various medical disorders often leading to late diagnosis and poor prognosis[30]. 
1.3.6 The Ovaries and Ovarian cancer  
1.3.6.1 Anatomy of the Ovaries: 
The ovaries are two small organs within the female reproductive system; they have the 
shape of an almond and are located on both sides of the uterus [55]. The two organs are 
attached to their corresponding fallopian tube by the mesovarium. The latter is a membrane 
consisting of a double layer of peritoneum that supplies the ovaries with blood vessels, nerves 
and lymphatics. The ovaries are also attached to the lateral pelvic wall via infundibulo-pelvic 
ligaments (the thickened parts of the broad ligaments which suspend the ovaries to the lateral 
pelvic wall) [56]. The measurements of a normal ovary including longitudinal, transverse and 
antero-posterior diameters are 2.5-5cm, 0.7-1.5cm, and 1.5-3cm, respectively [55, 56].  
The ovaries are formed of several types of cells from different origins. Histologically, the 
surface of the ovary is covered by a single layer of cuboidal coelomic epithelial cells [57]. 
The cortex consists of the main bulk of the ovary containing a large number of Graafian 
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follicles. The development of these follicles is a characteristic of the active sexual years [57]. 
The Graafian follicles are covered with spindle shaped theca cells and the cavity of each 
follicle contains the ova with its germ cells. The ova are surrounded by granulosa cells within 
a gonadal stroma [58]. Other contents of the ovarian stroma, following ovulation, include the 
corpus luteum, corpus albicans (both lined internally by luteinised granulosa cells), 
connective tissue cells and smooth muscle fibers [59-61]. Connective tissue fibers, smooth 
muscle cells, lymphatics, nerves and clusters of hilar Leydig cells make up the medulla of the 
ovary. This wide range of histologically distinct cell types and tissue varieties contributes to 
the disparate types of ovarian tumours and therefore there is a need for variable types of 
treatments that aim for particular targets. 
The ovaries have two main roles. The first role is the production of the female hormones 
progesterone and estrogen and small amounts of testosterone [62, 63]. These hormones 
control the development of secondary sex characters of females e.g. they control the 
development of the breasts, body shape, and body hair. They also control the menstrual cycle 
and pregnancy. The second role of the ovaries is to store and produce ova [64]. A female 
ovary contains a huge number of minute ova (300,000-400,000) but only around 400-500 ova 
will mature and be released between menarche and menopause [63]. Their release is 
controlled by pituitary follicular stimulating hormone (FSH) and luteinizing hormone (LH) 
[65]. Every month when a female is at reproductive age, ovarian follicles start to grow in 
different stages, yet, only one or two reach the full size stage and will be released while the 
rest will disintegrate. The ovum travels to the uterus through the fallopian tube [66] reaching 
the endometrial cavity where if it remains unfertilised it will disintegrate as part of the 
sloughing off of the endometrium at the end of the menstrual cycle [63]. Figure.1.1. 
illustrates the diverse cellular biology of the ovary, fallopian tube and uterus [67].  




Figure.1.1. Anatomy and biology of the ovary, fallopian tube and uterus. The functional 
cells that are relevant to organ physiology and ovarian tumorigenesis. a | The secretory and 
ciliated cells in fallopian tube epithelium. Immune cells, which are present in the epithelium 
and stroma. b | Cells of the ovarian cortex, ovarian surface epithelium, stromal cells, and 
various stages of ovarian follicles. Granulosa cells and theca cells. c | The endometrial 
epithelium (EME) and endometrial stroma (EMS) [67]. Image permission was purchased 
from NATURE REVIEWS | CANCER. 
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1.3.6.2 Cancer of the ovary  
Ovarian cancer is the leading cause of mortality in women with gynaecologic cancers [68]. 
In the past, ovarian cancer was considered to be one disease while it is now recognised as a 
group of diseases with distinct biological and histopathological appearances [69]. The rates of 
the disease vary in different regions of the world. Europe and the United States report the 
highest incidences of the disease followed by Australia and New Zealand, while Asia and 
Africa reported fewer incidences as shown in Figure.1.2. [70]. The variation in ovarian 
cancer incidence between different regions is suggested to be linked to smaller family sizes, 
high socioeconomic levels, high fat diets, older age and genetic background e.g. Caucasian 
descent.  
Many pre-disposing factors have been suggested in the development of ovarian cancer. 
These include advanced age (women in the age range of 40-60 years are more susceptible 
than younger individuals) [59] and genetic mutations. 5-10% of ovarian cancer patients have 
been found to have a family history of ovarian, fallopian tube and peritoneal cancers as well 
as mutations including BRCA1 and BRCA2 [12, 71, 72]. Other factors include the 
environment, nulliparity [73, 74] and Caucasian descent. It has also been suggested that 
prolonged ovarian stimulation, for example through IVF, may increase the risk of developing 
ovarian cancer, however, this link is yet to be ascertained [75]. It should also be noted that 
pregnancy, breast feeding, and oral contraceptives may reduce the probability of ovarian 
cancer [76, 77].  
Mutations in BRCA1/2 are found in 5-15% of breast and ovarian cancers [78-80] and these 
have several copy number aberrations (CNAs) in high grade serous ovarian cancer (HGSOC). 
TP53 mutations are also present in 96% of HGSOC according to the Cancer Genome Atlas 
[79]. Tp53 encodes a protein that which terminates cell cycle progression, stimulates DNA 
repair, and activates apoptotic pathways [81, 82]. Thus cells with TP53 mutations are more 
prone to retain and pass down damaged DNA, resulting in aggressive tumours. Epigenetic 
factors have also been implicated in the development of advanced ovarian cancer, for example 
alternative splicing of histone variants type H2A [83]. Overexpression of growth factor and 
/or adhesion receptors [84-86] have also been shown to alter the genome-wide methylation 
patterns in breast and ovarian cancers [87, 88].  
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It’s commonly agreed that there are three cellular origins of ovarian cancer: the epithelium, 
germ cells, and stromal cells [89, 90]. 
 
Figure.1.2. Age Standardised Incidence Rate (ASR) of ovarian cancer by region across the 
world. Image was taken with permission from IARC [70], and modified by the author to show 
the incidence of ovarian cancer primarily in New Zealand and Australia in comparison with 
selected worldwide populations. 
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1.3.6.3 Subtypes of Ovarian Cancer 
The diverse cell types that form the ovaries mean that different types of ovarian cancer can 
have different histological and molecular properties [12] and the majority of tumour cells are 
often phenotypically distinct from normal ovarian cells [67]. The World Health Organisation 
(WHO) classified ovarian cancers according to tumour histology and cell origin into: 
epithelial, germ cell and sex cord stromal tumours [12, 91]. 
1.3.6.3.1 Epithelial ovarian cancer  
Epithelial ovarian cancers are the leading cause of death from gynaecological cancers in 
USA and Europe [14, 76]. They account for 3% of all types of malignancies in females and 
are the second most common after uterine cancer [92]. Well established predisposing factors 
for acquiring epithelial ovarian cancer include family history (a first degree relative with the 
disease), early menarche, late menopause, old age and nulliparity [70] 
Patients with familial susceptibility have a life time risk of acquiring epithelial ovarian 
cancer of 10-40% [12]. However, it has also been reported to occur sporadically at a rate of 
1.7% (in a population of women without family history) [12]. This group of ovarian tumours 
are the most common types of ovarian cancers representing nearly 90% of all ovarian 
neoplasms (both benign and malignant) [92] and 98% of ovarian cancers [93]. 
Epithelial ovarian cancers originate from the mesothelial lining of the ovaries (which has the 
ability to differentiate into epithelial or mesenchymal tissue) either from the ovarian surface 
epithelium (OSE) or from its invagination into the ovarian cortex forming an ovarian cyst [94-
97]. Based on the heterogeneity of different types of Müllerian epithelia and the 
histopathological, immunohistochemistry, and molecular genetic analysis [69], a recent 
guidelines report published in 2014 by the International Federation of Gynaecology and 
Obstetrics (FIGO), divided epithelial ovarian cancer into 5 subtypes: serous, mucinous, 
endometrioid, clear cell and undifferentiated carcinomas [69].  
Although categorized as one group, these cancers are distinct entities differing in their 
molecular, biological, pathogenesis and clinical behavior [98]. According to their clinical 
behavior the tumours from each subtype can be further sub-categorised into: benign, 
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borderline, and malignant [59, 70, 98]. Images of the histological subtypes are shown in 
Figure 1.3. [99]. 
1.3.6.3.1.1 Ovarian Serous Carcinoma  
Serous carcinoma is the most common type of epithelial cancer [91] accounting for 70% of 
all ovarian epithelial cancers [100] and is a major cause of death in patients with epithelial 
ovarian cancer. It originates from the Müllerian epithelium and is characterised by peritoneal 
dissemination [7, 101, 102]. Based on their nuclear atypia and mitosis, serous ovarian 
carcinomas can be classified into low grade and high grade carcinomas [103]. These differ in 
their genomic and molecular characteristics in that low grade serous carcinomas exhibit 
minimal nuclear atypia and low levels of mitosis ( ≤ 12 per 10 high-power fields); while high 
grade carcinomas show significant nuclear atypia and mitosis [103]. Cytogenetic and single 
nucleotide polymorphism (SNP) analyses have revealed that low grade serous carcinomas 
exhibit fewer molecular abnormalities than high grade serous carcinomas [104, 105]. For 
example, low grade serous carcinoma have wild type TP53 and mutations in either KRAS, 
BRAF or ERBB2 (HER-2) are common, while high grade serous carcinomas are characterised 
by TP53 and BRCA1/2 mutations and amplification in CCNEI (encoding cyclin E1) [92, 98]. 
The ErbB receptor (described in more detail below) has been shown to be significantly 
depleted in serous ovarian tumours. However, 5.1% were found to harbour the amplification 
reported by TCGA for high grade serous ovarian carcinoma [80]. 
Given that these two ovarian serous carcinomas present with different 
morphological features and arise from different genetic pathways [105-107], Singer 
and colleagues categorized them into type I and type II tumours [108]. While type I 
are low grade tumours that progress in a sequential fashion from “adenoma-
borderline tumour-carcinoma”, type II are high grade tumours that develop directly 
on the surface epithelium i.e. without precursor lesions [92], Table 1.1 demonstrates 
some of the key differences between high and low grade serous ovarian carcinomas. 
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Table 1.1 Some of the key differences between high and low grade serous ovarian carcinoma (HGSOC and LGSOC). 
 
HGSOC LGSOC Ref 
Significant nuclear atypia Minimal nuclear atypia [103] 
Significant mitosis Low levels of mitosis (≤ 12 per 10 high-power fields) [103] 
High molecular abnormalities Few molecular abnormalities [104, 109] 
Mutations in TP53 Wild type TP53 [92, 98] 
Amplification in CCNEI (encoding cyclin E1) Mutations in KRAS, BRAF and HER-2 [92, 98] 
Type II tumours Type I tumours [108] 
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1.3.6.3.1.2 Molecular subtypes of HGSOC 
HGSOC is of particular interest due to its high incidence of disease related deaths and low 
overall survival rate [79]. Using high-density expression oligonucleotide microarrays to 
profile 285 well-annotated serous and endometrioid invasive ovarian, fallopian tube, and 
peritoneal cancers, Tothill and colleagues [110] were able to identify six distinct molecular 
subtypes of HGSOC. 
1- C1 High stromal response Tumours  
2- C2, High immune signature Tumours  
3- C4, Low stromal response tumours. 
4- C5, Mesychymal low immune signature tumours. 
5- C3, Serous low malignant potential (LMP) tumours  
6- Low grade early stage endometrioid tumours. 
 [110]. 
A follow up paper by Leong and colleagues [100] in 2015 suggested further description to 
these molecular subtypes where C1 were suggested to show intensive dysmoplasia, an 
epithelial–mesenchymal gene expression signature, and linked with primary treatment failure 
and poor survival. Immune reactive C2 tumours were characterised by extensive intra-
tumoural T-cell infiltration and generally have a better prognosis. However, C4 demostrates 
an intermediate outcome and the gene expression signature of these tumours shares some 
features with serous borderline tumours. Finally, C5 proliferative tumours show low 
expression of differentiation markers such as CA125 and limited infiltration with poor 
outcome [100] 
Diversity in clinical responses is also recognized between the low and high serous ovarian 
carcinomas. The initial response of high-grade serous carcinoma to standard chemotherapy of 
platinum and taxanes (Carboplatin and Paclitaxel) is good following debulking surgery. 
However, 20-30% of patients experience relapses of the disease within less than 6 months 
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[111]. This relapse appears to be associated with the nature of mutations observed in the high 
grade serous carcinoma [112], specifically amplification of CCNE1 which have been shown 
to be a poor prognostic factor [113]. A five-year survival rate of 20-35% is expected for 
patients with serous ovarian carcinoma [12, 114].   
1.3.6.3.1.3 Endometrioid cancer 
These tumours are common mostly in women in the age range of 50-59 years. They account 
for 10-20% of all epithelial ovarian cancer cases [92]. A 5-year survival rate of 40-63% and 
good prognosis is observed in ovarian endometrioid carcinoma [9, 114, 115]. This type of 
epithelial ovarian cancer can also be classified into low grade endometrioid and high grade 
endometrioid.  
At the molecular level, low grade endometrioid ovarian cancer is typically a type I tumour 
molecular subtype which is genetically stable and found to carry several somatic mutation 
such as PIK3CA, PTEN, KRAS, BRAF, and CTNNB1 (the gene encoding for β-catenin 
protein). The β-catenin protein was found to be involved in cell-cell adhesion and gene 
transcription processes and seems to play a major role in the development of endometrioid 
ovarian carcinoma [92, 116]. High grade endometrioid ovarian carcinoma is classified as a 
type II tumour, which is aggressive, unstable with > 95% of cases carrying TP53 mutations 
[117]. 
  
1.3.6.3.1.4  Mucinous adenocarcinoma 
Mucinous ovarian carcinoma accounts for 5-20 % of epithelial ovarian cancers and patients 
with advanced stages have worse prognosis and survival rates [118]; the 5 year survival rate is 
40-69% for patients with mucinous ovarian cancer. They are heterogeneous tumours in terms 
of cellular components as well as the degree of differentiation [92]. Mucinous ovarian 
tumours have been found to retain a mixture of benign, borderline and malignant cells in the 
same neoplasm suggesting a step by step progression. Mucinous ovarian carcinomas were 
found to carry mutations in 17q12, which encodes for ERBB2 (HER-2) and the gene was 
significantly amplified [119]. The presence of KRAS mutations in all three areas (benign, 
borderline and malignant) suggests its involvement in the early stages of the development of 
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mucinous ovarian carcinoma [92, 120, 121]. RAS oncogene is a small GTPase within the 
intracellular proliferative pathways that leads to mitosis and thus mutations in this gene was 
found to enhance cell proliferation [122, 123]. ECM proteins including E-cadherin and matrix 
metallo protein (MMP), which are cell adhesion and migration molecules, are also found 
expressed on mucinous ovarian cancer cells [124, 125].  
 
 
1.3.6.3.1.5 Clear cell ovarian carcinoma 
Clear cell ovarian carcinomas represent between 3-10% of epithelial tumours. The 5 year 
survival rate is 35-50 % in patients with clear cell carcinoma [9, 12, 114, 126]. A genome 
wide analysis revealed molecular genetic somatic inactivation in ARID1A genes [127, 128]. 
Studies of morphologic and molecular characteristics of clear cell ovarian carcinoma have 
revealed a sequential pattern of progression [127, 129]. This type is characterised by 
activating mutations in PI3KCA and amplification of chr20q13.2 (encodes for ZNF217 
oncogene) [127, 130].  
Regardless of the stage upon diagnosis, the response rate to standard platinum-taxane 
chemotherapy is very low and the disease has a significantly poor clinical outcome [131-133]. 
Clear cell ovarian carcinomas have found to carry a unique genetic profile in that they have 
upregulation of certain genes including HNF-1β [134, 135]. ARID1A and PIK3CA mutations 
are more frequent (>40%) in clear cell carcinoma compared to other histological types of 
epithelial ovarian cancers [127, 128, 136, 137]. 
1.3.6.3.1.6 Undifferentiated ovarian carcinoma 
Undifferentiated ovarian carcinoma is a rare type of ovarian tumour that usually present as 
large, solid, necrotic tumours. According to the WHO, these tumours are characterised by 
cells that show no differentiation or rare areas of differentiation [115]. It accounts for just 1% 
of all epithelial ovarian cancers [9, 12] and in most cases the patients would present with 
metastatic tumours and therefore a poor prognosis is often observed [138].  
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The 5-year survival rate is approximately 11-29% [12, 114]. According to its molecular and 
clinical properties, undifferentiated ovarian carcinoma is suggested to be a type II tumour 
[97]. Like all other cancers with type II molecular profiles, this ovarian carcinoma exhibits 
morphologic and molecular homogeneity with an unstable tumour that primarily harbours 
TP53 mutations [97].  
 
Figure 1.3. Histopathological images representing the different subtypes of epithelial 
ovarian carcinoma which account for 98% of all ovarian malignancies. A) High grade serous 
carcinoma. B) Low grade serous carcinoma. C) Endometrioid carcinoma. D) Mucinous 
carcinoma. E) Clear cell carcinoma. Image taken from World Cancer Report 2014 [99] with 
permission from the author Dr Jamie Prat [69]. 
 
1.3.6.3.2 Ovarian Germ cell tumours  
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Ovarian germ cell tumours are a group of tumours that originate from primordial germ cells 
derived from the embryonal gonads [139]. These types of cancers represent 3-7% of ovarian 
cancers, however most tumours that originate from germ cells of the ovary are benign [25, 60, 
69, 140]. They can be classified as dysgerminoma, yolk sac tumour, embryonal carcinoma, 
poly embryoma, nongestational chorio carcinoma, mixed germ cell tumours and teratoma 
[141]. Ovarian malignant mixed germ cell tumours are highly aggressive and usually affect 
young women below the age of 20 years. However, if diagnosed at an early stage, a good 
prognosis is expected and the patient’s fertility could be spared [141, 142].  
1.3.6.3.3 Ovarian Sex cord-stromal tumours 
Ovarian sex cord-stromal tumours originate from the sex cord and mesenchyme of the 
embryonic gonads. Most of these tumours are benign or are of low grade malignancy with a 
good prognosis and usually affect younger women <40 years of age. Hormone secreting sex-
cord tumours represent 90% of functioning ovarian tumours [143]. Granulosa cell 
(estrogenic), and androblastoma (androgenic) are examples of sex cord tumours, which are 
generally associated with symptoms of hormonal effects. Ovarian sex cord tumours represent 
7% of all cancerous ovarian tumours [60]. 
1.3.6.4 Stages of Ovarian Cancer 
According to FIGO staging ovarian cancers can be categorised into four stages and each of 
these can be split into three subdivisions. These are summarised in Table.1.2.[12, 71, 144, 
145]. Patients with stage IA tumours in which the disease is restricted to one ovary, and there 
is no ascitic fluid have a good prognosis and this can be treated by surgery. Stage IB tumours 
can be in both ovaries but without malignant ascites. Following surgery alone, there is a 5-
year survival rate of 90 % for both IA and IB [146].  
Stage IC is characterised by rupture of the tumour surface, malignant ascites and can be 
limited to one or both ovaries. Stage II ovarian cancer presents with pelvic extension and can 
be further classified into stage IIA in which tumours may be present in the uterus or fallopian 
tube and stage IIB, in which the tumour reaches other pelvic organs (bladder, rectum or pelvic 
side walls). Stage IIC is identified by tumour extension to other ovary, with a ruptured surface 
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and malignant cells in the ascites. The 5 year survival rate for stage IC and stage II reaches 
80% when postoperative adjuvant therapy is given [12, 147, 148].  
Stage III of the disease involves spread to the lymph nodes or upper abdomen and is further 
sub divided into stage IIIA in which the disease is found in microscopic small deposits in the 
omentum. Stage IIIB deposits are 2 cm or less and are outside the pelvis. Stage IIIC of the 
disease has gross deposits more than 2 cm and these are outside the pelvis. Stage IV of the 
disease involves the dissemination of the disease to distant organs such as pleural space, the 
liver and /or splenic parenchyma. For patients with advanced stages of epithelial ovarian 
cancer (stage III and IV), following debulking surgery with residual disease of 1 cm or less, 
the 5 year survival rate is around 20-30 % and may reach 10% if insufficient debulking is 
achieved [12, 147-149]. 
The prognosis for patients with ovarian cancer can be complex and depends on several 
factors that contribute to the development of the disease and the outcome of response to 
management. These factors include the stage of the disease, histopathological findings, size of 
the tumour mass, the amount of remnants of tumour after surgery, and the presence of 
malignant ascites. 
Chapter One                                                                                                      Introduction 
34 
 
Table.1.2. FIGO Staging system for epithelial ovarian cancer. the stages of ovarian cancers 




Stage I Tumour only involving the ovaries 
IA Only one ovary is affected without ascites 
IB Both ovaries involved without malignant ascites 
IC One or both ovaries with ascites. 
Stage II One or both ovaries with local metastasis. 
IIA The tumour is spread to the uterus. 
IIB 
Metastasis reaches other pelvic organs, such as bladder, rectum, and pelvic side     
walls. 
IIC 
One or both ovaries and the tumour spread to the uterus and other pelvic organs 
causing ascites formation. 
Stage III 
Tumour affecting one or both ovaries with extensive spread of the disease to the 
peritoneal cavity and pelvic lymph nodes. 
IIIA Minute spread of the disease towards upper abdomen reaching the omentum. 
IIIB Large metastasis that can be recognized by naked eye, over 2cm in size. 
IIIC In addition to findings in 3B, metastasis to lymph nodes occurs. 
Stage IV Further metastasis reaching distant organs, i.e., liver, spleen, and plural cavity 
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1.4 Intraperitoneal dissemination of Ovarian Cancer 
Whilst the primary tumour is generally confined to the ovary, the cells may be able to 
become mobile and spread as they undergo epithelial- mesenchymal transition (EMT) to 
attain motility. EMT is a crucial progressive mechanism that allows polarised epithelial cells 
to transform into motile mesenchymal cells [150, 151], which enables the exfoliation of 
cancer cells from the primary tumour and their migration to local and distant organs [151-
153].  
This transition involves changes in the behaviour of molecules that are involved in 
adhesions [33, 101, 154, 155]. Malignant cells that disseminate from the primary tumour 
survive as single cells or aggregates floating in the excess body fluid that can accumulate 
(ascitic fluid) as a result of ascites [156]. It has been suggested that intraperitoneal fluid and 
peritoneal surface motion (peristalsis) is a key driving in cell migration and further spreading 
through the abdominal cavity [157-159]. The seeding of malignant cells into the peritoneal 
cavity and the subsequent metastasis are often associated with the formation of the malignant 
ascites which is a manifestation of advanced stages of the disease. This is also the case for 
several other types of cancers but occurs most prominently in ovarian cancer [153, 160].  
Once cells reach the mesothelial lining of the abdominal cavity, they lose their migratory 
capacity undergoing mesenchymal epithelial transition (MET), which is the reverse process of 
EMT. This transition is believed to be a driver of cells seeding on the peritoneal cavity and 
other organs, thereby seeding a new secondary tumour as the cells regain their epithelial 
characteristics such as polarity and the ability to form cell junctions [154]. Figure 1.4 depicts 
a model for the intraperitoneal dissemination of advanced ovarian cancer cells [153]. 
 





Figure 1.4. A proposed model for intraperitoneal dissemination of ovarian cancer. Primary 
tumours are generally confined to the ovaries. To metastasize, tumour cells undergo 
epithelial–mesenchymal transition (EMT) to attain motility and shed from the tumour, 
surviving as single cell or compact aggregates. Aggregates undergo invasive mesenchymal 
changes to maintain survival and motility. Upon reaching the abdominal wall cells adhere and 
implant on the peritoneum and mesothelial linings of pelvic and abdominal organs. To initiate 
metastasis cells undergo a reverse transition (MET). Through the activity of MMPs, matrix 
degradation occurs & and invasive tumour cells infiltrate the mesothelial lining and the 
extracellular matrix. Permission to use the image was granted from the authors [153]. 
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1.5 Ascites: Malignant Ascites in ovarian cancer 
 Around 150-200 mL of free fluid is normally present in the pelvic cavity, especially at times 
of ovulation, and this is usually asymptomatic. Higher volumes (>1L) of ascitic fluid in the 
abdominal cavity can be a sign of several diseases such as heart failure, renal failure, liver 
cirrhosis, tuberculous peritonitis, and various cancers [161-165]. It has been reported that 10 
% of cases presenting with ascites are due to cancer [164].  
In the case of cancer, ascitic fluid can be tested for the presence of malignant cells by 
sampling via peritoneocentesis (aspiration of the fluid) [166] although definitive diagnosis 
requires cytological analysis of the fluid [164]. Ascitic fluid from diseases other than cancer 
would appear different, cloudy in the case of infections, have a clear straw- or light green 
colour in the case of liver cirrhosis, appear milky white in the case of lymphatic obstruction.  
In the case of malignant ascites, they would usually be light yellow colour with less or no sign 
of red blood cells apparent.  
Malignant ascites can be defined as the accumulation of ascitic fluid containing cancer cells 
in the abdominal cavity [156], which can occur as a result of multiple factors such as 
lymphatic obstruction, increased vascular permeability and stromal immune cells associated 
with tumour transudate secretions [101, 156]. However, ascites can occur with both benign 
and malignant tumours [59]. The presence of cancer cells is the main feature of malignant 
ascites where the tumour sheds malignant cells into the ascitic fluid [164]. These cells form 
clusters and compact aggregates in order to survive. Ascites due to ovarian cancer account for 
37% of malignant ascites, followed by pancreato-biliary cancer (21%), gastric (18%), 
oesophageal (4%), colorectal (4%) and breast cancer (3%) [167].  
The components of malignant ascites can be divided into two main categories, cellular and 
acellular. Cellular components include malignant cells (single and aggregates), endothelial 
cells, adipocytes, and inflammatory cells. Acellular (soluble) components include growth 
factors (e.g. EGF, HGF and VEGF), cytokines, chemokines, ECM fragments and various 
proteins [168, 169]. These proteins include human serum albumin (HSA), which is usually 
found at high levels in malignant ascites due to increased vascular permeability [170]. HSA is 
a 585 amino acid, single chain protein carrying several negative charges that can bind 
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reversibly to many substances including drugs and hence plays a pivotal role in drug delivery 
[171-174]. This binding may cause significant pharmacodynamics alterations due to changes 
in drug properties including absorption, distribution, metabolism and excretion [175]. 
Additionally, the high levels of vascular endothelial growth factor (VEGF) from ovarian, 
colon, and gastric cancer cells may contribute to the formation of ascites. It has been 
suggested that the presence of VEGF in ovarian cancer is crucial for ascites formation [164]. 
The production of VEGF by ovarian cancer cells is suggested to be driven by several factors 
including growth factors [176]. Therefore, inhibition of VEGF dramatically halts the 
production of ascitic fluid [177]. 
1.6 Treatment of ovarian cancer 
1.6.1 Surgery 
Surgical procedures are the cornerstone treatment for tumours in the early stages of the 
disease. The aim of surgery is the excision of the entire tumour growth and is performed in 
patients with stage I/II ovarian cancers. In some early stages of ovarian cancer a good 
prognosis would be expected after surgery. However, since nearly two-thirds of ovarian 
cancer patients present with advanced stages of the disease by the time they are diagnosed 
debulking surgery is then recommended. Unfortunately, some of the tumour tissue may 
remain in the abdominal cavity after surgery[178]. Additionally, the advanced stage of the 
disease may lead to a deterioration of the patients’ health and thus may affect the fitness of the 
patient for surgery. Another option for such patients is a reduction of the bulk of the tumour 
by chemotherapy prior to surgery [179].  
1.6.2 Chemotherapy 
Chemotherapy is the normal treatment for advanced ovarian cancer patients. Cytotoxic 
agents are used to target fast dividing cells. The rationale is that these agents slow down the 
tumour growth and induce cell death. Newly diagnosed ovarian cancer patients have high 
response rates to such platinum-based chemotherapy. Therefore, primary chemotherapy has 
emerged as a preferable treatment prior to debulking surgery [68]. First line chemotherapy for 
advanced ovarian cancer patients is currently the therapeutic backbone which involves a 
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platinum agent (mostly carboplatin) and a taxane (mainly Paclitaxel) [180, 181]. Second line 
chemotherapy is an option when the patient is not responding to first line treatments. These 
include doxorubicin, etoposide, gemcitabine, ifosfamide and cyclophosphamide [182]. The 
resistance to chemotherapy is mainly characterised by a reduction in the efficacy of the drug 
to inhibit tumour growth over time. Recurrence of the disease is observed in 80% of cases 
with high grade serous ovarian carcinoma [181, 183]. Some suggested mechanisms for chemo 
resistance include 1) overexpression of multidrug resistance genes (MDR), which are 
basically responsible for pumping the drug out of the cells. 2) Alterations in drug 
metabolising enzymes (e.g. glutathione transferases). 3) Increased DNA repair and evading 
apoptosis due to mutations in tumour suppressor genes (e.g. P53, BRCA1/2). 4) Defective cell 
cycle checkpoints at the mitotic spindle step, causing to resistance to microtubule inhibitors 
[184].  
A phase II trial of Bevacizumab, a humanised anti-VEGF monoclonal antibody, was 
conducted on patients with recurrent epithelial ovarian cancer by burger and colleagues [185]. 
The study included 62 patients with average age of 57 years. Two patients showed complete 
response while 11 showed partial (total response rate of 21%), 32 patients (51.6%) had stable 
disease and 40.3%  had progression-free for at least 6 months [185].  
Carboplatin is an FDA approved, platinum-based chemotherapeutic drug for the treatment of 
advanced epithelial ovarian cancer [186]. Carboplatin and cisplatin act by crosslinking 
interstrand DNA covalently binding with the DNA [186]. Paclitaxel is a member of the taxane 
mitotic inhibitor-based chemotherapeutic agents that have been approved as an effective 
treatment (alone or in combination with other chemotherapeutic agents) for several types of 
cancers including breast [187], prostate [188], bladder [189], NSCLC [190] as well as ovarian 
cancer [147].  
Several drug trials have been attempted for the treatment of mucinous ovarian cancer but the 
lack of sufficient number of participants has been an obstacle. For example, in a trial 
conducted by McGuire and colleagues on treatment with cisplatin and cyclophosphamide vs. 
treatment with cisplatin and paclitaxel the total number of patients was 410 but only 14 of 
these had mucinous carcinoma [148]. Another trial with 680 supposed patients, for treatment 
with cisplatin and cyclophosphamide vs. treatment with cisplatin and paclitaxel, only 30 
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patients had this tumour [191]. However, a study by Shimada and colleagues [192], on 24 
patients with mucinous ovarian cancer showed a response rate of 12.5 % when treated with 
platinum-based regimens [192]. The same study was also conducted on 189 patients with 
serous ovarian carcinoma showed a response rate of 67.7 %. This suggests that mucinous 
tumours may be platinum resistant. 
 
The chemotherapeutic agents described above exert their effect by impairing mitosis, hence 
killing rapidly dividing cancer cells. However, in addition to malignant cells, there are normal 
cells that are frequently going through rapid division for example bone marrow cells, hair 
follicles, and gastro-intestinal lining epithelial cells [193]. Thus the drugs will target non-
malignant cells as well as the cancer cells. This may cause numerous adverse effects that 
include mouth ulceration, nausea, vomiting, diarrhoea, alopecia (hair loss). Laboratory 
findings include low white blood cell count (neutropenia), myelosuppression (reduced RBCs 
production), and low platelets count (thrombocytopenia) [15]. The efficiency and/or toxicity 
of the chemotherapeutic drugs can be affected by several factors including the levels of drug 
absorption, distribution, metabolism, excretion and drug resistance [186, 194]. There is 
therefore a need for novel drugs that target only the malignant cells and which leave the 
normal cells unharmed.  
1.6.3 Radiotherapy  
Radiotherapy is considered one of the conventional methods for the treatment of cancer. The 
aim is to damage the DNA of the cancer cells at certain check points of the cell cycle [195], 
using radiation released from the decomposition of radioactive isotopes, or a radiation beam 
delivered by X-ray. Radiation dose depends on tumour type and volume to achieve the best 
cure with least toxicity. During the treatment, patients may experience nausea and fatigue 
[196].  
Adverse effects of radiotherapy affect normal rapidly growing cells of the bladder (cystitis), 
rectum (proctitis), lung fibrosis and skin usually appear 2-3 months after completing the 
treatment. The skin is the first site where the radiation contacts the body and this can lead to 
the development of erythema due to inflammation of the skin and subcutaneous tissue [196].  
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For several decades, radiotherapy was the best treatment for primary ovarian cancer, but as 
chemotherapy advanced, trials to compare radiotherapy and chemotherapy proved superiority 
of the latter approach [196].  
Pelvic radiotherapy for early stage ovarian cancer reduced the relapse rate in the pelvis yet 
showed no overall increase in survival rate [197]. Currently radiation is rarely used as first 
line therapy for ovarian cancer treatment. It is possible that combining radiotherapy and 
chemotherapy can improve disease control in patients with stage I or those with chemo 
resistance. Radiation can be achieved by external Deep X-ray therapy to one side of the 
pelvis, protecting the epsilateral hemi pelvis and thus protecting the other ovary and head of 
the femur. The other method is intraperitoneal instillation with radiocolloid agents which had 
been previously used for the treatment of patients with stage I ovarian cancer. However, it 
was did not decrease rates of relapse or improve survival rates [198]. 
Generally, this type of treatment is considered out of date because of the small number of 
patients that may benefit from it. Additionally, the patients are showing better tolerance to the 
new chemotherapeutic agents [199]. 
1.6.4 Hormone therapies 
Several hormonal agents have been investigated in the treatment of advanced ovarian 
cancer. Studies on anti-estrogenic and aromatase inhibitors have been done on patients with 
recurrent ovarian cancer that show resistance to platinum group chemotherapy [200]. 
Aromatase inhibitors lead to short-term stabilisation of the recurrent disease in 50% of heavily 
treated patients [201, 202]. This was aimed at patients who have recurrent elevated tumour 
markers following initial remission of stage III and IV ovarian epithelial cancer [203]. 
Preclinical studies have shown that agents such as tamoxifen can inhibit the growth of ovarian 
cancer cells in vitro which provided a base for further investigation [204]. Hormones or 
hormone blocking agents may be used for the treatment of some ovarian cancers including 
ovarian stromal tumours. Oestrogen stimulates cancer cell growth through oestrogen receptors 
(ER) which are overexpressed in 36% of ovarian cancers [205].  
Some available hormone therapies were approved by the FDA for the treatment of several 
cancers; these include drugs such as luteinising-hormone-releasing hormone agonist (LHRH), 
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also known as gonadotropin releasing hormone agonists (GnRH). The function of this group 
of drugs is reducing oestrogen release from the ovaries in pre-menopausal women. Several 
adverse effects were seen on patients including menopausal symptoms such as hot flushes, a 
dry vagina and osteoporosis. The latter occurs with prolonged administration. Another 
example is Tamoxifen; this treatment is mainly used for breast cancer and ovarian stromal 
tumours but rarely for advanced epithelial ovarian cancer. Tamoxifen is an anti-oestrogen 
agent that inhibits the stimulatory effects of circulating oestrogen. It shows similar side effects 
as the GnRH agonists except for the osteoporosis. However, it may increase the risk of 
serious deep vein thrombosis. Aromatase inhibitors including Letrozole (Femara), 
Anastrozole (Arimidex) and Exemestane (Aromasine) elicit a good anticancer response and 
have stabilised recurrent disease in patients with positive ER tumours. They function by 
blocking the enzyme aromatase which converts other hormones to oestrogen in post-
menopausal women. These have been mainly used in breast cancer as well as relapsing 
ovarian stromal tumours following initial treatments (e.g. surgery and chemotherapy) [202, 
206]. Adverse effects from the use of aromatase inhibitors include hot flushes, nausea and 
skeletal pain (muscles and joints), osteoporosis and bone fracture in prolonged use of 
treatments [203]. Hormone therapies are sometimes considered to be part of targeted 
therapies. 
1.6.5 Immunotherapy 
Immunotherapy involves the modulation of the immune system and is based on the theory 
that the immune system can recognise and destroy malignant cells as foreign bodies. New 
research is suggesting that it may be possible to overcome chemotherapy resistance in ovarian 
cancer by combining immunotherapy with chemotherapy [207]. There are two types of 
immune cells that have been investigated, fibroblasts (the stroma) and immune T cells. 
Fibroblasts lead to cisplatin resistance by releasing two components: glutathione and sesteine. 
Adding immune T cells to the fibroblasts can lead to disintegration of tumours. The T cells 
alter the metabolism of glutathione and sesteine in the fibroblast [208].  
Trials of vaccinations of ovarian cancer patients with a variety of antigens including MUC-1 
carbohydrate epitope (P53 peptide) and HER-2 peptide have emerged as promising methods 
of treatment [70]. Clinical trials using whole tumour cells as vaccine means immunising 
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against many antigens at the same time, however, no promising results have as yet been 
achieved with this method [209]. 
The in vitro generated tumour reactive T cells are used to test for the ability to identify intact 
cancer cell antigen found on cancer cell surface. New methods of treatment of cancer have 
been investigated, such as immunisation of patients with variety of immunogens. Because of 
delayed response to immunotherapy (tumour regression) there is confusion over the efficacy 
of cancer immunotherapy. This may be due to the use of inappropriate animal models in 
studies [210, 211]. 
 
 
1.6.6 Targeted Therapy 
In the past decade, targeted therapy has emerged as a novel anti-cancer treatment that aims 
to inhibit specific proteins involved in carcinogenesis, tumour growth and angiogenesis The 
goal is for these treatments to be more effective than current treatments and to be less harmful 
to normal cells and thus cause less systemic toxicity [212]. The chosen targets are usually 
over expressed in cancer cells compared to low or no expression in normal cells, therefore the 
drugs have minimal effect on normal cells. Examples are the variety of targeted anti-cancer 
agents that are designed to block EGFR and HER-2. These include monoclonal antibodies 
(trastuzumab and cetuximab) and small synthetic inhibitors (gefitinib, erlotinib, lapatinib, 
canertinib, afatinib and dacomitinib) [213-223]. 
One of the most studied cell signalling pathways is the PI3K/Akt pathway, which has been 
shown to be important in many cellular processes [224], and found to be deregulated in many 
cancer cells including those in the ovary [106, 225]. Numerous PI3K inhibitors have been 
investigated as potential agents of targeted therapy and these have shown anti-tumour 
activities as single agents, or when used in combination with chemotherapy, in both in vivo 
and in vitro ovarian cancer models [226, 227]. The inhibitors of PI3K have shown good 
outcome in both PI3K mutant and wild type tumours in several cancers including breast and 
colorectal cancers [228, 229]. For example an orally available pan PI3K inhibitor, BKM120 
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was shown to have anti-tumour effects in a phase I/II clinical trials in several xenograft 
models of advanced solid tumours [230-232]. 
Poly (ADP-ribose) polymerases (PARPs) are a group of catalytic molecules involved in in 
numerous cellular activities including cell cycle progression, DNA repair and genomic 
stability [233]. PARP inhibitors have been shown to induce anti-tumorigenic activities in 
BRCA-1 and BRCA-2 mutant breast and ovarian tumours [234, 235]. A response rate of 30-
45% to PARP inhibitors such as Olaparib was observed in platinum sensitive relapse cases of 
high grade serous carcinoma carrying mutations in BRCA1/2 [236, 237].  
Olaparib is an FDA approved targeted therapy for advanced ovarian cancer patients with 
BRCA1/2 mutations [238]. The poor response from a fraction of ovarian cancer patients with 
BRCA1/2 led Wang and colleagues to suggest combining PI3K with PARP inhibitors in 
ovarian cancer cell lines that have mutant or wild type PI3K [239]. In another study, the same 
authors demonstrated the effectiveness of this combination in ovarian cancer cell lines with 
wild type PI3K and suggested that concomitant downregulation of BRCA expression may 
probably be a biomarker for a patient’s response to combined inhibition of PI3K and PARP in 
ovarian cancer [240]. 
Certain small synthetic molecules have been used as targeted drugs in clinical trials and this 
class of compound is of interest in the research described in this thesis. There are many small 
molecule inhibitors that have been approved by the FDA, these have been shown to be 
efficient in inhibiting the activity of the receptors in patients with breast, endometrial, colon 
and non-small cell lung cancer [241, 242]. These inhibitors target EGFR and HER-2 and 
include gefitinib and erlotinib, which are first generation reversible inhibitors of EGFR. These 
block EGFR activity, phosphorylation and downstream signalling molecules [243]. Afatinib 
and dacomitinib are second generation small molecule inhibitors that block EGFR and HER-2 
by forming a covalent bond at the ATP binding site. These second generation inhibitors are 
irreversible, inhibit multiple EGFR family receptors and have high affinity for the binding 
sites. Therefore, they are suggested to be more efficient than first generation inhibitors [221, 
244]. 
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The first generation small molecule tyrosine kinase inhibitor canertinib (Figure 1.5. [245]), 
is an irreversible, pan EGFR inhibitor that permanently binds intracellularly to the ATP 
binding site of all 4 members of EGFR receptor tyrosine kinase family [245-247]. These two 
characteristics of canertinib (being a pan inhibitor and irreversible) increase the efficacy of the 
drug and these ensure prolonged availability in the system in addition to meaning that lower 
doses of the drug are effective [218]. Canertinib has shown anti-tumour activity in both in 
vitro and in vivo studies [248, 249] and has also shown dose-dependent inhibition of tumour 
growth in murine models [250, 251]. It has shown anti-tumour activity in both in vitro and in 
vivo animal models of breast cancer [248], and phase II studies with NSCLC and breast 
cancer are ongoing. However, in trials with ovarian cancer canertinib has exhibited limited 
efficacy when used as a single agent [219].  
PHA665752 is a second generation small molecule reversible c-MET receptor tyrosine 
kinase inhibitor (with the structure shown in Figure.1.6). It inhibits ATP binding to the 
tyrosine kinase domain of the receptor, down regulating its phosphorylation and thus 
impairing cell growth, proliferation and migration, leading to apoptosis in in vitro cell culture 
models of oesophageal, gastric and NSCLC cancers [252-254]. Several in vivo studies have 
shown that PHA665752 inhibits c-MET phosphorylation and cell growth of tumour 
xenografts in athymic mice [255, 256]. Recently, PHA665752 was also suggested to work in 
combination with cisplatin and appears to reverse resistance to cisplatin in SKOV-3, 
OVCAR-3 and OV-90 ovarian cancer cell lines [257]. Furthermore, Jia and colleagues [258] 
demonstrated that a combination of PHA665752 with cetuximab inhibited in vitro and in vivo 
growth of human colorectal cancer cells [258]. 




Figure 1.5. Chemical structure of canertinib Figure 1.6. Chemical structure of PHA665752 
There have been numerous reports of clinical trials using a combination of small molecule 
tyrosine kinase inhibitors for chemotherapy [259-264]. In a phase I clinical study of solid 
tumour cancers, canertinib in combination with docetaxel (which is effective against breast, 
NSCLC, advanced stomach, head and neck and metastatic prostate cancer) exhibited anti-
tumour effects with complete response from patients with cervix uteri cancer and a partial 
response from NSCLC [263]. To evaluate the tumour response to treatments, the authors used 
the Response Evaluation Criteria for Solid Tumours [265] and were able to categorise the 
changes in tumour size to: complete response, partial response, stable disease, and progressive 
disease ( where the appearance of new lesions is also considered) [263]. 
 A phase 3 trial study in HER-2 overexpressed breast cancer patients [266] has shown that 
combining Herceptin, also known as trastuzumab, (an anti-HER-2 monoclonal anti-body), 
with standard chemotherapy was more effective than single agent treatments [266]. The 
antibody has previously been shown to exhibit synergistic effects with cisplatin and 
carboplatin [267, 268], docetaxel [269], doxorubicin, paclitaxel, methotrexate and 
cyclophosphamide [268-272] in in vitro and pre-clinical studies [273, 274].  
In a pre-clinical study by Ciardiello et al., 2001, gefitinib (Iressa) an EGFR small molecule 
inhibitor enhanced the anti-tumour effects of taxanes and of platinum compounds [275]. 
Others have shown that a combination of BKM120 (a PI3K inhibitor) and Olaparib (a PARP 
inhibitor) may be effective in suppressing growth of ovarian cancer cells [240]. In view of the 
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effectiveness of such combinatorial approaches, this thesis will investigate the efficacy of 
combining two receptor tyrosine kinase inhibitors, canertinib and PHA665752 on growth, 
metabolism and adhesion of two advanced ovarian cancer cell lines in a novel 3 dimensional 
(3D) cell culture model to simulate the in vivo microenvironment. 
1.7 Cell Signalling in Cancer Cells 
Many cellular activities are regulated by an intricate system of interacting signal 
transduction pathways [276]. These include cell growth, proliferation, metastasis, and cell 
death. Signals from the extracellular environment are transmitted into the cells via 
transmembrane receptors or through the utilisation of membrane permeable ligands. Ligands 
can be growth factors, extracellular matrix components and/or cell adhesion molecules. The 
ligands bind to the extracellular domains of their specific receptors while other ligands bind to 
the cytosolic portion of the receptor by diffusing through the plasma membrane and binding 
to the receptors in the cytoplasm [277]. As a consequence, conformational changes of the 
receptors occur, resulting in dimerisation and subsequently autophosphorylation of the 
intracellular domains; e.g. the binding of c-MET receptor tyrosine kinase with hepatocyte 
growth factor (HGF) ligand [278]. Autophosphorylation in turn stimulates the transmission of 
specific signals that lead to the formation of different protein-complex molecules and their 
corresponding second small-molecule messengers [277]. The combination of the signalling 
cascades within the cells gives optimum cellular response that eventually cause cell growth, 
proliferation, and invasion [279]. Cell signalling in ovarian cancer envolves many types of 
receptors including nuclear hormone receptors, type 1 cytokine receptors as well as tyrosine 
kinase receptors. Nuclear receptors a intracellular proteins that are responsible for sensing of 
steroid and thyroid hormones and other molecues. They also participate in the regulation of 
the expression of specific genes. These receptors directly bind to DNA regulating the 
expression of adjacent genes. The focus of this thesis will be on tyrosine kinase receptors. 
In cancer cells genes undergo mutations that may affect the signalling pathways either by 
upregulation or inhibition, for example amplification of EGFR and HER-2 receptor tyrosine 
kinases in ovarian cancer is thought to enhance tumour cell growth [280].  Amplification of 
the HER-2 oncogene in breast and ovarian cancer have also been linked to tumour progression 
and constitutive activation of cell survival signal transduction pathways [281]. In follicular 
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lymphomas and chronic lymphocytic leukaemia, cancer cells may also evade programmed 
cell death by amplification of BCL2 which in turn blocks apoptotic downstream signalling 
pathways [281]. 
1.7.1 Receptor Tyrosine Kinases 
Receptor tyrosine kinases are a family of high affinity cell surface receptors for many 
cytokines, poly peptides, hormones and growth factors [218, 282]. Examples of receptor 
tyrosine kinases include epidermal growth factor receptors family (EGFR, HER-2, HER-3 and 
HER-4), mesenchymal epithelial transition factor (c-MET), insulin receptors (InR), and 
Platelet-derived growth factor receptors (PDGFR). They have been shown to not only be key 
regulators of normal cellular regulatory processes but also play a critical role in the 
development and progression of many types of cancers [283]. These receptors comprise three 
domains, an extracellular domain, a transmembrane domain and a cytoplasmic domain which 
represents the catalytic core and regulatory sequence [277, 284]. 
As detailed in section 1.9, once activated, either by binding to growth factors or by somatic 
mutation, receptor tyrosine kinases undergo hetero or homo dimerision and leading to 
conformational changes and auto phosphorylation and activating the cytoplasmic tyrosine 
kinase domain. Tyrosine phosphorylation is suggested to be a requirement for activation of 
these receptors to trigger cascades of intracellular signalling proteins that are recruited to 
promote cell growth, DNA replication and cell division [285]. Dysregulation of these 
receptors has been linked to the development of several types of malignancies. Therefore, 
these proteins have become a key target for cancer chemotherapy [218].  
1.7.1.1 ErbB (Her-B) Family of Receptor Tyrosine Kinases 
The ErbB family of receptor tyrosine kinases regulate cell growth, survival, proliferation, 
migration and differentiation. They are encoded by four genes: epidermal growth factor 
receptor (EGFR or ErbB1 (Her-1), human epidermal growth factor 2 (ERBB2 or HER-2/neu), 
ERBB3 (HER-3), and ERBB4 (HER-4). These transmembrane receptors have a molecular 
weight of  between 170 and 185 kDa [286] and in the ovaries play a key role in the 
development of normal ovarian follicles and regulate the growth of the ovarian surface 
epithelium [287]. Aberrant catalytic activity that may occur through mutation or over 
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expression of these receptors can play a pivotal role in cancer progression [288]. This family 
of receptors have shown elevated expression in several types of cancer including NSCLC 
[289], breast [246, 248], prostate [290], head & neck [291], brain [292] and stomach cancer 
[293] as well as ovarian cancers [294].  
EGFR was the first member of the tyrosine kinase receptor family to be identified [295]. It 
interacts either with another EGFR (homodimerisation) or with other members of the family 
HER-2, HER-3 and HER-4 (heterodimerisation) [286, 296]. Upon binding with its ligand, 
EGF, homo-dimerisation of EGFR (or hetero-dimerisation with other members of the family) 
occurs, and this promotes auto phosphorylation of the receptor and downstream signalling 
proteins [297]. ERBB2 has no known ligand and the activation is triggered via hetero 
dimerisation with other ERBB family members. However, the active kinase domain in 
ERBB3 facilitated the heterodimerisation with ERBB2 making it the preferred partner for 
ERBB2 sharing each other's active domains to activate transphosphorylation of the tyrosine 
kinases [298]. 
Amongst these signalling molecules are RAS/RAF/ Mitogen-activated protein kinase 
(MAPK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of 
rapamycin (mTOR) which regulate cell adhesion, proliferation, differentiation, apoptosis, and 
metastasis [299] (Figure 1.7). 
The Human Epidermal Growth Factor Receptor 2 (HER-2), also known as neu does not 
have a naturally binding ligand, but it may be constitutively activated or co-activated with 
EGFR to form a hetero- or a homodimer [84] and this partnering is suggested to inhibit EGFR 
degradation [300, 301]. This complex will auto-phosphorylate through its tyrosine kinase 
activity. It will then consequently activate the downstream signalling proteins [84, 302]. 
HER-2 receptors have been implicated as key drivers in cancer development and resistance to 
therapy in breast [303], colon [304], liver and ovarian cancer [305, 306] and their 
overexpression is a poor prognostic factor [86, 305]. Therefore, they have become a target for 
the development of anti-cancer treatments [307-309].  
Abnormal expression of EGFR and HER-2 in cancer cells has been reported in 60% of 
ovarian cancers and in almost all histologic subtypes [310-312] and this has been found to be 
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correlated with a poor prognosis in several types of cancers [302, 305, 313, 314]. The 
mechanisms underlining the activation of EGFR include gene amplification, overexpression 
and deletion of the extracellular domain. The latter will induce constitutive activation of the 
receptor [315]. HER-2 mutations in such as increased copy number have been reported in 
many cancers including ovarian cancer are mostly expressed as gene amplification and 
protein overexpression [316, 317]. Since tumours tend to express high levels of EGFR, more 
EGF binds to the cancer cells promoting cell survival, proliferation [318, 319], and migration 
[320]. EGFR and HER-2 have therefore been suggested as potential targets for the treatment 
of ovarian cancers that express high levels of these receptors [309, 321].  
 
Figure 1.7 EGFR and c-MET signalling pathway. Dimerisation of EGFR and c-MET upon 
ligand binding leading to the activation of the relevant downstream intracellular proteins 
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involved in cell survival, proliferation and migration. Image adapted from Wang et al. with 
permission from the authors [322].  
 
1.7.1.2 The c-MET receptor tyrosine kinase 
The c-MET proto-oncogene is mostly found in epithelial cells [323-327], however it can be 
also be expressed in muscle cells, cytotrophoblasts, neurons, endothelial cells and 
macrophages [328-331]. The protein it encodes is an hepatocyte growth factor receptor that is 
associated with cancer progression and contains a tyrosine kinase domain that activates 
signalling pathways involved in cell proliferation, motility, adhesion, and invasion [332]. The 
c-MET signalling pathway plays a critical role in the growth, migration and spreading of 
ovarian cancer cells [323, 333-336]. The c-MET protein is comprised of two subunits; an α 
subunit of 145-kDa and a β subunit of 50-kDa (Figure 1.8 a) [337].  
Following binding of HGF to its receptors, this binding initiates dimerisation of the 
receptors and autophosphorylation of tyrosine residues occur. First, the phosphorylation of 
residues Y1234 and Y1235 is then followed by residues Y1249 and Y1356 leading to the 
transmission of signals to downstream molecules. The overexpression of c-MET has also 
been correlated with poor prognosis in various cancers [338-343]. Reports suggest that high 
expression of c-MET is found in 11% -60% of epithelial ovarian cancers [333, 344] and some 
studies suggest that c-MET is overexpressed in the majority of ovarian cancers [288]. 
Treatment with c-MET inhibitors has been shown to significantly reduce tumor burden, 
ascites formation, protease activity and the number of peritoneal implants in an animal 
xenograft model [256, 345]. Despite this however, there are no reported notable changes of 
tumour size or angiogenesis. It has been suggested that c-MET overexpression is a prognostic 
factor in ovarian cancer and that targeting c-MET in vivo may inhibit peritoneal dissemination 
and invasion [334, 346]. 
 The c-MET receptor can interact with EGFR/HER-2 suggesting that a mutual dependency 
may exist between these receptors [347, 348]. However, the exact mechanism by which 
potential co-activation may elicit the progression of ovarian cancer is still unclear. However, 
the fact that all three receptors can be overexpressed in ovarian cancer [29, 288, 349] suggests 
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a possible opportunity of a novel approach of treatment by combining two types of inhibitors. 
Targeting all three receptors may increase the longevity and potentially the survival rate of 
advanced ovarian cancer patients. These receptors normally have low expression in non-
cancerous cells and so the inhibitors should have less of an impact on normal cells. 




Figure 1.8. The structure of MET and its specific ligand HGF. a) The structure of MET, 
showing the phosphorylated tyrosine residues (Y1234, Y1235, Y1349 AND Y1356) in the 
tyrosine domain subsequently to HGF stimulation shown in blue. b) The structure of HGF 
before and after cleavage with matriptase, c) The crystal structure of the binding complex of 
HGF-MET. Red balls indicate the missense mutations found in cancer patients. Image taken 
with permission from the author Dr Donald Bottaro (NIH/NCI) [337]. 
 
1.7.2 Integrins 
1.7.2.1 Integrins Structure and Binding Properties 
Integrins are proteins that link the cytoskeleton with components of the ECM. They exist as 
heterodimers that are comprised of one α and one β subunit. They play an important role in 
numerous cellular processes including mediation of adhesion, migration, proliferation, 
differentiation and apoptosis. In addition to their adhesive capabilities, through 
conformational changes they are able to facilitate both inside-out and outside-in signalling 
across the plasma membrane. As detailed below they can play an important role in advanced 
stages of cancer. 
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In total there are 18 different integrin α subunits and 8 different β subunits that can dimerise 
non-covalently to form at least 24 distinct integrins which are capable of binding to different 
components of the ECM (as detailed in Table 1.3) [350, 351]. The α and β subunits each have 
a single transmembrane domain (TMD) comprised of at least 700 amino acid residues, a 
transmembrane helix, and a short cytoplasmic domain comprised of <50 residues (figure 1.8). 
The β4 integrin subunit differs in that it has a longer cytoplasmic domain of >1000 amino acid 
residues [352-354]. The cytoplasmic tale of integrin subunit β4 is believed to be the mediator 
of the association of the integrin with hemidesmosomes [355] in both in vitro cell culture and 
in vivo studies unlike β1 which is found located in the focal adhesion linked to actin filaments 
[356]. Integrins are able to undergo conformational changes and also to cluster with other 
integrins and receptors [357-359]. 
1.7.2.2 Integrin activation  
Integrins can exist in bent, open extended and closed extended conformations (Figure 1.8). 
Previously, what was described as the bent conformation of integrins was thought to be the 
active form [360]. However, it was later shown that the bent structure is the inactive state and 
in order to be activated, the integrin needs to extend in shape and separate the “legs” in a 
process referred to as “switch blade” opening [361]. Takagi and colleagues demonstrated that 
the integrins in the inactive state mainly embrace the bent shape while activation of integrins 
with Mn
2+ 
or cRGD will force the integrin to extend. They suggested that integrins are trapped 
in the bent shape by a disulphide bond which is broken upon activation to release the integrin 
[362]. Hynes and colleagues introduced the “angle-Poise” model suggesting that when 
inactive, the legs are bent close to the membrane while during activation the integrin will 
extend like an angle-poise lamp. This in turn will enhance the interaction with 
macromolecular ligands [363].  
1.7.2.3 Integrins and cancer 
It has been suggested that certain integrins may be highly expressed in cancer cells [364, 
365] and this overexpression is associated with poor disease outcome and more aggressive 
metastasis [365-367]. Cell adhesion to the ECM is essential for cellular response to certain 
growth factors and vice versa these growth factors regulate the integrin-mediated cell 
adhesion and invasion [368]. Some studies have shown the synergistic effect and crosstalk at 
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the intracellular signalling pathway levels of the growth factor receptors and integrins [369, 
370]. In particular this effect may involve interactions with receptor tyrosine kinases. Co-
localisation studies suggest that integrins may associate with EGFR, HER-2 and c-MET [29, 
371-374] and this may influence migration and metastasis through the mesothelial lining of 
the peritoneal cavity [370, 375, 376].  
A pertinent example is the α6β4 integrin that is found in hemidesomosomes, cell-ECM 
attachment structures that link epithelial cells to the basal lamina [377]. The β4 subunit has a 
big cytoplasmic tail that is crucial for the assembly of hemidesmosomes [378]. Upon ligation, 
tyrosine phosphorylation of integrin α6β4 can fully activate the ERK and PI3K signalling 
molecules through the activation of integrin signalling pathway involving molecules such as 
Sch, Ras and Rho [379].  
This subunit can be associated with EGFR/HER-2 receptor tyrosine kinases and the large 
cytoplasmic domain can become phosphorylated at several tyrosine residues upon activation 
of EGFR or binding to laminin 5 [380]. Thus a complex formed between EGFR and α6β4 
which can cause the disassembly of hemidismosomes [173, 376, 380]. This disruption is 
thought to be a prerequisite for cell migration and invasion [376].  
Ligand independent activation of the c-MET receptor tyrosine kinase has also been found 
highly dependent on integrins [381]. The crosstalk between c-MET and integrins is mainly 
regulated by many downstream signalling proteins including FAK [382]. 
Integrins commonly bind to components of the ECM at an RGD motif and as such studies on 
the inhibition of integrins have typically involved RGD containing peptides [383-385]. These 
have also been investigated with respect to cancer and a number of RGD-based (Arg-Gly-
Asp) integrin inhibitors with low molecular weight have been have been approved for the 
treatment of several cancers [354]. Cilengitide, for example, is highly active against αvβ3 
integrins with an IC50 = 0.6nM, which is in clinical trials for the treatment of several cancers 
[354]. However, these peptides show poor oral bioavailability and are usually quickly 
excreted.  
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Table 1.3. Integrin subunits and their suggested protein ligands. The table shows the 8 β and 
18 α integrin subunits with different combinations of the two subunits and the different ECM 
protein ligands [377]. 
 






































Collagens, Fibronectin, Vitronectin, Fibrinogen, Thrombospondin 
Fibronectin, Vitronectin, Fibrinogen, Thrombospondin 
β4 α6 Laminins 
β5 αv Vitronectin 




Fibronectin, VCAM, MAdCAM 
E-cadherin 
β8 α6 Collagens, Laminins, Fibronectin 
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Figure 1.8. Integrin overview and complexes for ECM. The conformational changes of 
integrin. Dash lines show alternative conformations of the lower β leg, Calf1 and 2 are 
domains on the integrin subunit [386]. Image adapted and modified with permission from the 
correspondent author Dr. Donald P. Bottaro.  
1.8 Growth Factors 
Growth factors are polypeptides, which exert binding to their receptors and set off signal 
transduction cascades that regulate cell proliferation, motility and differentiation [387, 388]. If 
their receptors are present in abnormal levels, the growth factors can play a pivotal role in the 
establishment of METastatic microenvironment [389]. Examples of well-known growth 
factors are hepatocyte growth factor (HGF), epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth 
factor (TGF)-beta [153, 390]. 
1.8.1 Epidermal Growth Factor (EGF) 
Epidermal growth factor is a 6-kDa protein [391] of approximately 40 amino acid residues 
which contains 3 disulphide bonds [392, 393]. It is a potent mitogen that plays a crucial role 
in cell growth, differentiation, invasion and angiogenesis [394, 395]. EGF belongs to the same 
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family as transforming growth factor-α (TGF-α), heparin-binding EGF like growth factor 
(HB-EGF) and epidermal growth factor (EGF) [392]. These are derivatives of a glycoprotein 
precursor type-I that is composed of extracellular, transmembrane and cytoplasmic domains. 
To become biologically active these precursors undergo proteolytic changes [396].  
EGF acts as a ligand for the ErbB family of receptor tyrosine kinases triggering 
autophosphorylation of several tyrosine residues, thus stimulating the phosphorylation of 
downstream  signalling molecules [397]. The mechanism of EGF-EGFR binding is an 
asymmetric dimerisation [280, 398, 399]. The EGF-EGFR complex will bind to another 
receptor monomer (forming a homodimer or heterodimer) before binding to the second EGF. 
This in turn will cause conformational changes to the receptor prompting the kinase activity 
and autophosphorylation of the intracellular domains of the homodimers or heterodimers 
[397, 400]. EGF can bind to low and high affinity sites on cells with aberrant EGFR 
expressions [401]. High affinity binding is thought to be regulated by intracellular signalling 
proteins interacting with the intracellular tyrosine kinase domain of the receptor [402-404]. 
EGF has also been shown to stimulate the migration, invasion and metastasis of ovarian 
cancer cell lines through Matrigel [405]. 
1.8.2 Hepatocyte Growth Factor (HGF) 
Also known as scatter factor, HGF is a potent mitogen derived from mesenchymal cells that 
is responsible for mediation of stromal-epithelial cell interactions and communication in 
several organs including the ovaries [406, 407]. It is thought to induce cancer cell invasion in 
the tumour microenvironment by working as a stromal cell-derived factor [408]. This 
polypeptide is originally secreted as single chain precursor which is then cleaved 
extracellularly by serine proteases into two subunits  and Figure 1.8 b) [409]. The α sub 
unit is a 69-kDa polypeptide and the β sub unit is a 34-kDa polypeptide linked with a 
disulphide bond [410-417]. It binds specifically with high affinity to the c-MET receptor 
through the N-terminal and first kringle domains (NK1) and low affinity through the chain 
(Figure c[418]. Once bound to the receptor, HGF will activate a cascade of intracellular 
signalling pathways that regulates cell processes including cell growth, differentiation, 
migration, proliferation and survival [389]. In many types of tissues, including the ovary, 
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HGF is considered a mediator of mesenchymal-epithelial cell communications [406, 407, 
419].  
The ovaries regulate the expression of HGF through estradiol and Human Chorionic 
Gonadotropin (HCG) [406]. It is also pivotal for organogenesis in the early developing 
embryonic stage as well as tissue repair from organ diseases later in life [417, 420]. Ovarian 
cancer cells secrete HGF which can stimulate peritoneal implantation by inducing 
mesothelial-mesenchymal transition of the peritoneum [389, 418]. Expression of HGF was 
reported in normal ovarian cells of epithelial origin and benign ovarian tumour cells [421], 
and higher expression was found in ovarian carcinoma cells [422]. In an 
immunocytochemistry analysis of tissue from ovarian cancer cases, researchers found high 
expressions of HGF [175]. This high expression suggests an important role in the onset of 
ovarian cancer and tumour progression by stimulating the abnormal cell proliferation and 
metastasis [389]. Other cancer cells including breast [423] and lung [424] cancers are also 
known to secrete high levels of HGF. 
1.8.3 Vascular Endothelial growth factor (VEGF) 
Previously, VEGF was recognised as an endothelial cell-specific mitogen that played a 
crucial role in physiological and pathological angiogenesis and vascular permeability [425, 
426]. However, it was later discovered that VEGF can be a key driver in cancer cell 
migration, invasion and survival of tumour cells and is associated with poor disease outcome 
[427]. The potent pro-oncogenic cytokine stimulates vascularisation and angiogenic processes 
[428, 429]. VEGF was shown to target not only endothelial cells, but rather other cells in the 
tumour microenvironment including immune cells [430].  
The ovaries, being distinct from other endocrine organs, require angiogenesis within their 
various compartments [431]. This means that the production of VEGF is crucial for normal 
reproductive function [432]. Also associated with ovarian pathogenesis, VEGF levels in 
ovarian cancer-induced malignant ascites are significantly higher compared to those in non-
malignant ascites [433]. Ovarian tumours are known to be highly vascularised neoplasms 
predominantly reliant on VEGF-mediated angiogenesis [434]. Hence VEGF has been shown 
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to play a critical role in the peritoneal dissemination of ovarian cancer and the development of 
malignant ascites [153]. 
VEGF binds to vascular endothelial growth factor receptors (VEGFR), which are receptor 
tyrosine kinases found overexpressed in most solid malignant tumours [435]. VEGF is a 
critical molecule for angiogenesis and its specific receptor, VEGFR2 is a key regulator of the 
proliferation, differentiation and invasion of endothelial cells and most importantly 
microvascular hyper permeability, the first step towards angiogenesis [436]. In addition to 
inducing vasculature, VEGF produced by tumour cells works in an autocrine loop by binding 
to the highly expressed VEGF receptors on tumour cells [430]. These receptors are present at 
low levels in normal cells while in cancer cells they have high expression [437]. This means 
that more VEGF will bind to its receptors on cancer cells therefore  promoting cell survival 
[438], proliferation [318, 319], and migration [439]. Consequently, treatment schemes that 
involve inhibition of VEGF may be beneficial for ovarian cancer patients. 
1.9  Ovarian cancer cell lines and molecular subtypes  
The development of in vitro tumour cell cultures has greatly enhanced research into cancer. 
Tumour cell lines have been developed and used as models to increase our understanding of 
the various aspects of disease progression. However, the drawback of using cell lines is that 
they may not accurately represent the in vivo situation. Nevertheless, the in vitro models have 
been the first line of tools to investigate the response of tumour cells to anti-cancer drugs. 
In the process of cell line selection for preclinical settings that model newly-discovered 
molecular sub-groups, the integration of gene expression data sets is of most 
importance.[440]. This is of specific significance in any ovarian cancer in vitro research given 
the heterogenous nature of the disease. 
One of the important characteristics of ovarian cancer cells is the diversity of mutations that 
can accumulate leading to their development. These define the molecular subtypes and the 
behaviour of these cells . Low grade ovarian serous carcinomas, for example, are categorised 
as type I ovarian tumours which have mutations in PIK3CA, PTEN, KRAS, BRAF and 
CTNNB1. Cell lines that express these mutations are known as type I tumour cells. High grade 
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serous ovarian carcinoma cells have TP53 and BRCA1/2 mutations and fall under the type II 
molecular subtype.  
However, unrelated model systems do offer an incentive for investigation of biochemical 
processes but particular cellular context needs to be applied to assess relevant therapeutic 
strategies. The HGSC cell lines may not have the mutations in RTK [441]. 
Recently, Ince and colleagues [442] characterised 25 ovarian cancer cell lines that 
phenocopy primary tumours and highlighted the importance of culture medium in the use of 
cell lines. In their study they collected 90 tumour samples from 67 patients with 44 serous, 2 
clear cell, 2 endometrioid and 3 mixed mullerian cancers, in addition to 16 specified 
adenocarcinomas. They proposed that the cell culture medium, being a rich environment with 
artificially added ingredients such as tissue extracts, antibiotics, serum, and feeder layers may 
induce biological variability and confound cytostatic assays. In light of this they developed a 
highly efficient cell culture system that was thought to preserve the original tumour phenotype 
with over 80 ingredients for providing essential nutrients for maintaining basic cellular 
metabolism [443]. They concluded that given appropriate condition it was possible to 
establish a comprehensive ovarian carcinoma cell panel from the tumours of advanced 
ovarian cancer patients, and established a culture medium that highly maintains the phenotype 
of the original tissue. 
The cancer genome atlas (TCGA) published a molecular description of over 500 tumour 
tissue types and the broad-Novartis Cancer Cell Line Encyclopaedia (CCLE), introduced a 
systemic evaluation of the tumour types and cell lines’ diverse molecular heterogeneity 
regarding the level of DNA copy number and the intensity of mutations [80, 444]. Based on 
these two reports, Domcke and colleagues have evaluated selected ovarian cancer cell lines 
and their mimicking of tumour models [445]. Focusing on high grade serous ovarian 
carcinoma cell lines, they showed that there were several cell lines, which have been 
extensively used in ovarian cancer research as models of HGSOC but that these they may 
have actually originated from a non-ovarian origin and thus may be a poor representative of 
HGSOC.[445].  
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Among the cell lines indentified by Domcke et al. were SKOV-3 cells which have been used 
in this thesis. SKOV-3 cells were shown to have a flat copy-number profile, null P53, and 
other mutations such as ARIDA, BRAF, PIK3CA and PTEN. While it can be argued that these 
molecular profiles do not match the HGSOC profile [441, 445, 446], SKOV-3 cells are a 
close representative of the ovarian clear cell carcinoma subtype, which shows an aggressive 
phenotype and for which currently there is no effective chemotherapy that can improve the 
survival of patients with ovarian clear cell cancer. 
The basis for using SKOV-3 in this thesis was the aberrant expression of the receptor 
tyrosine kinases, EGFR, HER-2 and c-MET which makes this cell line a good candidate in 
vitro model to study these receptors in terms of inhibition with TKIs, as well as their 
association with integrins and roles in cell adhesion. Tumour suppressor gene (TP53) is often 
deregulated in the tumorigenesis of many tumours including ovarian tumours [447] and is 
proposed to play a crucial role in the development of ovarian cancer [447]. 
In contrast, OVCAR-5 cell lines show P53 mutations with low expression of HER-2. 
Moreover, both cell lines are able to form 3 D cell clusters and spheroids that mimic the 
floating clusters and aggregates that are seen in malignant ascites from ovarian cancer 
patients, and thus these two cell lines were chosen as the molecular subtypes for this study. 
1.10  3-Dimensional microenvironment 
In many studies 2-dimensional cell culture models have been used for in vitro cell culture 
research and these have played a critical role in the development of anti-cancer drugs [448]. 
However, the 2 D monolayers may not faithfully replicate the properties and behaviour of 
cancer cells in the body with the result that the cellular responses to treatments in vitro were 
not replicated in the clinical setting [449]. There is evidence to suggest that 3-dimensional cell 
culture models may more accurately mimic the biological and physical properties of the cells 
in the in vivo microenvironment [450, 451]. Gene regulation and protein expression in cells 
that are part of a 3 dimensional cell suspension have been shown to be distinct from those in 
monolayer cell cultures [452, 453]. Additionally there are many other features that impact on 
cell behaviour such as mechanical forces and cell-cell and cell-ECM interactions which 
cannot be replicated in a monolayer [450, 454]. Recently, Lee and colleagues [450] described 
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several differences in cell morphology, adhesion, proliferation, division, heterogeneity and 
cell culture environment between free floating aggregates and monolayer cells [450]. These 
were: 
1) The 2D cells were flat and stretched while the 3D cultured cells maintained normal cell 
shape.  
2) Cellular adhesion occurred rapidly in 2D flat cells while the same process was much 
slower in the cell suspension.  
3) 2D cells showed a uniform proliferation rate that was faster than that of in vivo, however, 
3D aggregates showed a closer approximation to the in vivo rate  
4) 2D cells exhibited partial apical-basal polarisation whereas 3D aggregates displayed a 
more precise cell polarization.  
5) 2D cells were generally in the same state while cells in 3D suspensions were in distinct 
states such as quiescent, proliferating, apoptotic, necrotic and hypoxic cells and finally,  
6) Flat cells were exposed in equal measure to the growth media/treatments whereas this 
was not the case in 3D cultures where each cell essentially had their own microenvironment 
which mimics that of a tumour. [450].  
Furthermore, with respect to the current thesis ovarian cancer cells often form 3 dimensional 
cellular aggregates floating in the ascitic fluid and these are the major source of implantation 
and secondary tumour growth [455]. Thus it seems likely that studies of the effect of drugs on 
ovarian cancer cell lines should incorporate the use of 3D cell culturing techniques.  
1.11 The proposed research 
An anticancer drug, which inhibits the activities of cancer cell clusters/compact aggregates 
so preventing growth and adhesion onto peritoneal surface of internal organs, may have a 
significant clinical impact on the survival rate of women with ovarian cancer. EGFR 
inhibitors including gefitinib, erlotinib, and lapatinib have been used to fight several types of 
cancers and have shown that the use of a single agent inhibitor has a notable reduction of 
tumour progression and can increase survival rate of selected patients with minimal side 
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effects [456]. However, EGFR inhibitors have shown only modest clinical benefit in ovarian 
cancers [457]. Moreover, a combination of EGFR inhibitors with other cytotoxic agents has 
been found to be ineffective against ovarian cancer [458]. This lack of effect may reflect the 
possibility that the cancer cells may switch to alternative pathways, possibly by activating the 
c-MET receptors in order to overcome the inhibition of EGFR inhibitors.  
Given this, the effect of inhibition of c-MET will be investigated alongside EGFR inhibition 
in this project. The concept is that one-drug for one-target is not likely to be effective in 
ovarian cancer. The idea of using combined two or more targeted drugs, which exhibit 
inhibition of a broad range of receptors would be a more effective treatment. Canertinib is an 
irreversible pan-EGFR inhibitor. It has been shown to exert inhibitory effects on cancer cells 
which have high levels of EGFR and HER-2 proteins [247]. The rationale for using canertinib 
is that the drug can bind to both EGFR and HER-2 receptors permanently. Therefore, cellular 
activities of cell clusters/compact aggregates via EGFR/HER-2 receptors can be significantly 
reduced. Additionally the interaction of EGFR/HER-2 with the tyrosine kinase c-MET 
receptor needs to be explored and may introduce new aspects for treatments in advanced 
ovarian cancer.  
There are two important aspects of ovarian cancer that are of particular interest for this 
study. Firstly, the association between EGFR, HER-2 and c-MET and the survival process of 
the ovarian cancer cell lines in routine cell culture media supplemented with specific growth 
factors and in the ascitic fluid supplemented media will be investigated. Two advanced 
ovarian cancer cell lines will be cultured in non-adherent conditions to generate cell 
clusters/compact aggregates that mimic ascitic cell clusters. Secondly, the adhesion step 
which represents the early events of cancer cell attachment to the surface of the peritoneal 
membrane. The inhibitors of interest in this research are Canertinib (EGFR/ HER-2 inhibitor), 
and PHA665752 (c-MET inhibitor).  
1.12 Hypotheses  
- The combination of two receptor tyrosine kinase inhibitors (canertinib and 
PHA665752) will compromise cell growth, cellular metabolism, adhesion via 
mediating the activation of and EGFR, HER-2 and c-MET. 
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- Ascitic fluid will affect growth activity via EGFR, HER-2 and c-MET mediated 
activation and inhibitors will affect the activity. 
- EGFR, HER-2 and c-MET will play a role in cell adhesion process, which can be 
inhibited by blocking the receptors.
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2.1 Cell lines, media and chemicals 
Two human ovarian adenocarcinoma cell lines were used in this study, OVCAR-5 and 
SKOV-3, which were kindly provided by Dr. Kenny Chitcholtan, (Department of Obstetrics 
and Gynaecology, University of Otago, Christchurch). Cell lines were subject to STR and 
mycoplasma testing. Cell lines were as reported and there was no mycoplasma contamination.   
These cells were maintained in Dulbecco’s Modified Eagle Media: Nutrient Mixture F-12 
(DMEMF-12) (GIBCO
®
, Thermo Fisher, Auckland, New Zealand) and Minimum Essential 
Media (MEM) (GIBCO
®
, Thermo Fisher, Auckland, New Zealand), working media, 
respectively. For the base media, MilliQ water was autoclaved prior to the media preparation 
process; one sachet of medium powder (DMEMF-12 or MEM) was dissolved in the 
appropriate volume of the autoclaved MilliQ water, then 0.37% w/v and 0.22% w/v of 
Sodium bicarbonate (NaHCO3) was added to DMEMF-12 and MEM, respectively and the pH 
for the solution was adjusted to 7.2 using 0.1 N NaOH. Media were filter sterilised in a 
laminar flow cell culture hood into 1 L sterile bottles and kept at 4
°
C prior to use. The final 
pH of media was 7.4 after filtering. 
Fresh working media were prepared by supplementing the base media solution with 5% 
(v/v) Foetal Bovine Serum (FBS) (GIBCO
®
, Thermo Fisher, Auckland, New Zealand,), 2 mM 
Glutamax (GIBCO
®
, Thermo Fisher, Auckland, New Zealand, New Zealand), PenStrep 
antibiotics comprising 100 units/mL penicillin, 100 µg/mL streptomycin (GIBCO
®
, Thermo 
Fisher, Auckland, New Zealand) and 2 µg/mL Fungizone (Sigma). The working media were 
stored at 4
°
C prior to use. 
Both cell lines were cultured in 50 or 250 mL cell culture flasks containing the working 
media and incubated at 37
°
C in a 5% CO2 humidified incubator. Cells were allowed to grow 
until near full confluence by monitoring them with a light microscope with the media changed 
every second day. Once cells were confluent, cells were sub-cultured by discarding the media 
and washing the cells with 1x sterile Phosphate Buffer Solution (PBS) previously prepared 
from a stock of 10x PBS . One litre of 10x PBS was prepared with 1.4% Na2HPO4, 9% NaCl, 
0.2% KCl, the pH was adjusted to 7.4 with NaH2PO4 and topped up to 1000 mL with MilliQ 
water. 1x PBS was prepared using 100 mL of 10x PBS, diluted to 1000 mL with MilliQ water 
Chapter Two                                                                                        Material and Methods 
68 
 
and autoclaved for cell culturing purposes. Cells were then centrifuged to discard PBS 
solution and reconstituted in working medium then counted and sub-cultured in a new flask. 
2.2 Generating 3D Cell Cultures 
In order to set up 3D cell cultures, confluent cells were incubated for 20-30 minutes with 1x 
trypsin-ethylene diamine tetra acetic acid (trypsin-EDTA) (Thermo Fisher, Auckland New 
Zealand) to detach them from the culture flask. Once detached from the flask, cells were 
centrifuged at 400 g for 5 minutes, and the supernatant was discarded and cell pellets were re-
suspended in the appropriate working media. A cell count was performed using a 
haemocytometer and an Olympus CK40 light microscope in order to calculate the volume of 
cell suspension needed to obtain 1x10
5 
cells/mL in each well of a 24 well plate.  
To generate the 3D cellular aggregates, each plate was pre-coated with 300 µl of 24 mg/mL 
of poly-hydroxyethylmethacrylate (poly-HEMA) (Sigma, Auckland New Zealand). This was 
warmed prior to application. The coated plates were allowed to dry overnight on an orbital 
shaker at 37
°
C, and then were then left at room temperature to dry over night before washing 
them with 1x PBS prior to usage. The poly-HEMA prevents the cells from adhering to the 
bottom of the wells; hence cells tend to cluster forming 3D clusters and compact aggregates. 
A concentration of 24 mg/mL of poly- HEMA solution was prepared by mixing 2.4 g of poly-
HEMA with 100 mL of 95% ethanol. The solution was heated to 72
°
C with continued stirring 
until fully dissolved.  
The volume of cell suspension was determined in order to obtain 1x10
5 
cells/mL in each 
well. The final volume in each well was 1 ml. Approximately 500 µL of the remaining cell 
suspension was added into a new culture flask with fresh working medium for cell culture 
maintenance. Cell culture plates containing cancer cells were incubated for 6 days to generate 
cell clusters and aggregates. Cell media were refreshed with fresh media every second day. 
Prior to experimental stimulations, cells were maintained in a serum free medium (SFM) for 
an additional 24 hours (prepared as working medium minus the FBS). When changing 
medium, plates were allowed to rest at an angle for approximately five minutes to allow the 
floating cell clusters/compact aggregates to settle down before aspirating the medium in order 
to help to prevent any loss of cells. 




2.3  Making 2D Cell culture (cell monolayer) 
Some experiments with 2D cell cultures were performed for comparative purposes. For 
these experiments, cells were cultured in 24 well plates without the poly-HEMA, so that the 
cells would adhere to the bottom of the wells. Apart from that, culturing procedures were 
similar to those of 3D cell cultures. 
2.4 Treatments with growth factors and tyrosine kinase inhibitors (TKIs) 
2.4.1  Growth factor stimulation 
In order to investigate the role of growth factors in the activation of 3D cellular clusters/ 
compact aggregates, cells were exposed to epidermal growth factor (EGF), (Thermo Fisher, 
Auckland, New Zealand), hepatocyte growth factor (HGF), (Thermo Fisher, Auckland, New 
Zealand), or a combination of both growth factors (GF). Two concentrations of growth factors 
were used 20 ng/mL (a concentration used in most of the published literature) and 0.2 ng/mL 
(a physiologically relevant concentration, found in ascitic fluids of patients with advanced 
ovarian cancers). OVCAR-5 and SKOV-3 ovarian cancer cell lines were cultured in 3D 
clusters and aggregates for 6 days in working media, and then 24 hours in SFM before the 
addition of SFM supplemented with growth factors. Cells were maintained in growth factor 
stimulating conditions for 48 hours. Clusters/ compact aggregates were collected and assessed 
for cellular metabolism, using Alamar blue staining and a cell count was performed.  
2.4.2  Treatment with tyrosine kinase inhibitors (TKIs) 
Following the generation of 3D cellular clusters/ compact aggregates, as described above 
(see section 2.1.1.), cells were treated with two TKIs, canertinib, also known as CI-1033 (LC 
laboratories Massachusetts, USA) and PHA665752 (Sigma, Auckland, New Zealand), either 
singly or in combination for 48 hours before analysing for cellular metabolism and cell 
number. 
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In order to determine the lowest effective concentration of each inhibitor, concentration 
dependent experiments were initially performed with each inhibitor before conducting the 
combination treatments. 
All samples were normalised against the vehicle (which in this case is DMSO, the solvent 
used to dissolve the drugs), by calculating the amount of DMSO in each sample according to 
the volume of the treatment added and normalising the other samples by adding the difference 
in volumes. For the initial concentration dependent experiments, the concentrations of 
canertinib were 0.5, 1.0, 2.0, 3.0 and 4.0 µM, and the concentration of PHA665752 were 0.1, 
0.25, 0.5, 1.0 and 2.0 µM. Three replicates of each treatment within an individual experiment 
were carried out and the experiments were repeated at least 3 times for each cell line. Cellular 
clusters/ compact aggregates were analysed for cell morphology, cellular metabolism and cell 
number. 
2.5  Analysis of cluster and aggregate morphology 
For analysis of the morphology of cellular clusters and aggregates, the size of the clusters, 
their appearance and any changes induced by the treatments were monitored. After culturing 
for 6 days, cellular clusters of OVCAR-5 and compact aggregates of SKOV-3 were imaged 
using an inverted light microscope equipped with a digital camera, using a 10x/0.25 N.A. 
objective lens (ACCU-SCOPE" 3032). After completion of inhibitor exposure, cells in 
clusters and aggregates were harvested and digested with 1x trypsin-EDTA to obtain single 
cell suspensions, and cells were counted using a heamocytometer to assess cell number. 
2.6 Assay of Cellular metabolism using Alamar blue dye 
To assess cellular metabolic activity following the treatments, 100 µl of 400 µM Alamar 
blue dye (Resazurin, Thermo Fisher, Auckland, New Zealand), was added to each well 
containing cells and 1 ml media, and these were allowed to incubate in a CO2 atmosphere at 
37
°
C for 4 hours. Alamar blue is a resazurin blue dye that is metabolised by actively respiring 
cells and the blue dye is reduced to resorufin (a pink compound), which is then secreted into 
cell culture media. After 4 hours incubation, a 200 µL of cell suspension medium was 
transferred into a 96 well plate and the difference of absorbance of Alamar blue dye at 570 
and 600 nm was measured using a microplate reader (Spectra Max
®
 M5, Molecular Devices). 
Chapter Two                                                                                        Material and Methods 
71 
 
The difference in absorbance between 570 and 600 nm was used as an indicator of cellular 
metabolism. 
2.7 Measurement of cell number  
After the cellular metabolism assay was assessed, cells were collected to determine cell 
numbers. Cells were washed from the Alamar blue dye with 1x PBS at least two times before 
trypsinisation with 2x trypsin-Ethylene diamine tetra acetic acid (EDTA) and incubation at 
37
°
C for approximately 20 minutes before the number of cells was counted using a 
heamocytometer.  
2.8 Vascular Endothelial Growth Factor (VEGF) detection via Enzyme-
Linked Immunosorbent Assay (ELISA) 
Following the growth experiments, the clusters/ compact aggregates were centrifuged and 
the supernatant (media) was collected for VEGF secretion analysis. The protocol from the 
manufacturer was applied as follows: 96 well ELISA plates (Nunc, Thermo scientific, Illinois, 
USA) were pre-coated with mouse anti-human VEGF capture antibody (diluted in 1x PBS) 
and incubated overnight at room temperature. Next day the wells were washed using washing 
buffer (0.05% Tween-20 in 1x PBS) for four times and dried each time by tapping the plate 
on drying tissue before incubation with VEGF reagent diluent (1% BSA in 1x PBS) for 60 
minutes at room temperature. The wells were then washed x4 before loading the samples and 
standards (serial dilution of standards was with 1x PBS) and incubating at room temperature 
for two hours. The plates were then washed four times before adding biotinylated goat anti-
human VEGF detection antibody (this was diluted using reagent diluent) and incubated for 
further two hours a room temperature. Next step was washing x4 before incubating in the dark 
for 20 minutes with streptavidin-HRP (diluted with reagent diluent). Final washes x4 were 
executed before adding ultra TMB-ELISA and incubating for 7 minutes. Stop solution was added 
to stop the reaction (2 N NH2SO4) and the absorbance was measured using the microplate reader 
at 450 nm. 
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2.9 Assay of total Protein concentration produced by cancer cells  
To investigate the effects of the treatments on cell growth at cellular levels, protein 
concentrations of the treated samples were also assessed and compared to the untreated 
controls. Cells were cultured for 6 days in working medium, then 24 hours in SFM before 
incubating with the inhibitors for 48 hours. Cells were then washed with ice cold 1x PBS, and 
lysed using either radio-immuno precipitation assay lysis buffer, RIPA (made up with 50 mM 
Tris-HCl pH 7.4, 100 mM NaCl, 5 mM EDTA, 1% (v/v) NP-40, 0.1% (w/v) SDS, 10% (v/v) 
glycerol, 1 tablet protease inhibitor), or 0.1% SDS ( 0.1% SDS dissolved in 1x PBS ), or 
modified 0.1% SDS buffer (0.1% SDS was dissolved in 10 mL of 10x PBS, 10 mL Glycerol, 
0.183 g EDTA, 2 tablets of protease and topped up to 100 mL of MilliQ water). Cells were 
mixed and left on ice for 30 minutes. Cellular components were fractionised by centrifugation 
at 6700 g for 10 minutes and the supernatant was transferred into new Eppendorf tubes before 
determining the protein concentration of each sample using a Micro-BCA
TM
 Protein Assay 
Kit (Pierce Thermo Fisher Scientific, Rockford, IL, USA). A stock solution of 2 mg/mL 
bovine serum albumin (BSA) was prepared and aliquoted in small Eppendorf tubes and stored 
in -20˚C until use. A serial dilution of standard protein BSA was subsequently prepared 
according the manual provided by the BSA assay kit. Standards were run with all experiments 
individually and the optical density was measured and plotted against the protein 
concentration. A linear trend line with the equation was applied and protein concentrations 
were calculated accordingly, as described by the manual.  
2.10 Immunoblotting Analysis for protein expression 
To determine the expression of EGFR, HER-2 and c-MET, their phosphorylated forms, p-
EGFR, p-HER-2, p-MET and their downstream signalling molecules, PCNA, Akt, p-Akt, 
ERK, and p-ERK Western blotting was performed on the protein in cellular lysates. 
Following determination of the protein concentrations, the volumes of cell lysates to be 
loaded on the gels were calculated in order to obtain a total of 10 µg of protein. Protein 
lysates were denatured by boiling with 0.2% v/v of Laemmli 5x sample buffer (0.2% (v/v) 
bromophenol blue, 25% (v/v) glycerol, and 14.4 mM 2-mercaptoethanol in Tris-HCl pH 6.8), 
for 10 minutes. All samples were left on ice for 30 minutes before loading into freshly made 
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sodium dodecyl sulphate poly-acrylamide gel electrophoresis (SDS-PAGE) gels that were 1 
mm thick.  
For each individual gel preparation a 10% SDS-separating gel was made using 2.8 mL 
MilliQ water, and 1.66 mL Solution A (30% (v/v) acrylamide, 25 mL of 10% (NH4)4S2O8), 
1.25 mL solution B (75 mL of 2 M Tris-HCl pH 8.8 (24.2% Tris-base in MilliQ water, pH 
adjusted to 8.8) for final concentration of 1.5 M) and 2.5 µl TEMED. The mixture was loaded 
into the gel cassettes, topped up with MilliQ water to keep it hydrated, and incubated for 60 
minutes at 37
°
C. Then a  7% SDS-PAGE stacking gel was made using 1 mL MilliQ water, 0.5 
mL solution C (50 mL of 1 M Tris-HCl, pH 6.8 (12.1% of Tris-base in MilliQ water, pH 
adjusted 6.8) for a final concentration of 0.5 M.), 0.5 mL Solution A, 20 µL of 10% 
Ammonium per sulphate (NH4)SO4, and 2.5 µl TEMED. The mixture was added immediately 
to the separating gel and a 10 well comb was inserted before incubation for another 30 
minutes at room temperature. The SDS-PAGE was run for 3-4 hours at 120 Volts using 
freshly made up running buffer (0.3% Tris, 1.4% glycine, 0.1% Sodium dodecyl sulphate 
(SDS), all dissolved in 1.0 L of MilliQ water), to separate the proteins. Precision Plus 
Protein
TM 
standard (BioRad, Hercules, USA) and MagicMark (MagicMark
TM 
Western Protein 
Standard Life Technologies, New Zealand) were used as ladders. Once bands were separated, 
proteins were electro-blotted onto Poly Vinyl PVDF membrane (Immun-Blot
®
PVDF Bio-Rad 




 Transfer system. The PVDF 
membranes were incubated with methanol for 5 minutes before washing with MilliQ water 
and soaking with the transfer sponges in freshly made transfer buffer (0.19% Tris, 0.9% 
glycine dissolved in MilliQ water) at least 15 minutes prior the transfer. 
Membranes were then blocked with the specified blocking solutions, 5% skim milk or 1-4% 
BSA, dissolved in Tris-buffered Tween saline TBS-T (10% of 2 M Tris-HCl, pH 7.5 (24.3% 
Tris-base in MilliQ water adjusted to pH 7.5), 0.82% Sodium chloride (NaCl) in MilliQ water 
and autoclaved before adding 0.1% (v/v) of Tween-20). Blocking was carried out for 1 hour 
before incubation with the primary antibody solutions overnight at 4
°
C with gentle shaking. 
Primary antibodies were diluted at a range of 1:500, 1:1000 or 1:2000 with 50% (v/v) of TBS-
T and the appropriate blocking buffer (all primary and secondary antibodies are described in 
Table.2.1.). The next day, the membranes were washed with TBS-T 4 times for 10 minutes 
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before adding the secondary antibody and incubating at room temperature for 90 minutes on 
an orbital shaker followed by washing with TBS-T 4 times for 10 minutes. 
Secondary antibodies were diluted 1:5000 or 1:10000 with 50% (v/v) TBS-T and the 
specified blocker. Membranes were developed using Clarity™ Western ECL Blotting 
Substrates detection kit (Bio Rad, USA). Protein bands were visualised and densitometry 
analysis was performed using Alliance 4.7, Unitec software (Cambridge, UK). Densitometry 
readings were based on median bands from raw data images and normalised against the band 
intensity of GAPDH as a reference protein.  
2.11  Detection of cellular proteins using Immunofluorescence 
OVCAR-5 and SKOV-3 cells were cultured to generate cell clusters and aggregates for 6 
days. The media were refreshed every second day. Cell clusters and aggregates were collected 
and fixed with ice cold 50% (v/v) acetone/methanol solution. OVCAR-5 cell clusters were 
washed twice with ice cold PBS, pH 7.4 and re-suspended in 200 µl cold PBS. Clusters were 
then mounted on poly-lysine coated microscope slides left to dry at 37
°
C for 20 minutes 
before proceeding with the main procedure. Prior to frozen sectioning, SKOV-3 aggregates 
were washed with PBS pH 7.4 and stained with 1% aniline blue dye solution (Sigma-Aldrich 
LTD, New Zealand) for 15 minutes. The aniline blue dye binds to proteins on cell aggregates 
and makes aggregates more visible when a frozen section was cut. Cells were washed 2 times 
for 10 minutes each time with ice cold 1x PBS before they were embedded in a liquid CryO-
Z-T solution, OCT (Ted Pella Inc., USA), an embedding medium used to aid sectioning of 
frozen tissue samples in a cryostat. The liquid OCT blocks were frozen at -80°C for at least 24 
hours. Seven µm thick slices were sectioned from the block of frozen OCT using a 
CM186UV Cryostat, (Lieca BIOSYSTEM, Deutschland) and were placed on an appropriately 
labelled Superfrost plus slides (Menzel-glaser, Germany). Six slices per sample were 
collected, and stored at -20
°
C until analysis. Both cell lines were blocked with 4% BSA in 1x 
PBS for 1 hour at room temperature before incubation overnight with a 1:200 dilution of 
primary antibody at 4
°
C. Next day, cells were washed twice with ice cold PBS (pH 7.4) for 10 
minutes each time and further incubated with a 1:500 dilution of secondary antibody goat 
anti-rabbit IgG conjugated with FITC for 60 minutes in a 37
°
C incubator. 
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The secondary antibody solution was removed and 500 µL of 10 µg/mL of (4`, 6-diamido-2-
phenylindole (DAPI, Thermo fisher NZ), a fluorescent dye that binds to DNA, was added to 
the cells and left for 20 minutes in the dark. Cells were then washed twice with ice cold 0.1% 
Tween-20 in PBS pH 7.4 for 10 minutes each wash then mounted with ice cold anti-fading 
solution (2 mg/mL p-phenylenediamine in 80% glycerol, pH 7.8). Immuno fluorescent 
staining was carried out on both cell lines with anti-EGFR (SC120), anti-HER-2 (SC-7301), 
and anti-c-MET (SC10) primary antibodies (Santa Cruz). Fluorescent images were captured 
using an epifluorescence microscope with a 40x/1.3 N.A. oil/DIC objective lens (AxioVision 
4.5. Apotome software, Carl Zeiss, Oberkochen, Germany).  
2.12 Ascitic fluids from ovarian cancer patients 
Ascitic fluids from three advanced ovarian cancer patients were collected during debulking 
surgery, and they were referred as P1, P2, and P3 (kindly donated by patients from 
Gynaecology Department at Christchurch Women’s Hospital). Patient’s consents were 
obtained by Dr Kenny Chitcholtan prior to collection of ascitic fluids. The study protocol to 
obtain ascitic fluid from ovarian cancer patients was approved by Health and Disability Ethics 
Committees (Wellington, New Zealand). The Ethics reference number is 
URA/12/06/019/AM01 
 Cellular components in ascitic fluids were removed by centrifugation and cell free ascitic 
fluids were kept at -80
°
C for further studies. Ascitic fluids were aliquoted into 50 ml tubes and 
kept in -20
°
C freezer until use. The history of patient information was included in the 
Appendix. 
2.13 Effect of ascitic fluids on cell growth and cellular uptake of 
PHA665752  
In order to investigate the effect of ascitic fluids on cell growth and the cellular uptake of 
PHA665752, cells were exposed to a variety of conditions as summarised in Figure 2.1. 
The c-MET inhibitor, PHA665752 has a light green colour, which has fluorescent 
characteristic during FACS analysis (Chitcholtan, personal communication). This property 
made it possible to detect the cellular uptake of PHA665752 and determine whether the 
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inhibitor is entering the cells in the presence of ascitic fluids or in bovine serum albumin 
(BSA) which was used as a representative of human serum albumin. This would in turn give 
an insight of the effectiveness of the inhibitors on ovarian cancer cell clusters and compact 
aggregates in the presence of ascitic fluids or BSA. OVCAR-5 clusters and SKOV-3 compact 
aggregates were treated with PHA665752 in the presence of 50% v/v of patient’s ascites and 
incubated for 48 hours (ascites used in literature is approximately 5-10% but a more 
concentrated ascites could closer mimic the in vivo microenvironment so 50% was chosen ). 
Cells were then washed with 1x cold PBS, and trypsinised, before measuring fluorescent 
cells, as an indicator for cellular uptake using flow cytometry (Beckman & Coulter, USA).  




Figure.2.1. Treatment scheme to explore the effect of ascites and BSA on cellular uptake of 
TKI. OVCAR-5 cellular clusters and SKOV-3 compact aggregates were grown for 6 days in 
working medium supplemented with 5% FBS, then incubated in serum-free medium (SFM) 
for 24 hours before exposing them to the following conditions: (A) 50% (v/v) ascites with 
single agent (4 µM canertinib or 2 µM PHA665752), or a combination of 3 µM canertinib and 
1 µM PHA665752. Cells were incubated with the ascitic fluid and inhibitors for 48 hours and 
a cell count was performed to determine the growth. (B) Clusters and compact aggregates 
were exposed to 50% (v/v) ascitic fluids containing 2 µM PHA665752 for 48 hours before 
trypsinising and analysing via FACS, (C) Clusters and compact aggregates were exposed to 
50% ascites for 24 hours, and washed with SFM, then incubated with SFM supplemented 
with 2 µM PHA665752 and followed by incubation for further 24 hours, before trypsinising 
and analysing via FACS. (D) Clusters and compact aggregates were incubated with 
PHA665752 for 24 hours before the addition of 50% (v/v) ascitic fluids and further incubation 
for 24 hours before trypsinising and analysing via FACS. (E) Clusters and compact 
aggregates were incubated with SFM supplemented with 2, 4, and 5% (w/v) BSA 
supplemented with 2 µM PHA665752 for 48 hours before trypsinising and analysing via 
FACS. (F) Clusters and compact aggregates were incubated for 48 hours with SFM 
supplemented with 4% BSA, which also contain a range of concentrations of PHA (0-32) µM. 
Cells were trypsinised and analysed via FACS and cell count. All experiments were 
independently performed at least three times with triplicates. 
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2.14 Ovarian Cancer Cell Adhesion Assays 
In order to investigate cell adhesion in the presence of growth factors and tyrosine kinase 
inhibitors, cells were cultured as 3D cell clusters and aggregates for 6 days in working 
medium before further incubation for 24 hours in serum free medium (SFM) (see section 
2.2.). Cells were then treated with SFM supplemented with 0.2 or 20 ng/mL growth factor and 
canertinib or PHA665752 alone or a combination of the two inhibitors for 4 hours before 
performing the cell adhesion assay. Cells were then transferred onto a collagen-gel matrix and 
incubated for another 4 hours in a CO2 incubator at 37
ᵒ
C. After 4 hours of incubation, cellular 
metabolism was assayed by the Alamar blue dye assay (see section 2.6.), numbers of adherent 
and non-adherent cells were counted (see section 2.7.) and the expression of proteins of 
interest were investigated by Western blotting (see section 2.9).  
The cell adhesion assay was carried out on the surface of a collagen gel matrix, which was 
composed of 2 mg/ml collagen 1 and 25% Geltrex (a collagen IV and laminin rich matrix). 
The plates, coated with collagen, were freshly prepared during the 4 hours of incubation with 
the inhibitors. To prepare the collagen gel matrix, a total volume of 7 mL of collagen-gel 
matrix solution was made up as follows: 1.75 mL of 100% Geltrex, for a final concentration 
of 25% (Life Technologies, Auckland, New Zealand), 2.8 mL acid soluble collagen 1 
solution, for a final concentration of 2.5 mg/mL (Life Technologies, Auckland New Zealand), 
topped up with 2.45 mL base medium. For preparation of 2.8 mL of 2.5 mg/mL acid soluble 
collagen 1 solution, 2.33 mL of collagen 1 stock solution (3 mg/mL) was added to 280 µL of 
1x PBS and 35 µL of 1 N NaOH (for a final concentration of 0.0125 N), topped up with 155 
µL MilliQ water. Two hundred microliters were poured into each well of a 24 well plate and 
incubated at 37 
°
C for 30 minutes; these were left to cool down at room temperature before 
adding the cellular clusters and aggregates and incubating at 37 
°
C for a further 4 hours. 
Assessment of cellular metabolic activity was carried out using Alamar blue before 
trypsinisation of the cells and the number of adherent and non-adherent cells was counted. 
Immunofluorescent imaging of the receptor tyrosine kinases EGFR and HER-2 as well as 
the integrin subunits β1 and β4 were performed via staining the cellular clustars and 
aggregates with specific antibodies for the receptors as described before in section 2.11. 
Details of antibodies used are detailed in table 2.1.  
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Experiments exploring the effect of the presence of RGD motif on the cell adhesion in the 
presence or absence of the inhibitor combination were also performed. Cells were treated for 
4 hours as above with the combined inhibitors in the presence of RGDS, an integrin-ECM 
inhibitor, or RGES (as a control for RGDS inhibitory effects) and also acetate as a vehicle 
control. Then adhesion to collagen-gel matrix was applied and adherent cells were counted. 
2.15 Statistical analysis 
Statistical analysis of data was carried out using GraphPad Prism
®
 software (La Jolla, CA, 
USA). One way and two-way ANOVAs were carried out where p < 0.05 (*), p < 0.01 (**), p 
< 0.001 (***), and p < 0.0001 (****) were considered to indicate levels of statistical 
significance. Prior to analysis percentile and ratiometric values were logarithmically 
transformed. All data are presented as mean ± SEM. Each experiment was repeated at least 
three times. 
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Table. 2.1. Working concentrations of antibodies used for Western Blots and 
immunofluorescent analysis. 
 












EGFR 170 SC-03 1/500 1% BSA 1:10000 Rabbit 
p-EGFR 170 SC-101668 1/500 1% BSA 1:10000 Rabbit 
HER-2 185 SC-284 1/1000 1% BSA 1:5000 Rabbit 
p-HER-2 185 SC-12352-R 1/500 1% BSA 1:10000 Rabbit 
c-MET 145 SC-10 1/500 5% Skim milk 1:10000 Rabbit 
p-MET 145 SC-101736 1/500 1% BSA 1:10000 Rabbit 
ERK1/2 42 SC-94 1/2000 5% Skim milk 1:5000 Rabbit 
p-ERK 44 SC-7383 1/500 1% BSA 1:10000 Mouse 
Akt 56-63 SC-8312 1/500 1% BSA 1:10000 Rabbit 
p-Akt 56-63 SC-101629 1/500 1% BSA 1:10000 Rabbit 
GAPDH 37 SC-25778 1/2000 5% Skim milk 1:5000 Rabbit 
PCNA 36 SC-25280 1/500 5% Skim milk 1:10000 Mouse 
β1 132  1/500 1% BSA 1:10000 Rabbit 
β4 200 SC-9090 1/1000 1% BSA 1:5000 Rabbit 
Cytokeratin-18 
(CK-18) 
41-44 SC-5259 1/500 5% Skim milk 1:10000 Mouse 
β-Actin (C-4) 42 SC-47778 1/500 5% Skim milk 1:10000 Mouse 
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3.1 Introduction  
Some of the mutations that underlie cancer are those that lead to the over expression of 
growth factor receptors. These may affect the signalling pathways that regulate cell growth, 
migration and survival. EGFR, HER-2 and c-MET are receptor tyrosine kinases suggested to 
be highly expressed in several types of cancers including ovarian cancer [84, 280, 288, 306, 
456, 459-467]. Their over expression is associated with an invasive phenotype and poor 
prognosis in ovarian cancer patients [305, 342, 344, 459, 466, 468, 469]. Because these 
receptors are present at low levels in normal cells, inhibitors targeting EGFR, HER-2 and c-
MET can potentially inhibit the growth of malignant cells, but have limited adverse effects on 
normal cells [470]. Thus, an anticancer drug that could inhibit the growth of malignant cells 
and potentially prevent their spread to other organs may have a significant impact on the 
improving patient’s quality of life. Ovarian cancer cells have been shown to utilise multiple 
signalling pathways to promote growth and proliferation [467, 471, 472], therefore, targeting 
of one specific receptor or pathway may have limited effect on growth and proliferation [1]. 
For instance, a limited effect was observed upon treatment of ovarian tumours with EGFR or 
PDGFR inhibitors [473, 474]. It has been recognised that combining anticancer drugs that 
target multiple pathways can be beneficial in cancer treatments [475-477].  
A group of anti-cancer drugs collectively termed ‘small molecule tyrosine kinase inhibitors’ 
have been extensively investigated. Some of those inhibitors e.g. gefitinib, erlotinib, and 
lapatinib, which were approved by the FDA, are specific to EGFR and HER-2 and have been 
found to be beneficial for the treatment of different malignancies including breast cancer, 
endometrial cancer, colon cancer, head and neck cancer, and non-small cell lung cancer 
(NSCLC) [215, 241, 242, 259, 462, 478-480] However, in ovarian cancer trials these 
inhibitors have shown limited positive clinical outcomes as single agents [219, 481]. The 
abundance of EGFR/HER-2 and c-MET are thought to contribute to resistance to treatments 
and this may explain the low efficacy of cancer treatments in some types of cancers [482, 
483].  




EGFR and HER-2 belong to a family of four transmembrane receptors EGFR, HER-2, Her-3 
and Her-4. With the exception of HER-2, all other receptors are activated upon binding to the 
epidermal growth factor (EGF). HER-2 has no known binding ligands; instead it is co-
activated by heterodimerisation with other members of the family, especially EGFR [460, 
461, 484]. The c-MET proto oncogene is a receptor tyrosine kinase that binds to hepatocyte 
growth factor (HGF) [333, 483, 485]. EGF and HGF are growth factors known to be elevated 
in the ascitic fluids of women with advanced stages of ovarian cancer [486, 487]. Activation 
of EGFR, HER-2 or c-MET receptors subsequently triggers a cascade of downstream 
signalling processes essential for cell survival, motility, and invasion. Crosstalk between these 
three receptors may promote cancer progression and increase resistance to therapy [488]. 
Thus, targeting c-MET in addition to EGFR and HER-2 may impact cell survival.  
This chapter will investigate whether targeting two different receptor tyrosine kinases using 
two different specific inhibitors can enhance the efficacy of the drugs and possibly reduce the 
growth of ovarian cancer cell lines. 
The inhibitors tested were canertinib (CI-1033), an irreversible pan ErbB inhibitor [251, 
308, 489, 490], and PHA665752, which is a reversible c-MET inhibitor [254, 255]. Canertinib 
has shown potent effects against several cancer cell lines targeting EGFR and HER-2. Pre-
clinical and clinical trials of canertinib have been conducted against a number of tumours, 
including breast cancer [221, 491], NSCLC [478] and advanced ovarian cancer [219, 492]. 
However, canertinib alone showed modest activity in clinical studies with ovarian cancer 
patients [219]. In vivo studies indicated that PHA665752, at low concentrations, has anti-
tumour activities [255, 256]. The presence of growth factors in the tumour microenvironment, 
either naturally occurring or secreted by tumour cells, is essential for cell growth. EGF and 
HGF, specific ligands for EGFR/HER-2 and c-MET respectively, activate the receptors upon 
binding and autophosphorylation of the receptors occurs. Activation of these receptors may be 
useful for studying the efficacy of drugs in advanced ovarian cancer since most ovarian 
cancer cells are thought to express high levels of these receptors and utilise them for survival 
[397, 493-495]. 




3.2 Hypothesis and Aims 
The hypothesis of this chapter is that a combination of two receptor tyrosine kinase 
inhibitors (canertinib and PHA665752) will compromise cell growth, cellular metabolism and 
tyrosine kinase activity in a 3D cell model of advanced ovarian cancer.  
The aim of this chapter is to investigate the effects of canertinib and PHA66572 on clusters 
and compact aggregates of tumour cell cultures and correlate these with the expression of 
EGFR, HER-2, c-MET and their downstream signalling molecules. 
3.3 Results 
3.3.1 Morphology of 3D cell clusters/compact aggregates and expressions of receptors 
The first stage in the investigation was to study the morphology of OVCAR-5 cell clusters 
and SKOV-3 compact aggregates and determine any possible differences between them that 
may affect their respective responses to treatments. OVCAR-5 and SKOV-3 cells were grown 
in 12 well plates that were pre-coated with poly-hydroxy ethyl methacrylate (poly-HEMA) 
polymer to induce cellular aggregation. Cells were incubated for 4 days with culture media 
and allowed to form 3D clusters and aggregates. Cellular aggregates were then collected and 
imaged using an inverted light microscope. OVCAR-5 cells formed small clusters (Figure 3.1 
A) while SKOV-3 cells formed large, dense cellular aggregates (Figure 3.1 B).  
Next the expression of EGFR, HER-2 and c-MET in both cell lines was investigated. Cells 
were cultured for 4 days in working media before immunofluorescent labelling and imaging 
using a fluorescent microscope. OVCAR-5 cells expressed both EGFR and c-MET, however, 
HER-2 expression was undetectable (Figure 3.1 C, G and E respectively). In contrast, 
SKOV-3 compact aggregates stained positive for EGFR, HER-2 and c-MET (Figure 3.1 D, 
F, and H respectively). The staining of proteins is located at the cell membrane of cancer 
cells. These results are consistent with the literature confirming the presence of the receptors 
in the cell lines under investigation [334, 397, 465, 493].  






Figure 3.1. Morphology of cellular clusters/ compact aggregates and the expression of 
EGFR, HER-2 and c-MET (all indicated by green staining). Images shown: (A) OVCAR-5 
cellular clusters; (B) SKOV-3 compact aggregates; (C) EGFR in OVCAR-5 and (D) EGFR in 
SKOV-3; (E) HER-2 in OVCAR-5; (F) HER-2 in SKOV-3; (G) c-MET in OVCAR-5; and 
(H) c-MET in SKOV-3 clusters and aggregates. 




3.3.2  Growth factors induced cell growth, did not affect cell metabolism, and 
increased expression of proliferating cell antigen (PCNA) 
3.3.2.1 Cell growth and cellular metabolism  
To study the effect of growth factors on the ovarian cancer cell lines, two concentrations of 
EGF and HGF were used, a lower concentration that is physiologically relevant (0.2 ng/mL) 
and a higher concentration (20 ng/mL) matching that used by other workers [278, 435, 496]. 
Results showed a concentration dependent increase in cell growth of both cell lines with 
increased growth factor concentration [Figure 3.2. (A) OVCAR-5 and (B) SKOV-3]. The 
effect of HGF was more prominent than that of EGF. Using an Alamar blue assay no 
significant effect on cellular metabolism was observed (Figure 3.2. (C) OVCAR-5 and (D) 
SKOV-3). 






Figure 3.2. The effect of two growth factors on cell growth activity and cellular metabolism 
of the two ovarian cancer cell lines. Data are shown for OVCAR-5 (A, C) and SKOV-3 (B, 
D), clusters/compact aggregates, treated with 0.2 and 20ng/mL of epidermal growth factor 
(EGF), hepatocyte growth factor (HGF). Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), 
and p<0.0001 (****) compared to the control or the other concentrations. 




3.3.2.2 Expression of Proliferating Cell Nuclear Antigen (PCNA) increased in the 
presence of the growth factors 
Once cells are in the proliferative phase, PCNA expression would be expected to increase as 
it surrounds the DNA and acts as a platform for recruitment of proteins involved in DNA 
replication, DNA repair and chromatin remodelling. Since an increase in cell growth in the 
presence of growth factors was established in this chapter, an investigation of the expression 
of PCNA with the growth factors was carried out. Overall, PCNA expression was increased 
with increased growth factor concentrations (EGF or HGF), in both OVCAR-5 (Figure 3.3 A 
and E) and SKOV-3 (Figure 3.3 B and F). A densitometry index obtained by comparing the 
PCNA band intensity to the band intensity of the house keeping protein, GAPDH, also 
indicated increased levels of PCNA in both OVCAR-5 (Figure 3.3 C and G) and SKOV-3 
(Figure 3.3 D and H) cells. Protein concentrations in growth factor treated OVCAR-5 clusters 
and SKOV-3 compact aggregates were significantly higher than in untreated controls (see 
appendix). 







Figure 3.3. The effect of growth factors on the expression of PCNA in ovarian cancer cell 
lines. Western blotting and densitometry index of PCNA data are shown for clusters/compact 
aggregates of OVCAR-5 treated with EGF (A, C) and HGF (E, G), and SKOV-3 cells treated 
with EGF (B, D) and HGF (F, H). Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), 
and p<0.0001 (****) compared to the control or the other concentrations.  




3.3.3 The concentration dependence of canertinib and PHA665752 in the presence of 
fetal bovine serum (FBS) or growth factors 
In order to investigate the response of the cells to the inhibitor treatments, first their 
response upon activation with FBS was studied. FBS contains an array of growth factors, 
amino acids, lipids, cytokines, and chemokines that are essential for cell growth and thus may 
contribute to the activation of the receptors and thus a cellular response or resistance if any, to 
the inhibitors.  
3.3.3.1 Response to canertinib in the presence of 5%FBS 
Cell numbers of both cell lines were significantly reduced by canertinib in a concentration 
dependent manner, as shown in Figure 3.4 (A) for OVCAR-5 and (B) for SKOV-3 cell lines 
respectively. There were no observed changes in cellular metabolism for OVCAR-5 (Figure 
3.4 C), while SKOV-3 showed a significant reduction in metabolism (Figure 3.4 D). These 
results may suggest that SKOV-3 has an overall better response to canertinib than OVCAR-5, 
probably due to the higher expression of EGFR and HER-2. 






Figure 3.4. The effect of canertinib on cell growth and cellular metabolism of OVCAR-5 
(A, C) and SKOV-3 (B, D) ovarian cancer cell lines. Clusters and compact aggregates were 
treated with canertinib at concentrations of 0, 0.5, 1.0, 2.0, 3.0, 4.0 µM in the presence of 5% 
fetal bovine serum (FBS). Data are expressed as means ± S.E.M (n=3). Data considered 
statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 
(****) compared to the control or the other concentrations. 




3.3.3.2 Response to PHA665752 (PHA) in the presence of 5%FBS 
OVCAR-5 cell clusters exhibited a significant concentration dependent decrease in cell 
growth with PHA665752 (Figure 3.5 A). This may be due to the high expression of c-MET in 
OVCAR-5 cells and may suggest that OVCAR-5 cells utilise c-MET as a primary growth 
receptor. However, SKOV-3 compact aggregates showed a more modest response to the c-
MET inhibitor, with a significant decrease in cell growth only at concentrations of 2 µM or 
above (Figure 3.5 B). This may suggest that SKOV-3 compact aggregates may utilise 
EGFR/HER-2 as primary growth receptors. Only 2 µM PHA665752 significantly reduced 
cellular metabolism in both cell lines (Figure 3.5 C and D). 






Figure 3.5. The effect of PHA665752 on cell growth and cellular metabolism of the ovarian 
cancer cell lines OVCAR-5 (A, C) and SKOV-3 (B, D). Clusters and compact aggregates 
were treated with PHA665752 at concentrations of 0, 0.1, 0.25, 0.5, 1.0, 2.0 µM in the 
presence of 5% FBS. Data are expressed as means ± S.E.M (n=3). Data considered 
statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 
(****) compared to the control or the other concentrations. 
 




3.3.3.3 The effect of growth factors (GF) on the efficacy of cantertinib 
The tumour microenvironment contains different growth factors and other substances that 
may affect the drug efficacy and cellular response [497-499]. The focus of this study was to 
assess the effect of the growth factors, EGF and HGF on drug efficacy. As mentioned earlier, 
growth factors play a pivotal role in the growth of cancer cells. The presence of EGF or HGF 
is essential for activation of EGFR/HER-2 or c-MET, respectively. Upon binding to the 
growth factors, the receptors dimerise and auto phosphorylation of the tyrosine residues 
occurs at the intracellular portion of tyrosine kinase domain. This process would in turn 
induce phosphorylation of intracellular signal transduction proteins that signal cell growth and 
proliferation. To investigate the cellular response in the presence of growth factors, OVCAR-
5 clusters and SKOV-3 aggregates were treated with different concentrations of the inhibitors 
in the presence of 20 ng/mL EGF and HGF. Canertinib elicited a concentration dependent 
inhibition of cell growth in both EGF treated OVCAR-5 (Figure 3.6 A) and SKOV-3 (Figure 
3.6 B) cells. Similar results were obtained when HGF was present, as shown in Figure 3.6 C 
and D for OVCAR-5 and SKOV-3 respectively. 






Figure 3.6. The effect of canertinib on cell growth of ovarian cancer cell lines OVCAR-5 
(A, C) and SKOV-3 (B, D). Cell clusters and compact aggregates were treated with canertinib 
at concentrations of 0, 0.5, 1.0, 2.0, 3.0, 4.0 µM in the presence of 20 ng/mL of EGF or HGF. 
Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 




3.3.3.4 The effect of growth factors (GF) on the efficacy of PHA665752 
Both cell lines showed a concentration dependent decrease in cell growth, after treatment 
with PHA665752, in the presence of EGF [Figure 3.7 A (OVCAR-5) and B (SKOV-3)]. 
Similar results were obtained with HGF for both OVCAR-5 (Figure 3.7 C) and SKOV-3 
(Figure 3.7 D) cells.  
 
Figure 3.7. The effect of PHA665752 on cell growth of two ovarian cancer cell lines 
OVCAR-5 (A, C) and SKOV-3 (B, D). Cell clusters and compact aggregates were treated 
with PHA665752 (PHA), 0.1, 0.25, 0.5, 1.0, 2.0 µM in the presence of 20 ng/mL EGF or 
HGF respectively. Data are expressed as means ± S.E.M (n=3). Data considered statistically 
significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) 
compared to the control or the other concentrations. 




3.3.3.5  The effect of a combination of two growth factors on the efficacy of canertinib 
As demonstrated in the previous sections, catertinib concentrations above of 0.5 µM affected 
the growth of OVCAR-5 cell clusters and SKOV-3 compact cellular aggregates. In order to 
demonstrate the effect of the presence of growth factors on the cellular response to the 
treatments, OVCAR-5 clusters and SKOV-3 compact aggregates were exposed to 4 µM 
canertinib alone in a serum free medium (SFM), i.e., no growth factors or FBS). In the 
absence of growth factors, there was minimal effect of canertinib on cell growth of both 
OVCAR-5 clusters (Figure 3.8 A) and SKOV-3 aggregates (Figure 3.8 B). This may suggest 
that the presence of growth factors is mandatory for both ovarian cancer cell lines responding 
to the inhibitors. Therefore, OVCAR-5 clusters and SKOV-3 compact aggregates were 
stimulated with a mixture of EGF and HGF (henceforth this combination will be referred to as 
GF) and the effects of the inhibitors were investigated. The concentrations of the growth 
factor mixture used in this study were 0.2 ng/mL of GF, a physiologically relevant level for 
patients with advanced ovarian cancers [500], and 20 ng/mL of GF, a concentration that has 
been used in other studies [421, 465]. 
Canertinib significantly inhibited cell growth of OVCAR-5 cellular clusters in the presence 
of 0.2 or 20 ng/mL of GF, in a concentration dependent fashion, (Figure 3.8 C). This 
supports the suggestion that activation with growth factors is required to trigger the cellular 
response to the treatments. The inhibiter was more potent with SKOV-3 cell aggregates, 
having a greater inhibitory effect on cell growth (Figure 3.8 D). Cellular metabolism in 
SKOV-3 compact aggregates (Figure 3.8 F) was also decreased in a concentration dependent 
manner, regardless of the concentration of the growth factors. However, reduction in cellular 
metabolism of OVCAR-5 (Figure 3.8 E) was only statistically significant with 20 ng/mL of 
GF but not with 0.2 ng/mL of GF. 





Figure 3.8. The effect of canertinib on cell growth and metabolism of the two ovarian 
cancer cell lines OVCAR-5 and SKOV-3. Cell clusters of OVCAR-5 (A) and SKOV-3 
compact aggregates (B) were cultured in serum free medium (SFM), and exposed to 4 µM 
canertinib. OVCAR-5 (C and E), and SKOV-3 (D and F) treated with canertinib at 
concentrations of 0, 0.5, 1.0, 2.0, 3.0, 4.0 µM in the presence of 0.2 or 20 ng/mL GF. Data are 
expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as 
p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control or the 
other concentrations. 




3.3.3.6 The effect of a combination of two growth factors on the efficacy of PHA665752 
In the absence of growth factors, PHA665752 exhibited limited efficacy on both OVCAR-5 
cell clusters (Figure 3.9 A), and SKOV-3 compact aggregates (Figure 3.9 B). However, in 
the presence of growth factors, PHA665752 inhibited the growth of OVCAR-5 clusters in a 
concentration dependent manner, irrespective of the concentration of growth factors (Figure 
3.9 C). This effect was less prominent in SKOV-3 cellular aggregates, and only consistent at 
the lower concentration of growth factors (Figure 3.9 D). This may suggest that due the high 
expressions of EGFR and HER-2 on SKOV-3 compact aggregates, the cells may have been 
utilising them as an alternative pathway to maintain survival. In contrast, a significant 
concentration dependent reduction of cellular metabolism in OVCAR-5 (Figure 3.9 E) cells 
was found with 20 ng/mL of GF. However, when 0.2ng/mL GF was present, only higher 
concentrations of the inhibitor were effective. Cellular metabolism of SKOV-3 cells was not 
significantly reduced with increasing concentrations (Figure 3.9 F).  







Figure 3.9. The effect of PHA665752 on cell growth and metabolism of the two ovarian 
cancer cell lines OVCAR-5 and SKOV-3. Cell clusters of OVCAR-5 (A) and compact 
aggregates of SKOV-3 (B), were cultured in serum free medium (SFM) and exposed to 2 µM 
PHA665752. Clusters of OVCAR-5 (D and F), were treated with PHA665752, 0.1, 0.25, 0.5, 
1.0, 2.0 µM in the presence of 20 ng/mL GF. Data are expressed as means ± S.E.M (n=3). 
Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 
(***), and p<0.0001 (****) compared to the control or the other concentrations. 




3.3.4  The most effective concentrations for inhibitor combination experiments 
In order to investigate the optimal concentration for the inhibitor combination treatments a 
series of experiments were performed to identify their lowest effective concentrations. Cells 
were exposed to different combinations of the inhibitors, for 48 hours in the presence of 20 
ng/mL of GF and cell growth and metabolic activity were analysed. Results show a 
significant decrease in the growth of OVCAR-5 clusters (Figure 3.10 A) and SKOV-3 
compact aggregates (Figure 3.10 B), with a combination of 3.0 µM canertinib and 1.0 µM 
PHA665752. A marked decrease in cellular metabolism was observed for both cell lines at the 
same concentrations of the inhibitor combination (Figure 3.10 C and D).  






Figure 3.10. The effect of different combinations of canertinib and PHA665752 on cell 
growth and metabolism of the two ovarian cancer cell lines OVCAR-5 (A, C) and SKOV-3 
(B, D). Cell clusters and compact aggregates were treated with selective combinations of 
canertinib and PHA665752, (0.5, 0.1), (1.0, 0.25), (2.0, 0.5), and (3.0, 1.0) µM respectively, 
in the presence of 20 ng/mL GF. Data are expressed as means ± S.E.M (n=4). Data considered 
statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 
(****) compared to the control or the other concentrations. 




3.3.5 The effect of a combination of canertinib and PHA on cell growth and 
metabolism in the presence of 5%FBS 
While this study is focused on the effect of combining the two inhibitors in the presence of 
growth factors, the effect of the combination in the presence of FBS is also of interest. FBS 
can influence a number of additional growth promoting agents that may affect the cellular 
response to the treatments. In the presence of FBS, a significant reduction in cell numbers for 
both cell lines was observed with the inhibitors applied individually or in combination 
(Figure 3.11 A and B for OVCAR-5 and SKOV-3 respectively). There were no changes in 
cellular metabolism of OVCAR-5 (Figure 3.11 C), and the only slightly significant reduction 
in cellular metabolism for SKOV-3 was noted with the combination treatment (Figure 3.11 
D).  





Figure 3.11. The effect of a combination of canertinib and PHA665752 on cell growth and 
metabolism of the ovarian cancer cell lines OVCAR-5 (A, C) and SKOV-3 (B, D). Cell 
clusters and compact aggregates were treated with canertinib or PHA665752 alone or in 
combination in the presence of 5%FBS. Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), 
and p<0.0001 (****) compared to the control or the other concentrations. 




3.3.6 Effect of the combination of canertinib and PHA665752 on cell growth, 
proliferation and metabolism in the presence of 0.2 or 20 ng/mL GF. 
The data presented above indicate that the lowest effective combination of the inhibitors was 
3.0 µM canertinib and 1.0 µM PHA665752 and that the growth factor concentration of 0.2 
ng/mL (close to physiological levels for women with advanced ovarian cancer) was sufficient 
for activation of the receptors and triggering a cellular response to the treatments. However, 
for comparison with results reported by other workers, a concentration of 20 ng/mL of GF 
was also tested. The level of cell proliferation was determined by using proliferating cell 
nuclear antigen (PCNA) as a marker. In the presence of 0.2 ng/mL GF, cell proliferation was 
reduced and the expression of PCNA, as measured using Western blotting and densitometry 
readings relative to the housekeeping protein GAPDH, was reduced especially with the 
combination of inhibitors [Figure 3.12 A and B for OVCAR-5 and SKOV-3 respectively]. 
Cell growth of both OVCAR-5 clusters and SKOV-3 aggregates was reduced when each of 
the inhibitors was used separately; and further inhibition of the cell growth occurred when 
both inhibitors, canertinib and PHA665752, were used in combination (Figure 3.12 C and D 
respectively). Similar patterns of inhibition were observed in both cell lines when 20 ng/mL 
of GF was used (Figure 3.13.).  
There are two possible scenarios as to why increasing the growth factor concentrations did 
not enhance the cellular response to the inhibitors; firstly, the growth factors are such potent 
cytokines that the minimal concentration will activate the receptors and the excess growth 
factor concentrations are left in the cell culture medium.  
Cellular metabolism of OVCAR-5 clusters was reduced with PHA665752 alone and in 
combination, but not with canertinib, with both 0.2 and 20 ng/mL GF (Figure 3.14 A and C) 
respectively. However, SKOV-3 compact aggregates showed a significant decrease when 
canertinib and PHA665752 were used separately or in combination, with both growth factor 
conditions (Figure 3.14 B and D). Protein levels, in treated samples, as would be predicted, 
were significantly lower than the controls. 





Figure 3.12. Western blot showing the expression of PCNA and a reference protein 
(GAPDH) in ovarian cancer cellular clusters/compact aggregates of (A) OVCAR-5 and (B) 
SKOV-3 treated with each inhibitor separately or in combination, in the presence of 0.2 
ng/mL of GF. Cell growth of OVCAR-5 cells (C) and SKOV-3 (D) for the same conditions. 
Cell growth data are expressed as means ± S.E.M (n=3). Data considered statistically 
significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) 
compared to the control or the other concentrations. 






Figure 3.13. Western blot showing the expression of PCNA and a reference protein 
(GAPDH) in ovarian cancer cellular clusters/compact aggregates, OVCAR-5 (A) and SKOV-
3 (B), treated with each inhibitor separately and in combination, in the presence of 20 ng/mL 
of GF. Cell growth of OVCAR-5 cells (C) and SKOV-3 (D) for the same conditions. Cell 
growth data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 






Figure 3.14. The effect of a combination of canertinib and PHA665752 on cellular 
metabolism of the ovarian cancer cell lines OVCAR-5 (A, C) and SKOV-3 (B, D). Cell 
clusters and compact aggregates were treated with a single concentration and a combination 
of canertinib and PHA665752 in the presence of 0.2 or 20 ng/mL of GF. Cellular metabolism 
data are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 




3.3.7 The effect of the combination of canertinib and PHA665752 on the receptors and 
downstream signalling molecules 
The previous results suggest that cell growth and cellular metabolism are markedly reduced 
upon treatment with canertinib and PHA separately, and a further reduction was noted when 
the cells were treated with the combination of the inhibitors. There was also a reduction in 
cellular metabolism upon exposure to the inhibitors. In the following section, the effect of the 
inhibitors on total expression and phosphorylation of the target receptors EGFR, HER-2 and 
c-MET as well as the total expression and phosphorylation of the downstream signalling 
molecules Akt and ERK is investigated. 
3.3.7.1 The effect of inhibitors on the receptors and signalling molecules in OVCAR-5 
cellular clusters 
In the presence of 0.2 ng/mL of GF both canertinib and PHA665752 reduced the levels of p-
EGFR when they were applied individually or in combination (Figure 3.15 A, B).  
In contrast, total expression of EGFR was only slightly reduced when the cells were treated 
with canertinib alone (Figure 3.15 C). Treatment with PHA665752 alone significantly 
reduced the total expression of c-MET and levels of phosphorylated p-MET and this was 
further reduced when the cells were treated with the combination of the inhibitors (Figure 
3.15 D, E). Total expression of Akt and phosphorylation was reduced when the cells were 
treated with the combination (Figure 3.15 F, G). There were no significant changes in total 
expression of ERK, but treatment of the cells with the inhibitors individually reduced p-ERK. 
A further reduction was noted when they were combined (Figure 3.15 H, I). The expression 
of HER-2 was undetectable in OVCAR-5 clusters. Similar results were observed with 20 
ng/mL of GF (Figure 3.16). 







Figure 3.15. Western blotting and densitometry, showing the effect of a combination of 
canertinib and PHA665752 (PHA), in OVCAR-5 clusters, on total expression and 
phosphorylation of EGFR, Her-2, c-Met, Akt and Erk, with 0.2 ng/mL of GF. Densitometry 
values are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 






Figure 3.16. Western blotting and densitometry, showing the effect of a combination of 
canertinib and PHA665752 (PHA), in OVCAR-5 clusters, on total expression and 
phosphorylation of EGFR, Her-2, c-Met, Akt and Erk, with 20 ng/mL of GF. Densitometry 
values are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 




3.3.7.2 Effect of the inhibitors on the receptors and signalling molecules in SKOV-3 
compact aggregates 
The effects of the inhibitors were tested in presence of 0.2 ng/mL of the GF. Canertinib 
alone or in combination with PHA665752 reduced the expression of p-EGFR in SKOV-3 
compact aggregates in the presence of 0.2 ng/mL of GF (Figure 3.17 A, B). However, there 
was no significant reduction when PHA665752 was used alone indicating that the reduction 
was mainly due to canertinib inhibition (Figure 3.17 A, B). Total expression of EGFR, was 
also significantly reduced with the use of canertinib alone or in combination, but not with 
PHA665752 alone (Figures 3.17 C). A reduction in the phosphorylation and total expression 
of HER-2 was observed with canertinib alone or in combination (Figure 3.17 D, E). 
Canertinib alone and in combination, reduced p-MET, and both inhibitors, both individually 
and in combination significantly reduced total c-MET (Figure 3.17 F, G). A reduction in Akt 
and p-Akt was also notable with the combination (Figure 3.17 H, I). Canertinib alone 
reduced the total expression and phosphorylation of ERK, with a further reduction with the 
combination (Figure 3.17 J, K). Similar trends were obtained with 20 ng/mL of GF, but the 
reduction of c-MET and p-MET was more prominent and PHA665752 was more potent when 
applied individually (Figure 3.18). 





Figure 3.17. Western blotting and densitometry index showing the effect of a combination 
of canertinib and PHA665752 on total expression and phosphorylation of EGFR, HER-2, c-
MET, Akt and ERK of SKOV-3 compact aggregates, in the presence of 0.2 ng/mL of GF. 
Densitometry values are expressed as means ± S.E.M (n=3). Data considered statistically 
significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) 
compared to the control or the other concentrations. 





Figure 3.18. Western blotting and densitometry showing the effect of a combination of 
canertinib and PHA665752 on total expression and phosphorylation of EGFR, HER-2, c-
MET, Akt and ERK of SKOV-3 compact aggregates, with 20 ng/mL of GF. Densitometry 
values are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 




3.3.8 The effect of the combination of canertinib and PHA665752 on Vascular 
Endothelial Growth Factor (VEGF) secretion from OVCAR-5 and SKOV-3 
ovarian cancer cell lines  
VEGF secretion is the first step in the process of angiogenesis and it is a characteristic of 
malignant cells. VEGF stimulates microvascular hyper permeability before and during 
angiogenesis leading to tumour vascularisation and spread [436]. The presence of growth 
factors and cytokines in the surrounding microenvironment, of ovarian cancer cells, induces 
the secretion of VEGF, which acts as a signal to promote cell migration and metastasis. High 
expressions of certain oncogenes, such as EGFR /HER-2, has been shown to upregulate 
VEGF signalling and this in turn will contribute to resistance to EGFR inhibitors [501]. To 
investigate the effect of the combination of canertinib and PHA665752 on VEGF secretion, 
the cellular clusters and compact aggregates were exposed to the inhibitors and a VEGF 
ELISA was performed to estimate VEGF secretion.  
In the presence of 0.2 ng/mL of GF, OVCAR-5 clusters showed a significant decrease in 
VEGF with the combination treatment but no marked reduction with the single inhibitors 
(Figure 3.19 A). However, with 20 ng/mL of GF, a reduction in VEGF was observed with 
both, single inhibitors and with the combination (Figures 3.19 B). SKOV-3 compact 
aggregates showed a decrease in VEGF secretion with single treatment of canertinib and with 
the combination in both 0.2 and 20 ng/mL of GF (Figure 3.19 C and D). 





Figure 3.19. The effect of a combination of canertinib and PHA665752 on VEGF secretion 
in the two ovarian cancer cell lines OVCAR-5 (A, B) and SKOV-3 (C, D). Data show VEGF 
secretion from cell clusters and compact aggregates treated with canertinib and PHA665752 
alone or in combination in the presence of 0.2 or 20 ng/mL of GF. Data are expressed as 
means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 (*), 
p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control or the other 
concentrations. 





The effects of the combination of inhibitors targeting the receptor tyrosine kinases EGFR, 
HER-2 and c-MET were investigated in two ovarian cancer cell lines, OVCAR-5 and SKOV-
3. During intraperitoneal dissemination, ovarian tumour cells shed into the abdominal cavity 
and survive as single cells or free floating cellular clusters and aggregates in the ascitic fluid 
[7, 156]. Therefore, in order to closely mimic the tumour microenvironment, cells were 
cultured as floating cellular clusters and compact aggregates. Such 3D cultures have a better 
potential to replicate the cellular heterogeneity of malignant ovarian cancer cell clusters and 
compact aggregates that are floating in the ascitic fluid [502-505]. As such, the 3D cell model 
may reflect a closer representation of the potential response to the drug combination in vivo 
[502, 503]. 
3D cell culture models have been developed to mimic the in vivo environment and 
investigate the progression and resistance mechanisms of several types of cancer cells 
including those of the ovary [506, 507]. Muranen and colleagues studied the effect of small 
molecule inhibitors of the PI3K/mTOR pathway in a 3D cluster model of ovarian and breast 
cancer, a pathway that is frequently mutated in epithelial cancers [508]. They found that 
tumour cells that attached to the matrix in the core of the spheroid were resistance to the 
PI3K/mTOR inhibitors most likely through the upregulation of pro-survival proteins. In 
contrast, proliferation of 2D monolayers of cells was inhibited although apoptosis was not 
observed. It was suggested that the PI3K/mTOR pathway was not inhibited in the inner part 
of the spheroids while 2D cultures and outer cells exhibited strong survival [508]. This may 
explain the limited effects of PI3K/mTOR inhibitors in previous studies where 2D cell 
monolayer may exhibit loss of cellular polarity, and ECM-adhesion induced survival. In 
another study Lee and colleagues investigated 31 ovarian cancer cell lines. They compared 
the molecular and biological properties of ovarian cancer cells grown in 2D and 3D models 
with xenografts and ovarian tumours. They used poly-HEMA polymer coating of culture 
plates to establish the 3D spheroids. This study revealed a distinct alteration in protein 
expressions, proliferation rates and chemo-sensitivity in the 3D models which closer 
mimicked the xenograft in vivo characteristics than the 2D monolayer cultures [509]. 




With respect to cell morphology, my findings were similar to previous reports that indicated 
that OVCAR-5 cells form small clusters and SKOV-3 cells form larger cellular aggregates 
[509, 510]. Also consistent with other studies, the results showed that OVCAR-5 clusters 
express high levels of EGFR and c-MET, but have low HER-2 expression. SKOV-3 compact 
aggregates express high levels of all three receptors [397, 511, 512].  
Growth factors such as EGF and HGF are involved in phenotypical modulation of ovarian 
cancer cell behaviour and thus are likely to play a pivotal role in metastatic cell migration 
[278, 513-515]. They are associated with phenotypic modulation of ovarian cancer cells and 
aggressive tumours and this correlates with a poorer prognosis [516, 517]. High levels of EGF 
and EGFR have been detected in tumours, ascitic fluid and urine of patients with advanced 
ovarian cancer [518, 519]. Binding of EGF to EGFR will trigger a cascade of downstream 
signal transduction pathways including Ras-MAPK, PI3K-Akt, and STAT [520]. Moreover, 
the overexpression of epidermal growth factor receptors in advanced ovarian cancer cells and 
the association with rapid growth and disease spread have been reported [521, 522].  
HGF is responsible for activation of growth pathways that lead to invasive disease [470, 
523-525] and aberrant activation of HGF pathway induces invasive cell growth phenotype in 
cancer [526]. HGF stimulation of the PI3K-Akt signalling pathway has been correlated with 
increased motility and invasion of ovarian cancer cells [523].  The high levels of HGF found 
in the serum of women with a pelvic mass (>2 standard deviations above serum levels of 
women with benign tumours) is a sign of malignant manifestation and of a poor prognosis 
[527]. Additionally, the high levels of HGF in ascitic fluids from advanced ovarian cancer 
patients (reported levels of between 4.1-16 mg/mL) [487], are linked to resistance to targeted 
therapies, aggressive disease and poor prognosis in patients with epithelial ovarian cancers 
[337, 486, 487]. Moreover, high HGF levels in tumour cells are often associated with a 
reduced progression-free survival for the patient with advanced epithelial ovarian cancer 
[389]. HGF is a specific ligand for the c-MET receptor tyrosine kinase. The c-MET proto-
oncogene has been found to be overexpressed in 11% of advanced ovarian cancer patients 
[334]. Recently, Davies et al., have reported that 96% of malignant tissue obtained from 
ovarian cancer patients stains positive for the c-MET receptor [288]. Zhou et al. suggested 
that ovarian cancer cells are consistently exposed to both EGF and HGF in the tumour 




microenvironment and they both contribute to aggressive metastasis by activation of 
overlapping intracellular signalling pathways [526]. They found that EGF and HGF could 
increase cell growth in a concentration dependent manner within the range of 6.25-2400 pM 
(approximately 0.0375-14 ng/ml). Similar findings are presented in this study In contrast to 
these results, some studies report only a minor increase in cell proliferation in SKOV-3 
monolayer cells treated with HGF for 3-5 days [528].  
Cancer cells control their own metabolism according to their biosynthetic needs. Zhao et al. 
in reviewing literature suggest that energy production by many (but not all) cancer cells 
occurs mostly via aerobic glycolysis. The abnormally increased aerobic glycolysis, as well as 
other metabolic pathways in cancer cells has been associated with drug resistance. Zhao et al 
conclude that agents that reduce cellular metabolism may provide effective treatments [529]. 
Hence, the effects of the inhibitors on cellular metabolism were investigated. 
While the results in this chapter report an increase in cell growth and total protein 
concentration, there were no changes in cellular metabolism in the presence of the growth 
factors. This controversial outcome of cellular metabolism finding may be due to the fact that 
the experiments were carried out on 3D cell cultures. The 3D model is a complicated system 
where the cells are aggregated in floating clusters. These clusters and aggregates differ in 
surface area and the number of cells that form each cluster. Thus, the number of cells that are 
located on the outer surface of the cluster and hence that are not exposed to Alamar blue may 
not be equal even within the same sample and the bigger the cluster, the greater the number of 
cells that are exposed. This suggests that the assay of cellular metabolism may be influenced 
more by the surface area of clusters rather than the concentration of growth factors. 
Additionally microscopic observation revealed subpopulations of single floating cells that 
were not attached to the clusters. This is consistent with the fact that ovarian cancer cells 
survive in the ascitic fluid either as single cells or  as clusters and aggregates [156]. These 
numbers of these single cells differed between tested samples. Thus the relative amounts of 
these single floating cells may affect the results of the cellular metabolism assay. Given this, it 
would be interesting to investigate cellular metabolism in single cell suspensions of the 
samples of the same treatments via trypsinisation of the clusters prior to the metabolism 
assay.  




The effects of the small molecule inhibitors canertinib, which is an irreversible pan EGFR 
family inhibitor, and PHA665752, which is a reversible c-MET specific inhibitor, in the 
presence of EGF and HGF were evaluated. The selected inhibitor concentrations used were 
consistent with those in a previous study of hepatocellular carcinoma in mice [530]. Small 
molecule inhibitors of EGFR such as Gefitinib (ZD1839, Iressa) and Erlotinib (OSI-774, 
Tarceva) are reversible and have been approved by the FDA in the US for treatment of 
NSCLC [531]. However, many of these drugs do not induce a sustained clinical outcome with 
EGFR positive cancers [532, 533]. Canertinib is an inhibitor that irreversibly binds to the 
ATP pocket of the intracellular domain of the EFGR family of receptors. Unlike reversible 
tyrosine kinase inhibitors, an irreversible inhibitor may exert prolonged clinical activity 
against the target receptor. The advantage of the irreversible inhibitor is the permanent 
binding to the receptor, which can be translated into more sustained inhibition and the need 
for potentially lower doses [218]. A second favourable feature of canertinib is the rapid pan 
inhibition of all four members of the ErbB family of receptor tyrosine kinase [534]. There is 
thus good rationale for using an irreversible inhibitor to ensure a sustained inhibition of the 
receptors and their downstream signalling molecules [535].  
The efficacy of canertinib has been investigated in several types of cancers including breast, 
NSCLC, and ovarian cancer. In breast cancer, both in vitro and in vivo xenograft studies have 
demonstrated the anti-tumour effects of canertinib [248]. However, a phase II trial in platinum 
refractory ovarian cancer was indefinite, showing stable disease but no measurable response 
[219]. Adverse effects were seen in patients treated with canertinib, there include nausea, 
diarrhoea and skin rash [536]. 
The results presented here indicate that there is a concentration dependent inhibition of 
growth and metabolism of SKOV-3 compact aggregates treated with canertinib. The growth 
of OVCAR-5 clusters was inhibited less and there was no change in cellular metabolism. The 
higher effectiveness of canertinib on SKOV-3 compact aggregates may be due to their 
aberrant expression of EGFR and HER-2, compared to OVCAR-5 clusters that express less 
EGFR and have undetectable levels of HER-2 [537]. The low response of OVCAR-5 towards 
canertinib may be explained by the fact these cells show a low expression of HER-2 and have 
been shown to have frequent mutations in BRAF and KRAS [92, 98, 107]. Studies on NSCLC 




have shown that cells with high activation mutations in the KRAS pathway are resistant to 
tyrosine kinase inhibitors and this has been used to explain a poor prognosis with EGFR 
tyrosine kinase inhibitors [538-540]. 
Several other studies have shown the inhibitory effect of canertinib against different types of 
cancers. Irwin et al., [541] showed that canertinib can inhibit the growth of acute 
lymphoblastic leukaemia cells at concentrations of 0.1-5 µM [541]. The responsiveness of 
cancer cells to canertinib as a single agent was also observed in HER-2 positive tumours from 
breast cancer patients [309]. Other studies have shown the inhibitory effects of canertinib on 
cell proliferation of malignant melanoma cells [542] and breast cancer [246, 248]. 
PHA665752 is a reversible inhibitor of c-MET receptor tyrosine kinase. PHA665752 when 
used singly inhibited the growth of OVCAR-5 clusters and SKOV-3 compact aggregates in a 
concentration dependent manner. However, the effect on cellular metabolism was limited. In 
comparison with OVCAR-5 clusters, SKOV-3 compact aggregates were less responsive to the 
c-MET inhibitor. It is possible that the high expression of HER-2 receptors in SKOV-3 may 
enhance the cells ability to resist the c-MET inhibitor.  
Studies have previously suggested that cancer cells may utilise an alternative pathway for 
growth once the EGFR/HER2 pathway is blocked. Therefore, it can be speculated that when 
c-MET is blocked, cells that retain high expressions of HER-2 may utilise it as an alternative 
route. This co-activation of multiple RTKs in cancer cells confers resistance to single-agent 
therapy. However, this resistance can easily be overcome by simultaneously inhibiting several 
RTKs with rationally chosen drug combinations [543].  
 Many other studies have shown the effectiveness of PHA665752. Experiments on lung 
adenocarcinoma cells with KRAS gene mutations have shown that PHA665752 can inhibit 
growth, proliferation and metastasis [346].  In an in vitro study, Ma et al., showed a 
concentration dependent inhibition of growth of BaF3.TPR-MET cells upon exposure to 
PHA665752 [544] and Christensen et al., demonstrated that PHA665752, at concentrations of 
between 0.1-5.0 µM, elicited concentration dependent inhibition of gastric, pancreatic, and 
lung-carcinoma cell lines [256]. Other studies, in NSCLC and gastric cancers, showed a 
greater inhibitory effect on growth/metabolism across a range of concentration (0.01-10µM)   




It has been suggested that ovarian cancer cells may have the ability to activate multiple 
receptors for growth, proliferation and metastasis [241, 334, 338]. This co-activation of 
multiple receptor tyrosine kinases may explain the relatively limited effectiveness of single 
drug treatments targeting only one of these receptors in these cells [536, 545]. Therefore, 
there is a rationale for targeting multiple receptors to improve the efficacy of the drugs. 
Consistent with this, the combination of canertinib and PHA665752 at the lowest effective 
concentrations for each inhibitor, (which had been previously determined in the concentration 
dependent experiments with the single inhibitor treatments), compromised cell growth and 
cellular metabolism more effectively than the single inhibitor alone. Western blot analyses 
suggest that the combination may modulate the expression of the target receptors and/ or the 
phosphorylation of their downstream signalling molecules. This is consistent with other 
studies indicating the inhibitory properties of canertinib on the phosphorylation of EGFR and 
HER-2 receptor tyrosine kinases in malignant melanoma cells [542]. 
These results suggest that blocking multiple growth receptors may compromise cell survival 
in advanced ovarian cancer cell cultures and are consistent with studies on other cancer types. 
A study of NSCLC and gastric cancer cell lines, by Engelman and colleagues showed that 
combining PHA665752 with gefitinib reduced cell proliferation more effectively than the 
single treatments alone [482]. Also Tang et al., reported a greater impact of combined 
inhibition of both EGFR and HER-2 with reduced growth of EGFR-mutation mediated 
erlotinib-resistant lung cancer cells [546]. Additionally, Crosswell et al, established that a 
combination of PHA665752 with rosiglitazone, significantly compromised growth of 
neuroblastoma cell line [254].  
A combination of small molecule inhibitors or monoclonal antibodies with cytotoxic drugs 
has also been explored in clinical trials for ovarian cancer treatment. The combination of 
cetuximab, a monoclonal antibody against EGFR, and paclitaxel or carboplatin was effective 
as a primary therapy for ovarian cancer, but unfortunately this does not ensure a progression-
free survival [547]. Also a limited clinical benefit was observed with the combination of 
lapatinib with topotecan for the treatment of platinum-resistant ovarian cancer [548]. With 
respect to other cancer types, an in vivo animal model of head and neck carcinoma study by 
Chun et al., [259] demonstrated that a combination of gemcitabine and gefitinib reduced cell 




growth and phosphorylation of EGFR as well as levels of the downstream molecule ERK in a 
synergistic manner [259]. Moreover, a combination of capecitabine with the HER-2 antibody, 
trastuzumab, or with lapatinib, exhibited clinical potential in the treatment of breast cancer 
patients, although this was accompanied by an increase in undesirable side effects [549, 550].  
As aforementioned, EGF and HGF are potent cytokines that are implemented in the 
activation of cell growth and proliferation via the upregulation of growth markers including 
PCNA [496, 551, 552]. This is consistent with the results presented in this thesis that 
demonstrates the concentration dependent increase in the expression of PCNA in the presence 
of EGF. There was also a marginal increase in PCNA expression with increasing 
concentrations of HGF. The downregulation in PCNA expression was observed in both cell 
lines with single inhibitors and combination. The down regulation of PCNA is consistent with 
Mayer and colleagues who indicated a decrease in PCNA expression upon growth inhibition 
[553]. 
Vascular endothelial growth factor, VEGF, is a key driver of cell proliferation, survival and 
migration. VEGF receptors are highly expressed in the majority of solid tumours including 
endocrine, brain, NSCLC, gastrointestinal, breast, kidney, bladder, endometrium and ovarian 
tumours [554-560]. It plays a pivotal role in the development of normal and pathological 
ovarian biology, including cancers [432, 437, 473, 561]. Ovarian cancer is characterised by 
abundantly vascularised tumours and is dependent on VEGF secretion for angiogenesis [562]. 
VEGF is typically linked to more aggressive tumours and a poor prognosis [153, 563] with 
high levels of VEGF in malignant ascites from advanced ovarian cancer patients [433]. 
Studies suggest that blocking VEGF secretion can reduce ascites formation and tumour 
burden [437, 561, 564]. In this study, canertinib and PHA665752 inhibited VEGF secretion 
when applied singly and in combination. This is consistent with other studies suggesting that 
tyrosine kinase inhibitors can inhibit VEGF secretion and compromise vascularisation 
processes [153, 565].  
Functional interactions between VEGF and EGFR have been demonstrated in gefitinib and 
cetuximab resistant colon cancer cells [566]. Cancer cells that are resistant to EGFR inhibitors 
are found to express high levels of VEGF, which also correlates with aggressive tumours and 




angiogenesis in vivo [567]. This correlation is an indicator of intracellular crosstalk between 
the signalling pathways and poses a promising target for anti-cancer treatments. The tumour 
environment may be hypoxic and this is regulated by hypoxia-inducible transcription factors 
(HIFs) by binding to the VEGF promoter to trigger transcription [568]. In context, another 
transcriptional activation of HIF includes upregulation of EGFR and EGFR signalling [569]. 
The presence of high levels of VEGF in ovarian cancer malignant ascites is mediated by 
several factors including EGF and transforming growth factor-β (TGFβ). Furthermore, many 
EGFR inhibitors including cetuximab and panitumumab and small molecule tyrosine kinase 
inhibitors such as gefitinib, erlotinib and lapatinib have been shown shown inhibitory actions 
against VEGF in both in vitro and in vivo conditions [570]. Thus, angiogenesis is induced by 
the production of tumour derived VEFG which is stimulated by upregulation of EGFR 
receptors and activation of downstream signalling molecules [570]. 
In summary this chapter describes an in vitro investigation of the effect of combining two 
inhibitors of three receptor tyrosine kinases on two ovarian cancer cell lines that form clusters 
and compact aggregates in a 3D cell culture model. The combination of canertinib and 
PHA665752 compromised cell growth, cellular metabolism, the expression of receptors, the 
expression of downstream signalling molecules, and VEGF secretion. The efficacies of the 
inhibitors under these experimental conditions are of interest but further study on more cell 
lines is needed before any clinical relevance can be inferred. 







4 CHAPTER FOUR 
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4.1 Introduction  
During the progression of ovarian cancer, tumour cells undergo phenotypic differentiation 
and attain motility, subsequently shedding off from the ovaries. Cells then migrate into the 
abdominal cavity where they survive as single cells and cellular aggregates [33, 157]. Once 
the malignant cells seed on the surface of the peritoneum they grow and secrete cytokines and 
growth factors which, in turn, trigger the leakage of the vascular network underneath the 
peritoneal wall. This may result in the influx of fluids into the abdominal cavity, a process 
that is referred to medically as ascites [158, 571]. Malignant ascites is the abnormal 
accumulation of plural fluid in the abdominal cavity due to tumours and is an indicator of 
disease spread and a poor prognosis with a reduced 5-year survival rate [161, 165, 176, 572, 
573]. It is found in almost 37% of women with advanced ovarian cancers [165, 176, 574] but 
at a lower percentage with malignant tumours from other organs [575-577].  
Malignant ascites comprise a combination of cellular and acellular components [156, 168]. 
Cellular components include the tumour cells, which are present as both single cells and 
aggregates [578] along with stromal components that include adipocytes, adipose tissue-
derived stem cells, bone marrow-derived stromal cells, fibroblasts, inflammatory cells, 
endothelial cells, and immune cells [579, 580]. The acellular components of ascites include 
cytokines, growth factors, chemokines, extracellular matrix components as well as bioactive 
lipids. All of these can affect the cancer cell behaviour and disease progression [168, 581-
584]. Pro-tumorigenic cytokines such as IL-6, IL-8, IL-10 and VEGF are found in 
significantly increased levels in ovarian cancer ascites compared to plasma. Other cytokines 
including IL-2, IL-5, and IL-7 are found at lower levels. Collectively, these factors are part of 
a pro-inflammatory and immunosuppressive microenvironment [585] which plays a role in 
tumour progression. IL-6 and IL-8, for example are oncogenic stimuli, and are found highly 
expressed in ovarian cancer ascites and have been shown to be promoters of epithelial-
mesenchymal transition where cells regain their invasive properties and angiogenesis [586-
588]. VEGF has also been implicated as a promoter of ascites formation and in the metastasis 
of ovarian cancer cells [153, 589].  




Proteomic studies have revealed the presence of up to 2000 proteins in ascitic fluid from 
ovarian cancer patients [590, 591]. Other components present at high levels in ascites from 
ovarian cancer patients include RNA-binding proteins, exosomes (cell-derived vesicles that 
are present in most eukaryotic fluids), low molecular weight metabolites, lysophosphatidic 
acid (LPA), cholesterol and fatty acids [590].  
Ascitic fluids are thought to influence the effect of anti-tumour drugs. The significance of 
the surrounding microenvironment in the development of cancer is being increasingly 
acknowledged and it seems to play an essential role in mediating and sustaining the hallmarks 
of cancer [22, 592]. Cellular aggregates in the ascitic fluid are more likely to exhibit chemo 
resistance and enhanced malignant potential [158, 571, 593]. 
As described earlier in this thesis small molecule tyrosine kinase inhibitors (TKIs) are 
hydrophobic compounds that inhibit receptor tyrosine kinases (RTKs). These inhibitors are 
promising tools in the development of anti-cancer drugs [594, 595]. In the previous chapter, it 
was demonstrated that by blocking multiple receptor tyrosine kinases with a combination of 
two TKIs, canertinib, a pan inhibitor of EGFR family and PHA665752, an inhibitor of c-
MET, the growth of clusters and compact aggregates of the OVCAR-5 and SKOV-3 ovarian 
cancer cell lines can be compromised. The combination of these two inhibitors further 
reduced the phosphorylation of EGFR, HER-2 and c-MET receptors and downstream 
signalling proteins p-Akt and p-ERK [596]. However, these effects may not occur in the in 
vivo tumour microenvironment due to the presence of growth promoting substances in the 
surrounding ascitic fluid that may influence the cellular response to the inhibitors.  
In view of the above, this chapter will investigate the efficacy of the two inhibitors on 
ovarian cancer cell clusters and compact aggregates, in the presence of ascitic fluids from 
advanced ovarian cancer patients. Such an environment may represent a more accurate 
representation of the microenvironment for the ovarian cancer cells in the body. This chapter 
will also investigate the factors underlining any difference in cellular response to the tyrosine 
kinase inhibitors in this microenvironment. 





Ascitic fluid from ovarian cancer patients will modulate the behaviour of ovarian cancer cell 
lines OVCAR-5 and SKOV-3 and their response to treatments with TKIs.  
Ascitic fluid will modulate the uptake of TKIs by ovarian cancer cells via binding of 
albumin to TKIs.  
4.3 Aims of the study 
1. To determine the effect of malignant ascites on ovarian cancer cell growth and 
metabolism. 
2.  To investigate the efficacy of two small molecule tyrosine kinase inhibitors, canertinib 
and PHA665752, in the presence of ascites from advanced ovarian cancer patients. 
3. To investigate the mechanisms by which ascites affect the efficacy of the drugs  
4.4 Materials and Methods 
Materials and methods are as described in Chapter-2 sections 12 and 13. 
4.5 Results 
4.5.1 Inhibitor effects on cell morphology in the presence of ascitic fluid. 
Ovarian cancer cells can disseminate into the peritoneal cavity where they are exposed to 
ascitic fluid, which may affect the behaviour and responses of the cancer cells. This behaviour 
and responses could differ from those of cells in cultures in the lab that are exposed to cell 
culture media supplemented with growth factors. In an attempt to better replicate the normal 
environment of ovarian cancer cells and to investigate the effects of canertinib and 
PHA665752 on the morphology and growth of OVCAR-5 clusters and SKOV-3 compact 
aggregates under these conditions, experiments were carried out in the presence of 50% (v/v) 
ascitic fluids from advanced ovarian cancer patients and growth factor activated cells. The 
rationale of using 50% (v/v) ascitic fluid was to mimic the in vivo microenvironment which is 
characterised by undiluted ascitic fluid [597]. This is to ensure that the cells are exposed to 




high levels of cytokines and growth factors present in the ascitic fluid. However, other studies 
have used a much lower concentration of ascitic fluid (5-10%), which is not akin to 
physiological environment of advanced ovarian cancer  [598, 599].  
Growth factor treated cells showed notable morphological changes upon treatment with the 
inhibitors when compared to untreated controls. OVCAR-5 clusters appeared smaller with the 
single inhibitors and the inhibitor combination compared to untreated controls (Figure 4.1 A). 
There was also notable cell debris in the combination-treated cells.  
SKOV-3 cellular aggregates (Figure 4.1 C) were large and compact with smooth edges in 
the growth factor treated controls, but cells treated with canertinib had an irregular rim on the 
aggregates and cell debris was notable. Cells treated with PHA665752 alone did not show 
these features in SKOV-3 compact aggregates, but with the combination of both inhibitors 
smaller aggregates and single cells were present. These responses were not seen in the 
presence of ascitic fluid with both OVCAR-5 (Figure 4.1 B) and SKOV-3 (Figure 4.1 D) 
cultures. In these experiments the morphology of all clusters and aggregates were similar to 
the controls. These results suggest that ascitic fluid may be affecting the efficacy of canertinib 
and PHA665752. 





Figure 4.1. The effect of ascitic fluid on cell morphology of OVCAR-5 (A) and SKOV-3 
(C) clusters and aggregates. There was a marked change in morphology when cells were 
treated with single or combination treatments of canertinib and PHA665752, in the presence 
of 20 ng/ml growth factors (GF) when compared to controls. In contrast OVCAR-5 (B) and 
SKOV-3 (D) cellular clusters exposed to ascitic fluid showed no obvious differences in 
morphology between the treatments and controls. Data are shown with ascitic fluid from 
patient 1. No obvious differences were also observed with ascitic fluid from patients 2 or 
patient 3 (data not shown). All experiments were independently performed at least three times 
with triplicates. 




4.5.2 The effect of ascitic fluid on cell growth in the presence of TKIs. 
To investigate the effect of ascitic fluid on the efficacy of the inhibitors OVCAR-5 and 
SKOV-3 clusters and aggregates were analysed after 48 hours of exposure to the inhibitors in 
the presence of ascitic fluid or GF. The expression of the proliferative cell nucleus antigen 
(PCNA) protein was also determined as a marker for cell proliferation in the S-phase of the 
cell cycle. As shown in Figures 4.2 and 4.3 (and described earlier in the thesis), in the 
presence of the growth factors (GF) cell numbers of both OVCAR-5 clusters (Figure 4.2) and 
SKOV-3 aggregates (Figure 4.3), were significantly reduced in single inhibitor treatments but 
more markedly when the inhibitors were combined. The reduction of cell number correlated 
with a declined expression of PCNA.  
In contrast, the cell numbers of OVCAR-5 cultures and SKOV-3 compact aggregates with 
the inclusion of ascitic fluid were higher than the GF treated cells, and the treatments with the 
single inhibitors or combination of inhibitors did not reduce the cell number. Furthermore, the 
expression of PCNA did not decrease. Similar results were obtained with the ascitic fluid 
from all 3 patients. These results suggest that the ascitic fluids may promote cell growth. They 
also demonstrate that in the presence of the ascitic fluid the inhibitors have no effect.





Figure 4.2. Ascitic fluids increased cell number relative to GFs and negated the effects of the inhibitors. The graphs indicate that canertinib and 
PHA665752 applied singly or in combination reduced the growth of OVCAR-5 cellular clusters, activated by 20 ng/ml growth factors (also as 
detailed earlier in the thesis). In contrast cell number increased in cultures that included 50% (v/v) ascitic fluid. Expression of PCNA was largely 
unaffected by the inhibitors in the presence of the ascitic fluid. All experiments were independently performed at least three times with 
triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 
(***), and p<0.0001 (****) compared to the control or the other concentration. 





Figure 4.3. Ascitic fluids increased cell number relative to GFs and negated the effects of the inhibitors. The graphs indicate that canertinib and 
PHA665752 applied singly or in combination reduced the growth of SKOV-3 compact aggregates, activated by 20 ng/ml growth factors (also as 
detailed earlier in the thesis). In contrast cell number increased in cultures that included 50% (v/v) ascitic fluid. Expression of PCNA was largely 
unaffected by the inhibitors in the presence of the ascitic fluid. All experiments were independently performed at least three times with 
triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 
(***), and p<0.0001 (****) compared to the control or the other concentrations. 




4.5.3 Ascitic fluid may compromise the Alamar blue dye assay 
To investigate the effect of ascitic fluid on cellular metabolism in cell clusters and 
aggregates during treatment with the inhibitors, an Alamar blue dye assay was performed. As 
described earlier in the thesis Alamar blue is a non-toxic dye which is readily taken up and 
reduced in a redox reaction in viable cells. The reduced form of the Alamar blue dye has a 
pink colour which is then excreted into the cell culture media. This is a widely used technique 
to determine cell viability [600]. In the current experiments cells were exposed to the 
inhibitors either singly or in combination for 48 hours in the presence of 50% (v/v) ascitic 
fluid or GFs.  
Cellular metabolism in both cell lines was very low in ascitic fluid treated cells, compared to 
GF treated cells, (Figure 4.4 A and B). This may suggest that the ascitic fluid may 
compromise cellular metabolism. There are two possible scenarios that could explain these 
results. First, the ascitic fluid may compromise the cellular activity and make the cells 
quiescent. However, this notion is not supported by the increase in cell number described in 
the previous section. The second scenario is that components in the ascitic fluid may bind to 
Alamar blue dye and that subsequently limits the movement of dye into cells. 




Figure 4.4. Ascitic fluids reduced cellular metabolism as indicated with an Alamar blue assay. Clusters of OVCAR-5 (A), and 
compact aggregates of SKOV-3 (B) cell lines showed a significant reduction in cellular metabolism, when treated with inhibitors 
singly or combination, in the presence of 20 ng/mL of GF, compared with untreated cells. The same cells show a significantly 
lower metabolism in the presence of ascitic fluid from each of the 3 patients. All experiments were independently performed at 
least three times with triplicates. ). Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control or the other concentrations. 




4.5.4 Ascitic fluids compromised the uptake of PHA665752 in cell clusters and 
aggregates  
Like most small molecule inhibitors, canertinib and PHA665752 are hydrophobic and are 
thought to move freely across the plasma membrane [601]. The inhibitors then bind to the 
ATP binding site of the tyrosine kinase domain located on the cytoplasmic side of the target 
receptor. As a result, the autophosphorylation of specific tyrosine residues is inhibited with 
subsequent inhibition of the associated signalling cascade. As described in Sections 4.5.2 and 
4.5.3, the inhibitory effect of canertinib and PHA665752 was negated when ascitic fluids 
from 3 ovarian cancer patients were present. In order to determine why the ascitic fluids had 
this effect, the cellular uptake of PHA665752 was investigated to determine whether the 
ascitic fluid may prevent uptake of the inhibitors into the cells. PHA665752 shows fluorescent 
properties upon excitation with 488 nm light. This allows the determination of its uptake into 
cells using a flow cytometry.  
After 48 hours of exposure to PHA665752 in the presence of ascitic fluids, the amount of 
PHA665752 in OVCAR-5 and SKOV-3 cells was significantly lower compared to that in 
cells that had been incubated in a serum free media (SFM) (Figure 4.5. A and B). This 
suggests that the ascitic fluids may affect the movement of the inhibitor into the cells. 













Figure 4.5. The cellular uptake of PHA665752 in the presence and absence of ascitic fluid. Clusters of OVCAR-5 (A) and aggregates of 
SKOV-3 cells (B) show reduced uptake of PHA665752 upon exposure to 50% (v/v) ascitic fluids from 3 different ovarian cancer patients (for 
detailed methodology see Figure 2.12B). Negative controls were clusters and aggregates in SFM with no PHA665752 or ascitic fluid treatment. 
All experiments were independently performed at least three times with triplicates. ). Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 




4.5.5 Removal of ascitic fluids restored the cellular uptake of PHA665752 
To investigate whether the uptake of PHA665752 resumed after removal of the ascitic fluid 
cells were treated with 50% (v/v) ascitic fluid for 24 hours, the ascitic fluid was washed off 
and the cells were incubated with the inhibitor in SFM for a further 24 hours for a total 
exposure time of 48 hours (the method as shown in Figure 2.12 C). The uptake of 
PHA665752 increased in both OVCAR-5 clusters (Figure 4.6 A) and SKOV-3 aggregates 
(Figure 4.6 B), relative to uptake in the previous section, given that levels of PHA667252 
uptake were similar to cells in the serum free medium (SFM) (Figure 4.6 A and B). This 
result suggests that certain components in ascitic fluid may compromise the cellular uptake of 
PHA665752 but that this effect can be reversed with the removal of the ascitic fluid.













Figure 4.6. Removal of ascitic fluids restored the cellular uptake of PHA665752. OVCAR-5 clusters (A) and SKOV-3 aggregates (B) were 
able to take up PHA665752 when ascitic fluids were removed (For detailed methodology see Figure 2.12 C). All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control.




4.5.6 Treatment with PHA665752 for 24 hours before exposure to ascites reduced 
cellular uptake of the drug 
To further examine the effect of the fluids on cellular uptake of PHA665752 the 
cells were incubated with the inhibitor prior to the inclusion of the ascitic fluids. 
Cells were exposed to PHA665752 for 24 hours before the introduction of ascitic 
fluid for a further 24 hours giving a total exposure time of 48 hours. The uptake of 
PHA665752 was markedly reduced after the ascitic fluids were introduced in 
OVCAR-5 clusters (Figure 4.7 A) and SKOV-3 compact aggregates (Figure 4.7 B). 
This may suggest that ascitic fluids may facilitate the efflux of the inhibitor out of 
cells.














Figure 4.7. The cellular uptake of PHA665752 after an initial exposure of the cells to PHA665752 for 24 hours followed by 
exposure to ascitic fluids. OVCAR-5 clusters (A) and SKOV-3 aggregates (B) contained significantly less PHA665752 after they 
were exposed to ascitic fluid (methods shown in Figure 2.12 D). All experiments were independently performed at least three 
times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 
(*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 




4.5.7 Protein serum albumin compromise the cellular uptake of PHA665752 
The above results suggest there is a possible interaction between PHA665752 with 
components in the ascitic fluid. These components could be possibly binding to the inhibitor 
and subsequently reducing the amount of PHA665752 that is taken up into the cell and/or 
affecting efflux from the cell. One candidate for such an interaction is human serum albumin 
protein. Levels of serum albumin are high in ascitic fluids obtained from patients with ovarian 
cancers [170]. Furthermore several anti-cancer drugs, including tyrosine kinase inhibitors, are 
known to bind to serum albumin [602] and as a result the efficacy of these inhibitors can be 
compromised. 
In light of this an investigation of the effect of serum albumin on the uptake of PHA665725 
was carried out. Bovine serum albumin (BSA) was used as a protein representative of human 
serum albumin as the two proteins share 78.1% of amino acid sequence identity [603] which 
may be sufficient for reliable binding properties. Moreover, BSA is frequently used as a 
model protein due to its structural homology with HSA [604] and a study by Bourassa and 
colleagues demonstrated that both proteins have similar binding properties even though the 
binding of Tamoxifen (an anti-tumour drug used for treatment of oestrogen receptor positive 
breast cancer) with BSA was less prominent than that of HSA [603]. The levels of BSA in 
FBS is approximately 35.6 mg/mL, which is close to the normal concentration of BSA in 
plasma (35-55 mg/mL) [605]. Plasma levels of HSA are within the range of 35-50 g/L. In 
light of this clusters and aggregates of OVCAR-5 and SKOV-3 ovarian cancer cell lines were 
exposed to PHA665752 in media supplemented with different concentrations of BSA (using 
the method described in Figure 2.12 E). 
The uptake of PHA665752 in OVCAR-5 cellular clusters (Figure 4.8 A) and SKOV-3 
compact aggregates (Figure 4.8 B) was found to be significantly reduced with increasing 
concentrations of BSA, relative to the control of serum free media. While I have assayed only 
PHA665752 it is possible that the non-specific binding capabilities of serum albumin may 
mean that it could play a role in reducing the cellular uptake of other tyrosine kinase 
inhibitors and thus that the presence of serum albumin may thus affect the efficacy of the 
drugs.





Figure 4.8. BSA reduced the uptake of PHA665752 into OVCAR-5 cellular clusters (A) and SKOV-3 compact aggregates (B), 
in a concentration dependant manner. This assay was carried out using the methods shown in Figure 2.12 E). Negative controls 
were cellular clusters and aggregates in serum free media SFM and no drug. All experiments were independently performed at 
least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated 
as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 




4.5.8 Different concentration of PHA665752 affected the cellular uptake in the 
presence of 4% BSA 
To investigate whether the inhibition of the uptake of PHA665752 by BSA could be 
overcome by increasing the concentration of the PHA665752, a dose response study was 
conducted in the presence of 4% BSA. This BSA concentration is a physiologically relevant 
one in the ascitic fluid of ovarian cancer patients [605]. For this assay the control cells were 
activated with media supplemented with a mixture of growth factors (GF). An increased 
concentration of PHA665752 led to elevated uptake of the inhibitor in both GF and BSA 
stimulated cells. However, in order to reach 80% of the cellular uptake of PHA665752 in 
OVCAR-5 cell clusters with 4% BSA 8 µM PHA665752 was required compared to 2 µM in 
GF supplemented media (Figure 4.9 A). Similar results were obtained with SKOV-3 cell 
aggregates (16 µM compared to 4 µM) (Figure 4.9 B). The increased uptake of PHA665752 
was correlated with the reduction of growth activity. 
In OVCAR-5 cell clusters, the concentrations of PHA665752 that reduced cell number by 
50% (EC 50%) were 1.0 µM and 16 µM in GF and 4% BSA supplemented media respectively 
(Figure 4.9 C). In SKOV-3 cell aggregates, the EC 50% were approximately 2 µM and 32 
µM with a GF medium and 4% BSA, respectively (Figure 4.9 D). Thus despite similar rates 
of uptake of PHA665753 there was a greater decrease of cell number in the OVKAR-5 
clusters.  
 




Figure 4.9. The effect of PHA665752 concentration on cellular uptake and cell number in 
the presence of growth factors (GF) and 4% BSA supplemented media. The cellular uptake of 
PHA665752 by ovarian cancer cell lines OVCAR-5 (A) and SKOV-3 (B), increased with 
increasing concentrations of PHA665752. Uptake reached a saturation plateau at about 8 µM. 
Cell numbers of OVCAR-5 (C) and SKOV-3 (D) cultures decreased in a concentration 
dependent manner in response to increasing concentrations of the inhibitor in the presence of 
20ng/ml GF and 4% BSA (experimental methods were as shown in Figure 2.12 F). All 
experiments were independently performed at least three times with triplicates. Data are 
expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as 
p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control or the 
other concentrations. 




4.5.9 The expression and phosphorylation of receptor tyrosine kinases were affected by 
ascitic fluids 
Taken together, the above results suggest that there may be components in the ascitic fluid 
that bind to PHA665752 and thus prevent it from entering the cells and also enhance its efflux 
from the cells. It is unknown if a similar mechanism might also pertain to canertinib. 
However, drug resistance in ovarian cancer cells may also be attributed to the number of 
signalling proteins that are activated during exposure to ascitic fluids and subsequently cancer 
cells may thus be able to reduce the inhibitory effect of the drug(s). To investigate this 
possibility, the expression of EGFR, HER-2, and c-MET and their phosphorylation status 
were examined in the presence of ascitic fluid.  
4.5.9.1 The effect of ascitic fluid on EGFR and p-EGFR 
In both OVCAR-5 clusters (Figure 4.10 A) and SKOV-3 compact aggregates (Figure 4.11 
A) there was a significant decrease of phosphorylated EGFR (p-EGFR) with single and 
combination treatments of canertinib and PAH665752 in both GF and ascitic fluid exposed 
cells. The ascitic fluid from all three ovarian cancer patients produced broadly similar results. 
The ascitic fluids from all three patients decreased the total expression of EGFR in SKOV-3 
aggregates (Figure 4.11 B). However, the total expression of EGFR in the presence of ascitic 
fluid from patient 1 ascites was not significant in OVCAR-5 clusters. This was in contrast to 
the ascitic fluid from the other patients (Figure 4.10 B).  
4.5.9.2 The effect of ascitic fluid on c-MET and p-MET 
The combination of canertinib and PHA665752 significantly reduced the phosphorylation of 
MET protein (p-MET) in the GF exposed OVCAR-5 cell clusters (Figure 4.12 A). The 
combination also reduced p-MET in patient 1 ascitic fluid treated OVCAR-5 cell clusters. 
However, cells exposed to ascitic fluids from patients 2 and 3 showed less p-MET in all 
controls and treated cells (Figure 4.12 A). The inhibitory action of the two inhibitors showed 
a pronounced effect in p-MET in the GF and all ascitic fluid exposed SKOV-3 cells (Figure 
4.14 A). The total expression of c-MET in ascitic fluids exposed OVCAR-5 (Figure 4.12 B) 
and SKOV-3 cells (Figure 4.14 B) were lower than the GF exposed cells.  
 




4.5.9.3 The effect of ascitic fluid on HER-2 and p-HER-2 
Canertinib applied alone and in combination with PHA665752 significantly reduced the 
phosphorylation of HER-2 (p-HER-2) in the GF and ascitic fluids of patients 1 and 3 treated 
SKOV-3 cell aggregates (Figure 4.13 A), but cells exposed to ascitic fluid from patient 2 had 
marginally reduced expression. The total expression of HER-2 was also reduced in canertinib 
treated cells both as a single treatment and with the combination. Again, the total expression 
of HER-2 in SKOV-3 cells treated with the ascitic fluid from the three patients was lower 
than the GF treated cells (Figure 4.13 B). OVCAR-5 cell clusters are a HER-2 negative cell 
line. 
 





Figure 4.10. The effect of canertinib and PHA665752 on the expression and phosphorylation of EGFR in the presence of ascitic fluids from 
three ovarian cancer patients. Western blotting and densitometry analysis of OVCAR-5 cellular clusters, showing the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-EGFR, (B) EGFR, in the presence of ascites from 
advanced ovarian cancer patients. Each column colour represents ascites from a different advanced ovarian cancer patient. All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 





Figure 4.11. The effect of canertinib and PHA665752 on the expression and phosphorylation of EGFR in the presence of ascitic fluids from 
three ovarian cancer patients. Western blotting and densitometry analysis of SKOV-3 compact aggregates, showing the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-EGFR, (B) EGFR in the presence of ascites from 
advanced ovarian cancer patients. Each column colour represents ascites from a different advanced ovarian cancer patient. All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 






Figure 4.12. The effect of canertinib and PHA665752 on the expression and phosphorylation of c-MET in the presence of ascitic fluids from 
three ovarian cancer patients. Western blotting and densitometry analysis of OVCAR-5 cellular clusters, showing the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-MET, (B) c-MET, in the presence of ascites from 
advanced ovarian cancer patients. Each column colour represents ascites from a different advanced ovarian cancer patient. All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 





Figure 4.13. The effect of canertinib and PHA665752 on the expression and phosphorylation of HER-2 in the presence of ascitic fluids from 
three ovarian cancer patients. Western blotting and densitometry analysis of SKOV-3 compact aggregates, showing the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-HER-2, (B) HER-2 in the presence of ascites from 
advanced ovarian cancer patients. Each column colour represents ascites from a different advanced ovarian cancer patient. All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 





Figure 4.14. The effect of canertinib and PHA665752 on the expression and phosphorylation of c-MET in the presence of ascitic fluids from 
three ovarian cancer patients. Western blotting and densitometry analysis of SKOV-3 compact aggregates, showing the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-MET, (B) c-MET in the presence of ascites from 
advanced ovarian cancer patients. Each column colour represents ascites from a different advanced ovarian cancer patient. All experiments were 
independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 




4.5.10 Ascitic fluids decrease the expression of downstream signalling proteins.  
Akt and ERK are two of the downstream signalling proteins activated by EGFR, HER-2 and 
c-MET and these were investigated to further study the effects of inhibitors in the presence of 
ascitic fluid.  
4.5.10.1 Akt and p-Akt 
In comparison with the GF activated cells, the phosphorylated and total levels of Akt were 
significantly elevated in ascitic fluid activated OVCAR-5 cells (Figure 4.15 A and B). The 
levels of p-Akt and Akt in SKOV-3 cell aggregates were also significantly increased (Figure 
4.17 A and B). Single and combined inhibitors did not reduce the Akt and p-Akt levels in the 
ascitic fluid activated OVCAR-5 and SKOV-3 cells. These responses were consistent with 
ascitic fluid from all three patients. 
4.5.10.2 ERK and p-ERK 
The phosphorylation and total expression of ERK was lower in both cell lines in cells that 
were in the ascitic fluid compared to the GF treated cells. Both p-ERK and ERK in both cell 
lines were significantly reduced in single and combination treatments of canertinib and 
PHA665752 with GF (Figure 4.16 A and B for OVCAR-5 and Figure 4.18 A and B for 
SKOV-3). However, single and combination of both inhibitors did not reduce the levels of p-
ERK and ERK in OVCAR-5 cell clusters in the presence of ascitic fluid (Figure 4.16 A and 
B). The combination of both inhibitors reduced the levels of p-ERK in SKOV-3 cell 
aggregates in the ascitic fluid from patient 3 (Figure 4.18 A and B).  





Figure 4.15. The effect of canertinib and PHA665752 on the expression and phosphorylation of Akt in the presence of ascitic fluids from three 
ovarian cancer patients. Western blots and densitometry analysis of OVCAR-5 cellular clusters show the effects of canertinib and PHA665752, 
in single and combination, on total expression and phosphorylation of (A) p-Akt, (B) Akt in the presence of ascites from three ovarian cancer 
patients. Each column colour represents ascites from a different patient. All experiments were independently performed at least three times with 
triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 
(***), and p<0.0001 (****) compared to the control. 




Figure 4.16. The effect of canertinib and PHA665752 on the expression and phosphorylation of ERK in the presence of ascitic fluids from 
three ovarian cancer patients. Western blots and densitometry analysis of OVCAR-5 cellular clusters show the effects of canertinib and 
PHA665752, in single and combination, on total expression and phosphorylation of (A) p-ERK, (B) ERK, in the presence of ascites from three 
ovarian cancer patients. Each column colour represents ascites from a different patient. All experiments were independently performed at least 
three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are indicated as p<0.05 (*), 
p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control. 





Figure 4.17. The effect of canertinib and PHA665752 on the expression and phosphorylation of Akt in the presence of ascitic fluids from three 
ovarian cancer patients. Western blots and densitometry analysis of downstream signalling molecules, Akt in SKOV-3 compact aggregates 
treated with canertinib and PHA665752 in the presence of ascitic fluids from three ovarian cancer patients. Western blotting and densitometry 
analysis of SKOV-3 compact aggregates, showing the effects of canertinib and PHA665752, in single and combination, on total expression and 
phosphorylation of (A) p-Akt, (B) Akt in the presence of ascites from the patients. Each column colour represents ascites from a different patient. 
All experiments were independently performed at least three times with triplicates. Data are expressed as means ± S.E.M (n=3). Data considered 
statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control .





Figure 4.18. The effect of canertinib and PHA665752 on the expression and phosphorylation of ERK in the presence of ascitic fluids from 
three ovarian cancer patients. Western blots and densitometry analysis of downstream signalling molecules, ERK, in SKOV-3 compact 
aggregates treated with canertinib and PHA665752 in the presence of ascitic fluids from three ovarian cancer patients. Western blotting and 
densitometry analysis of SKOV-3 compact aggregates, showing the effects of canertinib and PHA665752, in single and combination, on total 
expression and phosphorylation of (A) p-ERK, (B) ERK, in the presence of ascites from the patients. Each column colour represents ascites from 
a different patient. All experiments were independently performed at least three times with triplicates. Data are expressed as means ± S.E.M 
(n=3). Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control. 





In this chapter, the effects of ascitic fluids, obtained from advanced ovarian cancer patients, 
on the inhibitory action of two tyrosine kinase inhibitors in a 3D cell model of ovarian cancer 
cell lines were documented. The main findings were firstly that ascitic fluids promoted cell 
growth and sustained cell viability in the absence or presence of canertinib and PHA665752. 
Secondly that the expression of PCNA was maintained at a significantly high level in 
inhibitor treated cells in the presence of ascitic fluids. Thirdly that, ascitic fluids reduced the 
cellular uptake of PHA665752 and may also enhance efflux from the cell suggesting that a 
component in ascitic fluids could have an important role in influencing the bioavailability of 
this inhibitor, however, the effect on canertinib is still unknown. Fourthly that the ascitic 
fluids reduced the expressions of EGFR, HER-2, c-MET, ERK and p-ERK, but the levels of 
Akt and p-Akt were significantly elevated with or without inhibitors.  
Ovarian cancer cells have been shown to increase their expression of tyrosine kinase 
receptors that are associated with the promotion of growth of tumours [464, 606]. Therefore, 
these receptors have been a major focus for the development of a target for drugs in the 
treatment of ovarian but also in several other types of cancers [84, 220, 313, 607-609]. It was 
established in the previous chapter, that the combination of canertinib with PHA665752 had a 
greater inhibitory effect on growth of 3D cell clusters than the single inhibitors alone [596]. In 
those experiments the ovarian cancer cells were exposed to growth factors supplemented in a 
culture medium, but this may not represent the true microenvironment that the cancer cells 
experience in advanced ovarian cancer patients. 
Almost 37% of ovarian cancer patients present with ascitic fluids with malignant growth in 
the peritoneal cavity [165]. The biology underlining the ovarian cancer cells’ behaviour when 
they are exposed to the ascitic fluid is under investigation. Ascitic fluid may provide a 
microenvironment that favours growth, survival and migration of the cancer cells [162, 168, 
169]. Further the presence of ascitic fluid is associated with aggressive disease, drug 
resistance and a poor prognosis [572].  
The mechanism(s) by which ascites contribute to aggressive disease, resistance to therapy 
and a poor prognosis is still poorly understood. There is evidence that cytokines play a crucial 




role in the progression of ovarian cancer [169, 610]. There appear to be two main roles for 
cytokines in promoting the growth and progression of tumour cells. Firstly, they may directly 
induce growth, increase cellular adhesion and enhance angiogenesis acting as growth factors. 
Secondly, they may block the cell-mediated mechanisms that enable the recognition and 
destruction of tumour cells. Certain cytokines which are present in the normal ovarian 
environment have a significantly increased expression in the tumour microenvironment [610]. 
Lysophosphatidic acid (LPA) has been shown to be elevated in the blood and ascites of cancer 
patients and there is evidence of its role in the development and metastasis of ovarian cancer. 
It has been reported to be a key driver in the formation of inflammatory cytokines that 
contribute to the aggressive behaviour of ovarian cancer cells [583, 611, 612]. This may 
explain the growth promoting properties of the ascitic fluids which contain abundant growth 
promoting agents.  
There have been limited studies investigating the effect of canertinib and PHA665752 under 
conditions that re-create as closely as possible those of the advanced ovarian cancer 
microenvironment. Ovarian tumours in the advanced stage proliferate on the surface lining of 
internal organs and abdominal walls. The tumours are constantly exposed to undiluted ascitic 
fluids, which are rich in a cocktail of proteins and bioactive small molecules [156, 168, 169, 
180, 486, 498, 613]. Therefore, the response of ovarian cancer cells to these drugs in the 
presence of ascitic fluids is of interest. 
This study, demonstrates that the morphology of OVCAR-5 cell clusters and SKOV-3 
aggregates is notably changed upon exposure to the inhibitors when growth factors are present 
in a cell culture medium. This observation is consistent with previous studies on cell 
monolayers of ovarian cancer cell lines [219, 256, 257, 515]. In the present study, in the 
presence of ascitic fluids, cell clusters and aggregates are more compact than those treated 
with GF medium. This is consistent with the previous studies showing that ascitic fluids 
promote compact aggregate formation [7, 162, 614, 615]. Puiffe and colleagues [162] showed 
that ascitic fluids from different ovarian cancer patients had the same effect as FBS on the 
formation of compact spheroids of the ovarian cancer cell line OV-90 [162]. This may be 
explained by the presence of cytokines and growth factors in both FBS and ascitic fluid that 
may enhance cell-cell adhesion.  




The morphology of the cell clusters and aggregates was not affected when the inhibitors 
were introduced in the presence of ascitic fluids. To the best of my knowledge, this is the first 
in vitro demonstration of the effects of tyrosine kinase inhibitors in the presence of ascitic 
fluids. There have been previous reports of ascitic fluids at lower concentrations stimulating 
ovarian cancer cells in in vitro conditions [162, 486]. In these studies the authors showed that, 
similar to FBS, a number of ascitic fluids increased growth in ovarian cancer cell lines, 
however, this characteristic was not universal and thus some ascitic fluids may not induce cell 
growth [162]. 5% FBS and 5% ascitic fluids were used in their experiments and the results 
were compared with cells in serum free medium [162]. Other studies have demonstrated that 
soluble factors in the ascites may be involved in the activation of survival pathways including 
Akt and ERK and that this may occur via integrins [598, 599]. Akt and ERK are important 
molecules in the process of cell growth, proliferation, and invasion. In context, the current 
study also showed that ascitic fluids can stimulate cells to produce high levels of PCNA. 
Furthermore in the presence of ascitic fluid the inhibitors canertinib and PHA665752 have no 
apparent effect on growth. These results are consistent with other studies on the effect of 
ascites on cell proliferation and growth [168, 616-618].  
In an attempt to ascertain why the drugs have no inhibitory effect in the presence of the 
ascitic fluid, this study demonstrates that cellular uptake of the drug (PHA665752) was 
decreased and/or efflux of the drug was increased. Uptake of the drug returned after removal 
of ascitic fluid. It appears that there is some component in the ascitic fluid that affects the 
membrane permeability of the PHA665752. Ascitic fluids contain high levels of serum 
albumin due to the increased intraperitoneal permeability [619] caused by ovarian tumour 
growth [7, 619]. 
This study demonstrates that the presence of serum albumin protein in the ascitic fluids may 
have an impact on drug concentration in the cell which may explain the lack of effect of the 
inhibitors in the ascitic fluid. While this conclusion appears to contradict the findings in 
Chapter 3 where the drugs were still effective in the presence of 5% FBS it should be noted 
that the concentration of albumin in the 50% ascitic fluid would likely be higher than that in 
the 5% FBS that was used in the assays of Chapter 3. 




Albumin has been shown to directly affect the pharmacokinetic and pharmacodynamic 
properties of anticancer drugs [620, 621]. The bioavailability of tyrosine kinases inhibitors, 
including gefitinib, erlotinib, lapatinib and afatinib have been shown to be affected by serum 
albumin in drug development studies [222, 479, 622-625]. Furthermore, the concentrations of 
the free unbound forms of these inhibitors in the plasma are below that which would be 
clinically active in ovarian cancer patients with EGFR and HER-2 positive tumours. Given 
that the structure of canertinib is similar to that of afatinib [609] it is possible that its 
bioavailability is similarly affected by albumin. 
This study, also describes the changes of EGR, HER-2 and c-MET expression and 
phosphorylation after cells were exposed to ascitic fluid. The overall basal level of EGFR, 
HER-2 and c-MET in ascitic fluid treated cells was significantly decreased when compared to 
levels in GF exposed cells. After incubation with the inhibitors, the phosphorylation of these 
receptors was lower in the ascitic fluid exposed cells. This suggests that both canertinib and 
PHA665752 may affect the receptors but that their inhibitory action may be insufficient to 
elicit the growth arrest. One possibility is that additional signalling proteins could become 
activated and thus overrides any effect of the inhibitor [626].  
This study demonstrates that levels of Akt and p-Akt are high in ascitic fluid exposed cells 
while the level of ERK and p-ERK does not change. This may suggest that the activation of 
Akt may be responsible for the growth promoting effect and acquired resistance to tyrosine 
kinase inhibitors. In comparison to benign plural fluids, tumour cells floating in the malignant 
ascitic fluid show over expression of Akt [627]. Akt can be activated and phosphorylated 
through several mechanisms such as the activation of cell surface receptors that utilise Akt in 
their downstream signalling processes. Lane and colleagues [599] showed that ascites from 
ovarian cancer patients promotes survival of ovarian cancer cells mainly via the activation of 
Akt [599]. Similar to results in this thesis, they show that inhibition of EGFR was not 
accompanied by inhibition of Akt and that ascites-induced activation of Akt was unaffected 
by the EGFR inhibitors PD153085 and AG1478, the EGFR inhibitors [599].  
Growth factors that are abundant in ovarian cancer ascites contribute to the activation of Akt 
via the tyrosine kinase receptors such as EGFR and HER-2 and hence promoting cell survival 




[628]. However, in this thesis, the tyrosine kinase inhibitors were able to partially inhibit the 
expression and phosphorylation of EGFR and HER-2 receptors but not Akt. This may suggest 
that an alternative mechanism for the activation of Akt may be utilised in ovarian cancer 
ascites.  
Akt could also be activated through G-protein-coupled-receptors. These receptors have been 
implicated in tumour growth and cancer cell survival [583]. One ligand for these receptors is 
LPA which has been found to promote cell survival via signalling through PI3K/Akt pathway 
in ovarian cancer [629]. LPA has been shown to act as a ligand for four distinct receptors, 
LPA1, 2, 3, and 4 of which LPA2, 3 and 4 have been shown to be highly expressed in ovarian 
cancer ascites [630]. These receptors can couple with many G-proteins including Gq, Gi, and 
G12/13. The coupling of LPA receptors with Gi can activate the PI3K/Akt pathway and the 
levels of LPA have been shown to be highly expressed in ovarian cancer ascites [631]. 
Activation of Akt may also be achieved through the interactions of ECM proteins with cell 
surface integrins leading to the activation of integrin/FAK signalling [599, 632]. Ovarian 
cancer ascites has been shown to induce an instant phosphorylation of focal adhesion kinase 
(FAK) which in turn is a key activator of Akt phosphorylation.  
Matte, et al. [486], have demonstrated that OC ascites enhanced migration of patient derived 
human peritoneal mesothelial cells (HPMCs) by c-MET RTK phosphorylation via HGF 
stimulation, (which is abundant in most ascites), and EGFR activation, which in turn activates 
ERK1/2 and Akt intracellular signalling pathways [486]. These findings are consistent with 
results from this thesis showing the upregulation of Akt and p-Akt in OVCAR-5 and SKOV-3 
clusters and compact aggregates. The inhibition of Akt activity is an area that warrants future 
investigation, for example a study of a combination of canertinib, PHA665752 and an Akt 
inhibitor for Akt in ovarian cancer cells exposed to ascitic fluids. The role of LPA in the 
activation of ovarian cancer cell growth also warrants further investigation to determine 
whether the presence of LPA activates Akt under the cell culture conditions used in the 
present study and whether inhibition of LPA in the ascites may enhance the cellular response 
to tyrosine kinase inhibitors or not. Given that ascitic fluids were from patients with high 
grade papillary serous ovarian carcinoma, and the fact that the response to the inhibitors was 




similar in all three fluids, it would be of interest to compare these with ascitic fluids from 
patients with other subtypes.  
In summary, the results suggest that there may be two main factors in ascitic fluids that 
affect the cellular response to TKIs; first, possible serum albumin binding to TKIs, which may 
prevent the drugs from freely entering the cells (and also enhancing possible drug efflux from 
the cells), and second an increased expression and activation of Akt could overcome the 
inhibitory effect of TKIs when ascitic fluids are present. 
It is acknowledged that increasing the concentrations of TKIs used in this study may not be 
feasible in a clinical setting due to possible adverse side effects. However, the results 
presented in this chapter may highlight the need for a novel approach to drug delivery 
platform of the TKIs to overcome the effects of components in the ascitic fluid. One 
limitation of this study is the small number of ascitic fluids and ovarian cancer cell lines that 
were used due to resource and time constraints. Clearly further studies in this area are 
warranted. 





5 CHAPTER FIVE 
 
AN INVESTIGATION OF THE EFFECTS OF 
CANERTINIB AND PHA665752 ON CELL 
ADHESION OF THE TWO OVARIAN CANCER 














Ovarian cancer progression is a complicated multistep process in which cancer cells can 
exfoliate from their primary site of origin (the ovary) into the peritoneal cavity and move to 
and adhere to other organs. The process of adherence is important for progression of the 
disease and is a key factor with respect to the disease morbidity. Floating ovarian cancer cells 
in ascitic fluid can escape anoikis (a type of apoptosis induced by loss of attachment to the 
solid ECM substratum) [633, 634] through their adherence to the peritoneal surface of the 
abdominal wall, colon, liver, omentum, fallopian tubes, and bowel serosa [7, 367, 614, 635, 
636]. The secondary growth of these cancer cells begins with their adherence to the surface of 
these organs. The cancer cells grow into larger tumour nodules, which can then compromise 
the normal function of the organs [636]. Patients with advanced ovarian cancer, for example, 
often present with bowel obstruction as a consequence of the tumour growing on the external 
wall of the gastrointestinal tract causing the blockage of bowel movement. This is a frequent 
cause of morbidity from ovarian cancer [637, 638]. As such, understanding the processes of 
adherence may provide important information about ovarian cancer progression. It is also 
possible that drugs that are able to delay the adhesion processes of the cancer cells may be of 
clinical significance. 
The early stages of ovarian cancer cell adhesion occur as the cancer cells interact with the 
peritoneal lining of the abdominal cavity. The lining comprises mesothelial cells and 
extracellular matrix (ECM) proteins including collagen I, IV and laminin, blood vessels, 
lymphatics and nerve fibres [636, 639-641]. The mesothelial cells form a thin monolayer that 
covers the abdominal wall acting as a protective barrier against infections or tissue injury. 
Once cancer cells reach the abdominal wall, they adhere to the mesothelial lining and 
eventually disseminate deeper into organ tissue [571]. There are several possible stages that 
have been suggested for the implantation of ovarian cancer cells on the surface of peritoneal 
lining. Cancer cells may induce apoptosis in the thin layer of the mesothelial cells thereby 
removing the defensive barrier and exposing the basal lamina. This in turn leads to 
penetration of the basal lamina by the tumour cells [642]. The presence of soluble tumour-
derived factors in the ascitic fluid can induce mesothelial retraction and disaggregation 
causing the basal lamina to be exposed, enabling the cancer cells to implant [643].  
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For the adhesion to be successful, the cancer cells must be in physical contact with either the 
mesothelial cells or the exposed collagens. As mentioned above, there is evidence to suggest 
that ovarian cancer cells can induce mesothelial cells to undergo apoptosis and that will 
expose the barrier between them and collagen matrix [642]. Integrins in the cancer cells can 
then facilitate contact with the ECM [644], binding to fibronectin, laminin and collagen [173]. 
The binding and activation of integrins can then trigger signal transduction pathways that play 
a role in the regulation of the cell cycle, cell shape, motility, and the addition of new receptors 
to the cell membrane [645].  
Integrins have been suggested to play a role in co-activating numerous growth pathways 
during tumour angiogenesis [646]. It is thought that they can control the activity of receptor 
tyrosine kinases (RTKs) such as the vascular endothelial growth factor receptors (VEGFR) 
and the epidermal growth factor receptor (EGFR) [366, 647-649]. Crosstalk between integrin-
mediated ECM signals and growth factors may contribute to control of the aggressive 
behaviour of cancer cells [650]. Collectively, the synergy between those signals may be a key 
driver of metastasis and tumour aggression [649, 651].  
OVCAR-5 and SKOV-3 ovarian carcinoma cell lines express several adhesion molecules 
including integrins [652]. Both cell lines have been found to express high levels of β1 and β4 
integrin subunits which can bind to several ECM components including laminin and collagen 
IV [653]. Integrins containing these subunits have been found to be responsible for the 
implantation of OVCAR-5 cellular clusters in the mesothelial lining of the abdominal cavity 
[364, 654] and the expression of these integrin subunits have been associated with a poor 
prognosis and aggressive disease [366, 367, 654]. As mentioned above, β4 integrin subunits 
have a specific affinity for laminin [655, 656]. In addition to their expression in OVCAR-5 
and SKOV-3 ovarian cancer cell lines [657] an association with receptor tyrosine kinases 
EGFR, HER-2 and c-MET has been reported [372, 654, 658, 659]. These associations would 
be consistent with downstream cross-talk between RTKs and integrins and may underlie the 
co-localisation and clustering of the receptors upon activation and consequently the adhesion 
of the cells [370, 375, 376]. Integrin clustering recruits numerous downstream signalling 
proteins leading to the formation of focal adhesions. Cell-matrix adhesions differ in 2 and 3 
dimension culture conditions [660]. The stable attachment of normal epithelial cells is to the 
basement membrane is maintained through the formation of hemidesmosomes as a result of 
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α6β4 integrin activation [661]. During wound healing and malignant development this 
integrin is phosphorylated causing the disassembly of hemidesmosomes. This in turn leads to 
a redistribution of α6β4 integrin to interact with the actin cytoskeleton where it contributes to 
cell migration and invasion via co-operating with tyrosine kinase receptors [375, 658]. 
In addition to their role in mediating cell adhesion, the overexpression of β4 integrin 
subunits in ovarian cancer cells can promote cell migration, proliferation and metastasis by 
controlling the localisation and action of ECM proteins [366]. Importantly some drug resistant 
cancer cells may occur due to the interaction between integrins and the ECM, and in fact it 
has been suggested that there may be cooperation between different integrins in the induction 
of drug resistance [645]. Some studies have shown that β4 integrins are involved in tumour 
propagation and drug resistance in NSCLC [645, 662], however, the resistance of matrix 
adherent ovarian cancer cells to treatments is thought to be due to a pro-survival response due 
to the interaction of β1and β4 integrin subunits with integrin linked kinase (ILK), and focal 
adhesion kinase (FAK) [645].  
The α6β4 integrin has been shown to induce EGFR clustering in breast cancer cells [658] 
leading to selective activation of EGFR signalling thereby affecting chemotaxis or motility 
[658]. This clustering has been shown to be inhibited when a PI3K inhibitor was introduced, 
suggestive of a  role of PI3K in inducing the clustering mechanism [663]. In addition, c-MET 
and its ligand HGF have been shown to increase peritoneal adhesion of OVCAR-3 and 
SKOV-3 ovarian cancer cell lines in an ex vivo cell culture model [528]. Inhibition of c-MET 
with the small molecule inhibitor INC280 (an orally bio-available c-MET inhibitor) reduced 
cell adhesion of these cell lines [528]. Other agents including PF-2341066 (c-MET-specific), 
Foretinib (c-MET and VEGFR-2), MK8033 (c-MET specific), DCC-2701 (c-MET/Tie-
2/VEGFR-2), and SU11274 (c-MET specific) have been tested in pre-clinical trials of ovarian 
cancer and shown to reduce cell invasion, adhesion, metastasis and tumour burden in animal 
models [335, 345, 525, 664, 665]. These all implicate a complex interplay between integrins, 
receptor tyrosine kinases and cell adhesion and thus a role for these membrane proteins in 
metastasis. 
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In view of the above and the results described in earlier chapters an investigation was made 
of the effect of the two tyrosine kinase inhibitors on cell adhesion in the two ovarian cancer 
cell lines.  
5.2 Hypotheses of this chapter 
Canertinib and PHA665752 will inhibit integrin-mediated cell adhesion of ovarian cancer 
cell clusters and compact aggregates.  
The effect on adhesion will occur due to the inhibition of the phosphorylation of 
EGFR/HER-2 and c-MET. 
 EGFR and HER-2 receptor tyrosine kinase will co-localise intracellularly with β4 integrin 
subunits, and the inhibition of the receptors will reduce the co-localisation leading to loss of 
adhesion. 
5.3 Objectives of this chapter 
1. To investigate the effect of EGF and HGF on the adhesion of ovarian cancer cell clusters 
and compact aggregates to collagen gel matrix. 
2. To investigate the effect of canertinib and PHA665752 tyrosine kinase inhibitors on the 
adhesion of ovarian cancer cellular clusters and compact aggregates to collagen gel 
matrix in the presence of growth factors. 
3. To investigate the downstream effects and internal co-localisation of EGFR/ HER-2 with 
β4 Integrin subunits. 
5.4 Materials and methods 
Materials and methods were as described in chapter 2 section 2.13. 





5.5.1 Expressions of β1 and β4 integrin subunits in OVCAR-5 and SKOV-3 cells 
Initially the presence of β1 and β4 integrin subunits in OVCAR-5 cellular clusters and 
SKOV-3 compact aggregates was investigated by immunofluorescent imaging. Both types of 
cell lines exhibited high expression of β1 and β4 integrin subunits (Figure 5.1 A, B, C and 
D). 
 
Figure 5.1.Immunofluorescent images of β1 and β4 integrin subunits in ovarian cancer cell 
lines. (A and B) OVCAR-5 cellular clusters and (C and D) SKOV-3 compact aggregates. 
DAPI stained nuclei are blue and the plasma membrane associated β1 or β4 integrin subunits 
are stained red. 




5.5.2 The presence of growth factors enhances cell adhesion to a collagen gel matrix in 
the two ovarian cancer cell lines 
As established in chapter 3, the presence of growth factors activates the EGFR, HER-2 and 
c-MET receptors, leading to increased proliferation and cell growth of OVCAR- 5 cellular 
clusters and SKOV-3 compact aggregates. Further, results presented in chapter 4 reported that 
ascitic fluid increased the growth of ovarian cancer cell clusters/aggregates. In the body 
ascitic fluid containing cancer cells is an environment that is rich in growth-promoting factors 
particularly EGF and HGF [46]. Hence the role of these growth factors in the adhesion of 
OVCAR-5 cellular clusters and SKOV-3 compact aggregates was investigated.  
A dose-dependent increase in the adhesion of OVCAR-5 cellular clusters and SKOV-3 
compact aggregates was observed with both EGF and HGF. This was more marked in the 
SKOV-3 cells than the OVCAR-5 cells (Figure 5.2 A, C and B, D). There were no significant 
differences between the 0.2 and 20 ng/mL of GF in OVCAR-5 clusters. However, SKOV-3 
compact aggregates exhibited significant differences between the two different concentrations 
of EGF. 




Figure 5.2. Effects of EGF and HGF on the adhesion of the OVCAR-5 and SKOV-3 
ovarian cancer cell lines. Numbers represent the number of adherent OVCAR-5 (A, C) and 
SKOV-3 (B, D) clusters/compact aggregates treated with 0.2 and 20 ng/mL of EGF or HGF. 
Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 
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5.5.3 Canertinib inhibits adhesion of OVCAR-5 clusters and SKOV-3 compact 
aggregates in a dose dependent manner 
To investigate the effect of the tyrosine kinase inhibitor canertinib on adhesion, cells were 
exposed to different concentrations of the inhibitor for four hours (the average time for 
ovarian cancer cells to achieve maximum adherence [364]), in the presence of 0.2 or 20 
ng/mL of the EGF - HGF combination (termed GF as described earlier). There was a 
concentration dependent decrease in the number of adherent cells of OVCAR-5 clusters 
(Figure 5.3 A, C) and SKOV-3 compact aggregates (Figure 5.3 B, D) in the presence of 0.2 
or 20 ng/mL of GF with increasing concentrations of the inhibitor. This result was found 
irrespective of the concentration of GF. The question of whether this loss of adhesion is due 
to cell death or to other intracellular responses to the inhibitor will be addressed below.




Figure 5.3. The effect of canertinib on cell adhesion of the two ovarian cancer cell lines 
OVCAR-5 (A, C) and SKOV-3 (B, D). Cell clusters and compact aggregates were treated 
with canertinib at concentrations of 0, 0.5, 1.0, 2.0, 3.0, 4.0 µM in the presence of 0.2 or 
20ng/mL GF for 4 hours before a further 4 hours adhesion assay. Adherent cells were 
counted. Data are expressed as means ± S.E.M (n=3). Data considered statistically significant 
are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 




5.5.4 PHA665752 inhibits adhesion of OVCAR-5 clusters and SKOV-3 compact 
aggregates in a dose dependent manner 
To investigate the effect of the c-MET inhibitor PHA665752 on cell adhesion, cells were 
exposed to different concentrations of the inhibitor, in the presence of 0.2 or 20 ng/mL EGF 
/HGF combination (GF), for 4 hours before the adhesion assay was carried out and adherent 
cells were counted. There was a significant dose dependant decrease in the adhesion of 
OVCAR-5 cellular clusters (Figure 5.4.A, C) and SKOV-3 compact aggregates (Figure 
5.4.B, D) irrespective of the concentration of growth factors in response to the presence of the 
inhibitor. This effect was more pronounced in OVCAR-5 clusters.  
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Figure 5.4. The effect of PHA665752 on cell adhesion of the two ovarian cancer cell lines. 
Number of adherent OVCAR-5 (A, C) and SKOV-3 (B, D) clusters/compact aggregates 
treated with 0, 0.5, 1.0, and 2.0 µM of PHA665752 in the presence of 0.2 or 20ng/mL GF. 
Data are expressed as means ± S.E.M (n=3). Data considered statistically significant are 
indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the 
control or the other concentrations. 
. 




5.5.5 A combination of canertinib and PHA665752 inhibits adhesion more effectively 
than single inhibitor treatments 
Since the focus of this thesis is the effect of combining the two inhibitors, canertinib and 
PHA665752 on the two ovarian cancer cell lines, the effect of a combination of both 
inhibitors in the presence of 0.2 or 20 ng/mL combined growth factors (GF), on adhesion was 
investigated. As described above and here there was a significant decrease in cell adhesion 
with single inhibitors for both OVCAR-5 clusters (Figure 5.5 A, C) and SKOV-3 compact 
aggregates (Figure 5.5 B, D). A further reduction in cell adhesion was observed when cells 
were exposed to the inhibitor combination. There was no difference in the response with the 
different concentrations of growth factors. 





Figure 5.5. The effect of a combination of the two tyrosine kinase inhibitors, canertinib and 
PHA665752, on the adherence of OVCAR-5 clusters and SKOV-3 compact aggregates. Cell 
clusters and compact aggregates were treated with single and combination of canertinib and 
PHA665752, in the presence of 0.2 or 20ng/mL GF for 4 hours before a further 4 hours of the 
adhesion assay. Adherent cells were counted. Data are expressed as means ± S.E.M (n=3). 
Data considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 
(***), and p<0.0001 (****) compared to the control or the other concentrations. 




5.5.6 Canertinib, alone or in combination with PHA665752 did not compromise cell 
growth and metabolism within 4 hours of cell adhesion assay 
In order to confirm that the effect of the inhibitors, in single or combination was not due to 
them reducing cell numbers (in the 4 hour exposure prior to an adhesion assay) rather than 
affecting adhesion, an investigation of the effect of canertinib alone and in combination with 
PHA665752 on cell number and cellular metabolism was carried out. With both growth factor 
concentrations, 0.2 or 20 ng/mL, there was in the majority of cases no significant decline in 
cell number of OVCAR-5 clusters (Figure 5.6 A, B) or SKOV-3 compact aggregates (Figure 
5.6 E, F) with the increased canertinib concentrations. However, SKOV-3 cells showed a 
slight, but significant, reduction in cell number with the combination of canertinib and 
PHA665752 (Figure 5.6 E). No significant effect on cellular metabolism was observed in 
both OVCAR-5 clusters (Figure 5.6 C, D) and SKOV-3 compact aggregates (Figure 5.6 G, 
H) in both 0.2 and 20 ng/mL GF. This suggests that canertinib is not compromising cell 
growth within the 4 hours timeframe but rather is inhibiting adhesion. 
 









5.5.7 PHA665752, alone or in combination with canertinib, did not affect cell growth 
or metabolism within the 4 hours of the adhesion incubation period 
In order to investigate whether PHA665752 alone, or in combination with canertinib, 
affected cell number within the 4 hours’ time frame, cells were treated with single 
concentrations of PHA665752 and in combination with canertinib in the presence of both 
growth factor concentrations 0.2 or 20 ng/mL. There was no significant difference in the cell 
numbers of OVCAR-5 clusters (Figure 5.7 A, B) and SKOV-3 compact aggregates (Figure 
5.7 E, F) in the presence of 0.2 or 20 ng/mL of GF, with increased concentrations of 
PHA665752 alone, nor in combination with canertinib. However, there was a slight, but 
significant decrease in SKOV-3 cell numbers with the combination and the lower GF 
concentration. No effect on cellular metabolism was observed in both OVCAR-5 clusters 
(Figure 5.7 C, D) and SKOV-3 compact aggregates (Figure 5.7 G, H) with both growth 
factor concentrations. This suggests that for the most part the inhibitors are not compromising 
cell growth within the 4 hours timeframe, but rather are inhibiting adhesion. 
Chapter Five                                                                                                                                          Adhesion of ovarian cancer cell clusters 
181 
 




5.5.8 An RGD-containing peptide reduced adhesion. 
The previous results suggest that the inhibitors compromise cellular adhesion to the collagen 
gel matrix. The integrin subunits β1 and β4 are transmembrane proteins that can form cell 
adhesions. They have previously been found to be associated with EGFR/HER-2 and c-MET 
and thus play a crucial role in the development and progression of ovarian cancer [372, 658].  
To investigate the involvement of integrins in the adhesion process, clusters of OVCAR-5 
and compact aggregates of SKOV-3 were exposed to RGDS-peptides both in the presence and 
absence of the combination treatment of canertinib and PHA665752. RGDS is a peptide that 
inhibits the binding of integrins to ECM proteins [366, 666]. Cells were maintained in serum 
free medium (SFM) supplemented with 0.2 or 20 ng/mL of GF and an adhesion assay was 
performed to determine the number of adherent cells. Control cells were treated with RGES 
which is an RGD-related peptide that serves as control for its inhibitory effects on fibrinogen 
binding. Aspartic acid is replaced with glutamic acid which abrogates the inhibitory effects on 
integrins and ECM proteins [667].    
 
In the presence of 0.2 ng/mL GF, OVCAR-5 cellular clusters showed a concentration 
dependent decrease in cell adhesion with RGDS when compared to three types of controls: an 
acetate control (cells treated with acetate at the same concentrations used for RGDS to ensure 
that the inhibitory effect of RGDS is not affected by the pH changing acetate), and cells 
treated with RGES. The combination of canertinib and PHA665752 strongly inhibited 
adhesion as described earlier although the addition of RGDS to the combination did not 
reduce adhesion any further (Figure 5.8 A). Similar effects were observed in the presence of 
20 ng/mL of GF (Figure 5.8 B).  
SKOV-3 compact aggregates showed similar trends in the presence of 0.2 and 20 ng/mL of 
GF (Figure 5.9 A, B).













Figure 5.8. The effect of an RGD-containing peptide on cell adhesion in the presence of the inhibitors. OVCAR-5 cellular clusters in the 
presence of (A) 0.2 or (B) 20 ng/mL of GF. Cells were treated with 20 or 40 µM RGDS alone, or in combination with canertinib (3µM) and 
PHA665752 (1µM). Controls were comprised of untreated, acetate or RGES treated cells. Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control.













Figure 5.9. The effect of an RGD-containing peptide on cell adhesion in the presence of the inhibitors. SKOV-3 compact aggregates in the 
presence of (A) 0.2 or (B) 20 ng/mL of GF. Cells were treated with 20 or 40 µM RGDS alone, or in combination with canertinib (3µM) and 
PHA665752 (1µM). Controls were comprised of untreated, acetate or RGES treated cells. Data are expressed as means ± S.E.M (n=3). Data 
considered statistically significant are indicated as p<0.05 (*), p<0.01 (**), p<0.001 (***), and p<0.0001 (****) compared to the control.




5.5.9 The effect of canertinib and PHA665752, singly and combined, on the total 
expression and phosphorylation of EGFR, HER-2, c-MET and the expression of 
β4 integrin subunits  
The results above suggest that the cells are viable within the 4 hours incubation period with 
the inhibitors, but the adhesion of the cells was reduced. Therefore, following 4 hours of 
incubation with the inhibitors, an investigation of the total expression and phosphorylation of 
EGFR, HER-2, c-MET and then the expression of β4 integrin subunits was carried out using 
western blotting. The β1 integrin subunits were excluded from this part of the study because 
of difficulties in reliably obtaining bands for these on the western blots.  
5.5.9.1 Effect on OVCAR-5 cellular clusters 
In the presence of 0.2 ng/mL of GF, both canertinib and PHA665752, alone or in 
combination inhibited phosphorylation of EGFR (p-EGFR) in OVCAR-5 cells (Figure 5.10 
A). Total expression of EGFR was slightly reduced with canertinib alone (Figure 5.10 B). 
PHA 665752 alone inhibited total expression and phosphorylation of MET protein (c-MET 
and p-MET) (Figure 5.10 C and D). The combination of inhibitors further decreased 
expression and phosphorylation. The expression of β4 was slightly reduced with the 
combination of the inhibitors, but not with the single treatments (Figure 5.10 E). HER-2 was 
undetectable in the OVCAR-5 clusters. Similar results were obtained with the presence of 20 
ng/mL of GF (Figure 5.10 F, G, H, I and J). 
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5.5.9.2 Effect on SKOV-3 compact aggregates 
In the presence of 0.2 or 20 ng/mL of GF, canertinib alone or in combination with 
PHA665752, inhibited total expression and the level of phosphorylation of EGFR 
(p-EGFR) (Figure 5.11 A, B, H and I). In contrast, in the presence of PHA665752 
there were no significant changes. Similar trends were observed with the total 
expression and phosphorylation of HER-2 (Figure 5.11 C, D, J and K). Both 
inhibitors, alone and in combination, reduced the total expression and 
phosphorylation of c-MET (Figure 5.11 E, F, L and M). There was no reduction in 
the expression of β4 integrin subunits with any of the treatments (Figure 5.11 G).  
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5.5.10 Immuno fluorescent imaging showed no changes in the expression of β1 integrin 
subunits in response to canertinib and PHA665752 alone or in combination 
To investigate the effects of canertinib and PHA665752 on the expression of the β1 integrin 
subunit immunofluorescent staining was used. Clusters of OVCAR-5 cells and compact 
aggregates of SKOV-3 cells were treated with single inhibitors or a combination of inhibitors. 
Immunofluorescent imaging of β1 integrin subunits indicate that no observable changes 
occurred in the expression of the subunits, with either the single or combined treatments of 
the inhibitors, in both OVCAR-5 clusters and SKOV-3 compact aggregates (Figure 5.12). 
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5.5.11 Immuno fluorescent imaging show no changes in the expression of β4 integrin 
subunits in response to canertinib and PHA665752 alone or in combination 
To investigate the effect of the inhibitors on the expression of β4 integrin subunits in the 
aggregates and clusters were stained with antibodies raised against the β4 subunit. 
Immunofluorescent images of β4 integrin subunits show no observable changes in the 
expression of the subunits in the presence of single or combined treatments with the 
inhibitors, in both OVCAR-5 clusters and SKOV-3 compact aggregates (Figure 5.13). The 
subunits appear to be mostly localised around the outside edges of the cell membranes. 
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5.5.12 Co-localisation of EGFR and HER-2 with β4 integrin subunits 
The previous results suggest that the expression and phosphorylation of EGFR and HER-2 
were reduced with single or combined inhibitor treatments resulting in a loss of cellular 
adhesion. However, the expression of β4 integrin subunits was unchanged. It was possible 
that the loss of adhesion might be due to a compromisation of the physical interaction 
between EGFR and HER-2 with β4 integrin subunits. To investigate this, the co-localisation 
of these receptors was studied using immunofluorescence. Cells were stained with antibodies 
for EGFR, HER-2 and β4 integrin subunits. There was a significant reduction in the co-
localisation of EGFR/β4 and HER-2/ β4 in both of OVCAR-5 cellular clusters (Figure 5.14 
A) and SKOV-3 compact aggregates (Figure 5.14 B and C). This may explain the observed 
reduction in cell adhesion without any observable change in the expression of integrin 
subunits. 
The fluorescent intensity of the receptors was also analysed. There was a significant 
reduction in EGFR intensity in OVCAR-5 cellular clusters, while no significant reduction in 
the intensity of staining of β4 integrin subunits was observed (Figure 5.15 A). Similar results 
were obtained with SKOV-3 compact aggregates with anti- EGFR, HER-2 and β4 antibodies 
(Figure 5.15 B and C). 
The co-localisation immunofluorescent images of EGFR and the β4 subunit for OVCAR-5 
cellular clusters with single and the combination treatment of inhibitors is shown in Figure 
5.16. Figures.5.17. and 5.18 illustrate the immunofluorescent images of SKOV-3 compact 
aggregates showing the co-localisation of EGFR and HER-2 with β4 subunits respectively. 
These results are consistent with the previous results obtained from Western blotting analysis.  
 

























Understanding the stages of ovarian cancer metastasis is important for identifying potential 
targets for cancer treatments. The spread of malignant cells into the peritoneum is a 
complicated multistep process that leads to cancer progression, and it involves many 
mechanisms and interactions between the malignant cells and the ECM. The ability of ovarian 
cancer cells to adhere to the ECM and mesothelial lining of the abdominal cavity is a unique 
characteristic of the malignant cells [616, 668] that exfoliate from the primary tumour and 
shed into the peritoneal fluid [669]. In the peritoneum, free floating malignant cells are found 
as single cells or forming clusters and aggregates [33, 157, 638]; hence studies that focus on 
multicellular in vitro responses may better mimic the in vivo microenvironment [364]. 
The ECM components, including fibronectin, laminin and type I and IV collagens [670, 
671] control a variety of cellular activities in normal and malignant cells including growth, 
proliferation and differentiation. This is achieved through their binding of integrins [364, 616, 
672, 673]. Integrins are cell surface receptors for ligands in the ECM [674], responsible for 
regulating cell-cell and cell-ECM interactions. They facilitate adhesion, migration and the 
invasion of tumour cells into other organs and angiogenesis [675, 676]. In addition to their 
role as ECM organisers [677], integrins have been shown to regulate cell adhesion to ECM 
components [653, 678, 679] and facilitate the motility of ovarian carcinoma cells [652, 680, 
681]. The presence of integrins in malignant cells is an indicator of a poor prognosis and the 
spread of the disease to other locations in the body [9, 669, 682]. Integrin β1 and β4 subunits 
have been suggested to be key drivers in the progression of ovarian cancer, particularly in the 
adhesion of the cells to fibronectin, laminin and type I collagen [668, 670, 683]. There is a 
well-established association between those integrin subunits and the receptor tyrosine kinases, 
EGFR, HER-2 and c MET that have been the focus of earlier parts of this thesis. Several 
studies suggest that the cross talk between these receptors is a key driver in metastasis and in 
angiogenesis in breast and ovarian tumours [372, 376, 658, 684, 685]. 
The main objective of this chapter was to evaluate the effect of two tyrosine kinase 
inhibitors, canertinib and PHA665752 on cellular adhesion of OVCAR-5 and SKOV-3 
ovarian cancer cell lines in the presence of EGF and HGF. These cell lines have been found to 
possess the ability to form multi cellular clusters and aggregates that resemble the in vivo 
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ovarian carcinoma spheroids formed in the ascites [686]. The ability of these cell lines to 
adhere to mesothelial cells has also been reported in an in vitro model [687, 688]. The major 
finding of the work presented in this chapter is that these inhibitors compromised cellular 
adhesion, via inhibition of the targeted receptors. The objective was to expose OVCAR-5 
cellular clusters and SKOV-3 compact aggregates to the inhibitors for a specified period of 
time that was sufficient to allow the cells to adhere to the collagen-gel matrix without 
compromising their cellular viability. Various time periods to facilitate cell adhesion have 
been used in other studies [528, 653, 668, 671]. A time frame of 4 hours incubation has been 
suggested to be optimal for cellular adhesion of OVCAR-5 cells [364] and therefore this was 
used in this study. Additionally, an incubation period with the inhibitors prior to the adhesion 
assay was also chosen so that the cell viability was not compromised [542].  
The data presented suggest that OVCAR-5 cellular clusters and SKOV-3 compact 
aggregates retain high expression of β1 and β4 integrin subunits and that these facilitate the 
adherence of these cells to the matrix. This is consistent with other studies showing the high 
expression of these integrin subunits in ovarian cancer cells [689]. Other studies have shown 
that β1 and β4 integrin subunits are highly expressed in epithelial tumours of breast and 
colorectal in addition to ovarian carcinomas and that these play a crucial role in cell motility 
and metastasis [690-693]. The SKOV-3 cell line has also been shown to exhibit high invasive 
behaviour by utilising β4 integrin subunits [694, 695]. 
As mentioned earlier, the in vivo microenvironment is rich with growth promoting factors 
that play a pivotal role in modulating cell adhesion [696-699]. Of particular interest in this 
study are EGF and HGF which are the specific ligands for the EGFR/HER-2 and c-MET 
receptors that have shown to synergistically modulate the integrin-induced adhesion of 
ovarian cancer cells [526]. Hence the effect of these growth factors on cell adhesion was 
investigated.  
The data presented indicates a concentration dependant increase in cell adhesion with either 
of the growth factors applied alone or in combination (GF). This is consistent with the 
previous data from this study, showing the growth promoting properties of EGF and HGF on 
ovarian cancer clusters and aggregates [596]. These results are also in line with other reports 
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indicating a role for EGF and HGF in promoting adhesion, migration and survival of 
malignant tumour cells, particularly ovarian cancer cells [278, 526, 528]. 
Small molecule tyrosine kinase inhibitors have been suggested to inhibit cell growth, 
motility, adhesion and invasion of advanced ovarian cancer cells [335, 345, 525, 528, 664, 
665]. Moran and colleagues demonstrated that INC280, a small molecule, ATP competitive c-
MET inhibitor, reduced migration and HGF-induced adhesion in SKOV-3, OVCAR-3, and 
CAOV3 ovarian cancer cell lines [528].  
As described earlier in this thesis, canertinib and PHA665752 have inhibitory effects on GF-
induced cell growth and metabolism of OVCAR-5 clusters and SKOV-3 compact aggregates 
[596]. To identify any anti-adhesion effects of the inhibitors, the impact on GF-induced cell 
adhesion to a collagen gel matrix was investigated. Canertinib inhibited adhesion of both cell 
lines in a dose dependant manner. To the best of my knowledge this is first work that 
demonstrates an inhibitory effect of canertinib alone and in combination with PHA665752 on 
cell adhesion. This inhibition was not affected by the concentration of the added growth 
factors. Although the presence of growth factors was essential for the activation of the 
receptors and thus the response to the drugs, there was no additive inhibition with higher 
growth factor concentrations. This is consistent with previous data from chapter 1 which 
suggests that a low concentration of 0.2 ng/mL of GF (the growth factor mixture) was 
sufficient enough to activate the receptors and to elicit a cellular response to the treatments. 
The second inhibitor PHA665752 also exhibited a concentration dependent inhibition of cell 
adhesion in both cell lines. This is consistent with previous reports of the inhibitory properties 
of PHA665752 on HGF-mediated adhesion of myeloma cells to fibronectin [700].  
The combination of both inhibitors elicited an additive effect and cellular adhesion was 
lower than that observed with single inhibitors alone. Again to the best of my knowledge 
there have been no previous reports that demonstrate the combined effects of canertinib and 
PHA665752 on GF-induced cellular adhesion of OVCAR-5 clusters and SKOV-3 compact 
aggregates 
As reported in previous chapters, the inhibitors were effective in inducing cell death after an 
incubation period of 48 hours during which cell number and cellular metabolism were 
significantly decreased. In the adhesion experiments no reduction in cell number or cellular 
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metabolism took place when the cells were exposed to the inhibitors for a total of eight hours 
(i.e. the 4 hours of exposure to the inhibitors was followed by another 4 hours of the adhesion 
assay). The suggested time frame to facilitate adhesion ranges from 30 minutes to 24 hours 
[528, 671, 695, 701-703]. Therefore, the reported loss of cell adhesion is unlikely to be due to 
cell death as the cell numbers and cellular metabolism were not affected by the 4 hours of 
exposure to the inhibitors. 
In order to address the mechanisms by which inhibition of tyrosine kinase signalling could 
affect the cellular adhesion to the collagen matrix, cells were exposed to RGDS alone or in 
combination with the inhibitors. Integrins bind to proteins of the ECM at an RGD containing 
motif and thus the inclusion of RGD peptides in culture media has commonly been used to 
inhibit cell adhesion [704]. RGDS at a concentration of 40 µM decreased cell adhesion, which 
would suggest the importance of integrins in adhesion. This finding is supported by other 
studies demonstrating that β1 integrins subunits play a role in the adhesion of ovarian cancer 
cells [364, 652, 705]. When canertinib and PHA665752 were included the reduction in 
adhesion was not enhanced further by the inclusion of the RGDS. While it could be predicted 
that the RGDS would reduce adhesion further it should be noted that the tyrosine kinase 
inhibitors had already elicited a very significant reduction in numbers of adherent cells. Those 
cells that remained adherent may represent a small subpopulation that are not affected by the 
RGDS. These may express other adhesion molecules or alternately integrin subunits that are 
less sensitive to the RGDS. Clearly this is an area that warrants further investigation but 
unfortunately due to time constraints this was not investigated further in the current study.  
There is evidence to suggest that there may be a co-activation of downstream signalling 
molecules of the integrins and growth factor receptors that regulate proliferation, migration 
and survival [706, 707] in normal and malignant cells. This co-operation is thought to regulate 
cell cycle responses [646, 708]. Gambaletta and colleagues suggested a mechanism by which 
β4 integrin subunits co-operate to promote tumour invasion of NIH373 cells in an in vitro 
model study [373]. They showed that expression of both HER-2 and α6β4 integrins is 
required for enhancing of PI3K-dependent invasion through matrigel. They suggested a 
specific region on the cytoplasmic tale of β4 subunits that is pivotal for the integrins’ ability 
to enhance invasion. It was suggested that neither the extracellular domain of the β4 subunit 
nor its hetero-dimerisation with the α6 subunit contribute to any enhancement of invasion and 
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that the cooperation of the β4 subunit with HER-2 is essential for this matter. This is also 
consistent with other reports indicating the ability of β4 subunits to enhance invasion 
independently of dimerisation with α6 subunits [656, 709]. 
Cross talk between integrins and RTKs has also been shown to result in regulation of the 
activities of RTK [710]. Furthermore, it has been suggested that the phosphorylation of 
several RTKs, including EGFR, may be stimulated by integrin signalling [711] in the absence 
of growth factor ligands. The integrin-dependent activation of EGFR subsequently activates 
downstream signalling molecules of growth pathways ERK1/2, MAPK and Akt [371]. On the 
basis of these reports, an analysis of the total expression and phosphorylation of EGFR/HER-
2 and c-MET and β4 subunit expression was studied. There was a down regulation of 
EGFR/HER-2 and c-MET but not β4 subunits upon exposure to the inhibitors and this may 
have affected the cross talk between the various receptors and have accounted for the loss of 
adhesion. However, this does not explain why cell adhesion was lost independent from β4 
expression, which was not affected by the inhibitors. A possible explanation is that these 
integrin subunits are phosphorylated upon activation of EGFR. This is based on the idea that 
certain integrins may have affinity for certain RTK i.e., the integrin β1 subunit is associated 
with EGFR [712-714] and the integrin β4 subunit is associated with EGFR [715], HER-2 
[370] and c-MET [375]. The association of β4 subunits with EGFR/HER-2 and c-MET, along 
with the above results could suggest that the downregulation of the receptors inhibited the 
adhesion through the inhibition of shared downstream signalling molecules, for example ERK 
and Akt. This possibility is consistent with the results presented in the previous chapter where 
there was a downregulation of total expression and/or phosphorylation of Akt and ERK in the 
presence of canertinib and PHA665752 individually or in combination. Moreover, this 
inhibition may lead to a decrease in the co-localisation of β4 and EGFR/HER-2. This latter 
possibility was further supported by the findings that both canertinib and PHA665752, alone 
or in combination, were able to inhibit the co-localisation of β4 integrin subunits and 
EGFR/HER-2. The co-localisation is due to a physical interaction at cell-cell contact sites as 
demonstrated by Yu et.al.[714].  
To the best of my knowledge, no previous studies have reported the effect of combining 
canertinib and PHA665752 on cell adhesion. The results suggest that although integrins are 
considered key drivers in the adhesion of ovarian cancer cells, inhibition of EGFR/HER-2 and 
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c-MET could potentially affect the downstream co-localisation of the receptors with integrin 
subunits and therefore inhibit cell adhesion. The co-localisation of EGFR and β4 was 
observed by immunofluorescent microscopy. This is consistent with other studies confirming 
the co-localisation of integrins with EGFR using immunofluorescent microscopy [714].  
In summary, the treatment of OVCAR-5 cellular clusters and SKOV-3 compact aggregates 
with canertinib and PHA665752 as single agent or in combination compromised cell adhesion 
and this may occur via the inhibition of downstream signalling molecules, thus affecting the 
intracellular co-localisation of the receptors. Further work is required to explore the effect of 
the two small molecule inhibitors on the co-localisation of β4 integrin subunits with c-MET 
and the β1 integrin subunits possible co-localisation with EGFR, HER-2 and c-MET.  

























Two of the hallmarks of cancer are uncontrolled, sustained cellular proliferation [22, 31, 
220] and the evasion of growth suppressors. Ovarian cancer is the eighth most common cause 
of cancer related deaths in women worldwide [716]. Almost 75% of ovarian cancer patients 
respond to chemotherapy [7], but due to a typically late diagnosis where approximately 75% 
of patients present with an advanced stage [7] there are high rates of recurrence of the disease 
and consequently high mortality rates [13, 14]. Like many cancers, ovarian cancer is a 
complex disease, in part due to the diverse tissues and different cell types forming the ovaries 
[717]. Consequently, multiple types of ovarian cancer can arise.  
In common with other cancers such as breast, colon, liver and gastric cancer, ovarian cancer 
can arise due to the elevated expression and activation of receptor tyrosine kinases. Elevated 
expression of these receptors can be linked not just to cancer development, but also to a poor 
prognosis with disease spread, resistance to chemotherapy and low 5 year survival rates [305, 
334, 465, 468, 718]. The receptor family comprises members that regulate signal transduction 
pathways that are key drivers in cell survival [719].  
Inhibitors that target EGFR and HER-2 which are members of the ErbB family of receptor 
tyrosine kinases have been used successfully in the treatment of breast, colon, gastric and 
NSCLC cancer [241, 462, 531] and their combination with other types of chemotherapy can 
have good outcomes [547, 550]. However, these treatments have not been as successful with 
advanced ovarian cancer and despite a reduction of tumour burden, the rate of disease 
recurrence can still be high [547]. Another tyrosine kinase receptor that is of interest is c-
MET [537, 720, 721]. which can be abnormally expressed in cancer cells of epithelial origin 
[721]. Its specific ligand is HGF which is present at high levels in the plural fluids and tissues 
surrounding tumours [486, 487]. It has been suggested that malignant cells from NSCLC and 
Head & Neck carcinomas may utilise c-MET as an alternative route to activate growth 
signalling pathways if  EGFR and HER-2 are inhibited and hence the cells can surpass 
attempts to stop their growth [720, 722]. The research described in this thesis was an attempt 
to simultaneously inhibit EGFR/HER-2 and c-MET and observe the effects on two ovarian 
cancer cell lines.  
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In Chapter-3 the aim was to investigate the effects of two receptor tyrosine kinase inhibitors, 
canertinib and PHA665752 on the growth, metabolism and proliferation of the OVCAR-5 and 
SKOV-3 ovarian cancer cell lines. Following this their effects on downstream signalling 
molecules were investigated. These experiments were carried out in the presence of the 
growth factors that bind these receptors i.e. epidermal growth factor (EGF, which binds 
EGFR) and hepatocyte growth factor (HGF which binds c-MET) which both were used at two 
different concentrations. The low concentration was 0.2 ng/mL GF, which is the approximate 
level in ovarian cancer patients [486, 487, 500] and the higher concentration was 20 ng/mL 
GF, a concentration which has frequently been used in laboratory studies [278, 435, 496].  
The cell lines were grown as 3D clusters and aggregates in an attempt to better represent 
their normal microenvironment where they exist as single cells or floating aggregates. This 
could be a better representation than the 2D monolayer cell culture where cell shape, cell-cell 
and cell-ECM interactions may be altered due to the growth on a flat plastic surface [454, 
723-725]. Studies have also shown that cells in 3D aggregates show gene expression profiles 
similar to those of in vivo cells, which is in contrast to those in a 2D monolayer [726]. The 
response of cells to treatments when in 3D culture may thus be more clinically relevant [727]. 
Furthermore, cells in the multi cellular aggregates are likely to go through similar 
stages/conditions as tumour cells in vivo such as being normoxic, hypoxic, quiescent, necrotic 
and/or dying [728]. Collectively, the use of 3D cellular aggregates appears to be a more 
biologically relevant model for this study.  
The inhibitors affected growth of the 3D cell cultures and the expression and 
phosphorylation of downstream signalling molecules that are part of the intracellular survival 
pathways. The expression of the cell proliferation marker PCNA was also reduced. The 
combined effect of these two inhibitors was more potent than each inhibitor alone and 
suggests that blocking dual receptors may induce a greater impact on cellular growth and 
survival. Additionally, cells showed lower metabolic activity in the presence of the inhibitors 
alone or with the combined treatment. VEGF secretion was also decreased upon treatments 
with the inhibitors.  
The cellular response to the inhibitors was less pronounced in the presence of 5% FBS. Cell 
growth decreased but this was not as marked as in the presence of the growth factors 
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Furthermore cellular metabolism was not affected. A possible explanation for this could be 
that FBS is rich in growth promoting factors that may contribute to the cellular resistance to 
the inhibitors. Further experiments investigating the effect of different concentrations of the 
FBS would be of interest 
The results of chapter 3 raise the possibility that combining small molecule inhibitors that 
block different receptors may be a potential treatment option for ovarian cancer. They also 
suggest an ability of ovarian cancer cells to utilise multiple pathways in order to survive 
apoptotic factors induced by the blockage of one main growth pathway [241, 334, 338]. To 
the best of my knowledge, this is the first time that the combination of these inhibitors has 
been studied in ovarian cancer 3D clusters.  
One limitation in this study is that only two ovarian cancer cell lines were investigated due 
to time and resource constraints. Further study of more ovarian cancer cell lines with 
differential expression of the RTKs could enhance our knowledge of the inhibitors actions. It 
would also be interesting to explore the effect of canertinib and PHA665752 on other 
downstream signalling pathways important for maintain the hallmarks of ovarian cancer cells 
such as JAK/STAT, PI3K and NFkB [729-733]. It would be of interest to study the effects of 
the combination on primary tissue from ovarian cancer patients and to in vivo preclinical 
studies using mouse models or chicken embryos. 
As mentioned above, ovarian cancer cells in the body are typically present as floating single 
cells or cellular aggregates. Malignant ascites is found in at least 37% of advanced ovarian 
cancer patients and this has been recognised as a poor prognostic factor in advanced ovarian 
cancer [165, 176, 574]. Ascitic fluid may be important in regulating the cell signalling 
processes of the malignant cells once they have shed into the abdominal cavity [626].The 
increased expression of growth receptors in cells floating in malignant ascites suggests that 
soluble factors in the fluid may then be able to enhance cell growth, migration [486] and 
resistance to chemotherapy [613, 734]. This raises the question of what effect ascitic fluid 
may have on the efficacy of the drugs that was described in chapter 3 and formed the basis of 
the results that were presented in chapter 4.  
The results in chapter 4 demonstrate that the ascitic fluid can have a significant effect in 
reducing the efficacy of canertinib and PHA665752 and suggests that components in the 
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ascitic fluid could lead to the resistance and survival of ovarian cancer cells in the ascitic 
fluid. These results were consistent with Mo and colleagues suggesting that ascites increases 
cancer cell chemo-resistance [180]. They showed that the treatment of murine ovarian cancer 
cells with paclitaxel (a first line chemotherapeutic agent) in the presence of ascitic fluid made 
cells less sensitive to the drug [180].  
One possibility explanation of these results is that the presence of ascitic fluids affects the 
uptake of the drugs or that there was increased efflux of the drugs. In addition to inducing the 
production of ascites, the presence of malignant ovarian tumours may also cause increased 
vascular permeability [619]. This may increase the protein content of the ascitic fluid and in 
particular human serum albumin [170, 735]. There have been reports that tyrosine kinase 
inhibitors can bind to albumin [602]. This would be consistent with the reported effects of 
BSA in the current thesis and thus this may prevent the drugs from entering the cells. Note 
that no such effects were observed with FBS in chapter 3 but the concentrations of albumin in 
that particular assay were much lower than the likely albumin levels in ascitic fluid. The 
serum albumin may not be the only factor affecting the uptake of the drug into the cells. 
Uptake was significantly lower in the ascitic fluid treated cells compared to the BSA treated 
cells and so it is likely that there may be other factors in the ascitic fluid that can influence 
drug uptake.  
It should be acknowledged that while the suggestion is made that the albumin may be 
limiting uptake of the PHA665752 there is no direct evidence to suggest that this may be the 
case. It is also unclear what effects the ascitic fluid may have on the uptake of canertinib. 
Experiments where albumin is removed from the ascitic fluid before the addition of inhibitors 
may give a clearer view of its effect on the efficacy of the drugs. Some researchers have 
suggested boiling the ascitic fluid in order to denature the protein contents [162] but this 
would effectively eliminate all proteins not just the albumin. Unfortunately the albumin 
concentration in the ascitic fluids was not determined in this project due to time constraints. 
This is something that a follow on study could investigate.  
Ascitic fluid from 3 patients was tested in the current thesis and it is notable that the reported 
effects were consistent irrespective of which patient the fluids were from. It would be of 
interest however to test the ascitic fluids from more patients. The clinical records of the three 
Chapter Six                                                                                                                   Summery 
209 
 
patients from whom the fluids were obtained revealed that all three patients were from the 
same molecular subtype (see appendix). Future studies could investigate the effects of fluids 
from patients with different subtypes of ovarian cancer. This could be coupled with studies 
involving additional ovarian cancer cell lines with distinct molecular backgrounds.  
Cell growth was significantly higher in the ascitic fluid, consistent with the observed 
increased expression of PCNA. Furthermore the ascitic fluid decreased the expression levels 
and activation of the receptors. This was also the case for the downstream protein, ERK. 
While the receptors were downregulated, the total expression and phosphorylation of Akt was 
significantly increased. Akt is part of the PI3K/Akt signalling pathway downstream of 
EGFR/HER-2 and c-MET and can regulate cell proliferation, invasion and angiogenesis 
[733]. Other studies have shown that Akt is elevated in the presence of ascitic fluid which 
may explain the enhanced proliferative properties of the cells [156, 618]. This is also in line 
with the studies indicating that ascites is rich with growth promoting factors that may 
augment cellular survival through other signalling pathways separate from EGFR/HER-2 and 
c-MET [736].  
The cellular aggregates floating in the ascitic fluid have the ability to adhere to the 
mesothelial lining of the abdominal cavity, to proliferate there and to generate larger tumour 
nodules. This is an important stage in dissemination of cancer cells to other locations in the 
body. Therefore adhesion is a hallmark of metastatic potential in advanced ovarian cancer and 
an understanding of this process and its response to inhibitors are of clinical relevance. 
Integrins are ECM receptors that play a key role in cell-cell and cell-ECM interactions 
[645]. As such they can function in cell adhesion, migration and invasion [366]. The β1 and 
β4 integrin subunits have been found to be highly expressed in ovarian cancer cells [689] a 
fact that was confirmed by the fluorescent micrographs presented in this thesis. Unfortunately 
experimental problems with respect to the β1 antibody and time and resource constraints 
meant that the study focused primarily on the β4 integrin subunit. The β4 integrin subunit is 
thought to play crucial roles in the formation of stable adhesion complexes that affix cells to 
the basement membrane [352] and secondly, in affecting the PI3K cell signalling pathway by 
forming a complex with HER-2 receptor tyrosine kinase thereby promoting its signalling 
[373, 685]. Cancer cells harbouring mutations in P53 are able to utilise the subunit to promote 
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cell survival and evade apoptosis [690]. It has strong basal expression in all epithelial tumours 
[737] and this correlates with poor prognosis and disease spread in breast, pancreas, head and 
neck carcinomas and ovarian cancers [352] . Furthermore, it has been shown to be 
significantly overexpressed in SKOV-3 ovarian cancer cell lines [694, 695]. 
In the cell adhesion experiments, it was noted that canertinib and PHA665752 inhibited the 
adhesion of OVCAR-5 and SKOV-3 clusters and compact aggregates to collagen-gel matrix 
(which also contains laminin) without compromising the viability of cells. The combination 
of the two TKIs was more effective in inhibiting cellular adhesion than the tetra peptide 
RGDS which inhibits integrin ECM interactions. There was no additive effect on cell 
adhesion after combining the TKIs and RGDS. Given that most of the cells had already lost 
adhesion those that remained may represent a subpopulation of cells that are resistant to the 
inhibitors/RGDS and that may possibly up regulate some other integrin or indeed some other 
cell-ECM adhesion protein. To the best of my knowledge, there are no previous reports of 
canertinib or PHA665752 affecting cell adhesion in ovarian cancer cell clusters and 
aggregates. In other systems, PHA665752 has been shown to affect HGF-mediated adhesion 
of myeloma cells to fibronectin [700].  
The loss of cell adhesion was accompanied with the reduced expression of the receptor 
tyrosine kinases, but not of the β4 integrin subunits. This may confirm the reports that 
indicate the association of these integrin subunits with EGFR, HER-2 and c-MET tyrosine 
kinase receptors [29, 372, 658, 684, 738, 739]. These results provide an impetus for future 
studies on the efficacy of combinations of small tyrosine kinase inhibitors in preventing 
cellular adhesion in these ovarian cancer cell lines. The crosstalk between the integrin 
subunits and EGFR, HER-2 and c-MET is well documented [710] and the phosphorylation of 
receptor tyrosine kinases has been shown to be associated with integrin signalling [711].  
To investigate the possible mechanisms underlining the loss of adhesion, I looked for co-
localisation of EGFR and HER-2 with β4 integrin subunits. In the presence of the inhibitors 
there was a decrease in the co-localisation of EGFR and HER-2 with the β4 integrin subunits. 
This may underlie the decrease in cell adhesion in the presence of the inhibitors. However, 
given that this is a preliminary finding and due to time and resource constraints was not able 
to be investigated further, more investigations are recommended, for example to determine 
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the expression of other downstream signalling molecules including Akt. Further investigation 
of the co-localisation of c-MET with the β4 subunit is also needed. The role of the β1 integrin 
subunits and their possible co-localisation with EGFR, HER-2 and c-MET is also of interest. 
It is possible to speculate that the reduction in the co-localisation of the receptors and integrin 
subunits was due to the effect of the inhibitors on the downstream signalling molecules, Akt 
and ERK, during the four hours of the adhesion assay. Further work including 
immunoblotting and immunofluorescence analyses addressing the expression and 
phosphorylation of these molecules may clarify this point.   
In summary, this thesis explored the effects of two inhibitors of receptor tyrosine kinases 
cantertinib and PHA665752 on two ovarian cancer cell lines. These compromised cell growth, 
cellular metabolism, and the expression and phosphorylation of EGFR, HER-2 and c-MET in 
3D cell cultures. They also inhibited VEGF secretion. The inhibitors also affected cell 
adhesion to a collagen matrix gel possibly due to a decrease in receptor expression which 
affected co-localisation with integrins. The inhibitory effects on growth and metabolism were 
compromised when ascitic fluids were included in the assay mixture and it is possible that 
high levels of proteins in the ascitic fluids may affect the ability of the drug(s) to freely enter 
the cells. Cell growth and metabolism was enhanced in the presence of the ascitic fluid.  
This thesis provides a foundation for further investigations of a combinatorial approach 
using these inhibitors in the treatment of advanced ovarian cancer. The treatments seem 
promising in their effects reducing the cellular growth, metabolism, proliferation and adhesion 
of ovarian cancer cellular clusters and compact aggregates in the in vitro environment. 
However, further work on their effects in an in vivo microenvironment is warranted given the 
results with the ascitic fluid.
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-Subtype: High grade papillary Serous 
- Cancer stage: IIIC 
-No chemo received when ascitic fluid was collected 
 
Patient 2 
-Subtype: High grade papillary Serous 
-Cancer stage: IC 
- Carboplatin+taxol+gemcitabine before ascitic fluid collected 
 
Patient 3 
-Subtype: High grade papillary Serous 
-cancer stage: IIIC 
-No chemo received when ascitic fluid collected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
